

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE				SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
001	ALAN	AMINO	ALT/SGPT	CLIA TEST ID #: 255		EVALUATION CRITERIA: TARGET VALUE 20 %						
	2024-391	5	ENZ. 37 C	194	BIOLIS-24S	154 (IDG)	10	87.700	4.076	4.65	70.000	105.000
	2024-391	5	ENZ. 37 C	197	ARCHITECT	1 ABBOTT	22	77.136	2.865	3.71	62.000	93.000
	2024-391	11	MOD. IFCC	38	SIEMENS DI	143 SIEMENS	89	86.573	2.583	2.98	69.000	104.000
	2024-391	11	MOD. IFCC	184	INTEGRA	93 ROCHE	19	75.333	1.414	1.88	60.000	90.000
	2024-391	11	MOD. IFCC	186	BECK. COUL	76 AU-BECKMAN	31	69.806	2.306	3.30	56.000	84.000
	2024-391	11	MOD. IFCC	191	RX-SERIES	126 RANDOX	34	89.500	5.606	6.26	72.000	107.000
	2024-391	11	MOD. IFCC	203	ROCHE	93 ROCHE	40	77.051	2.207	2.86	62.000	92.000
	2024-391	11	MOD. IFCC	219	ATELLICA	143 SIEMENS	15	90.867	3.180	3.50	73.000	109.000
	2024-391	12	IFCC witho	203	ROCHE	93 ROCHE	12	76.583	1.977	2.58	61.000	92.000
	2024-391	13	ALA &aKETO	165	VITROS	155 ALTV	134	73.652	2.192	2.98	59.000	88.000
	2024-392	5	ENZ. 37 C	194	BIOLIS-24S	154 (IDG)	10	331.100	19.403	5.86	265.000	397.000
	2024-392	5	ENZ. 37 C	197	ARCHITECT	1 ABBOTT	22	324.273	13.049	4.02	259.000	389.000
	2024-392	11	MOD. IFCC	38	SIEMENS DI	143 SIEMENS	89	338.798	8.131	2.40	271.000	407.000
	2024-392	11	MOD. IFCC	184	INTEGRA	93 ROCHE	19	311.611	5.251	1.69	249.000	374.000
	2024-392	11	MOD. IFCC	186	BECK. COUL	76 AU-BECKMAN	31	287.968	9.125	3.17	230.000	346.000
	2024-392	11	MOD. IFCC	191	RX-SERIES	126 RANDOX	34	358.364	25.282	7.05	287.000	430.000
	2024-392	11	MOD. IFCC	203	ROCHE	93 ROCHE	40	321.875	11.257	3.50	258.000	386.000
	2024-392	11	MOD. IFCC	219	ATELLICA	143 SIEMENS	15	370.067	10.395	2.81	296.000	444.000
	2024-392	12	IFCC witho	203	ROCHE	93 ROCHE	12	318.167	9.209	2.89	255.000	382.000
	2024-392	13	ALA &aKETO	165	VITROS	155 ALTV	134	283.940	7.980	2.81	227.000	341.000
	2024-393	5	ENZ. 37 C	194	BIOLIS-24S	154 (IDG)	10	235.600	14.340	6.09	188.000	283.000
	2024-393	5	ENZ. 37 C	197	ARCHITECT	1 ABBOTT	22	224.545	7.063	3.15	180.000	269.000
	2024-393	11	MOD. IFCC	38	SIEMENS DI	143 SIEMENS	89	239.382	6.492	2.71	192.000	287.000
	2024-393	11	MOD. IFCC	184	INTEGRA	93 ROCHE	19	219.474	6.261	2.85	176.000	263.000
	2024-393	11	MOD. IFCC	186	BECK. COUL	76 AU-BECKMAN	31	202.581	8.423	4.16	162.000	243.000
	2024-393	11	MOD. IFCC	191	RX-SERIES	126 RANDOX	34	254.636	15.924	6.25	204.000	306.000
	2024-393	11	MOD. IFCC	203	ROCHE	93 ROCHE	40	223.975	7.333	3.27	179.000	269.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	15	257.933	8.226	3.19	206.000	310.000	
2024-393	12 IFCC witho	203	ROCHE	93	ROCHE	12	223.083	5.392	2.42	178.000	268.000	
2024-393	13 ALA &aKETO	165	VITROS	155	ALTV	134	205.641	5.302	2.58	165.000	247.000	
001	ALAN AMINO ALT/SGPT	CLIA TEST ID #: 255				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-394	5 ENZ. 37 C	194	BIOLIS-24S	154	(IDG)	10	30.400	4.923	16.20	24.000	36.000	
2024-394	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	22	16.045	1.522	9.48	13.000	19.000	
2024-394	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	89	22.636	2.170	9.59	18.000	27.000	
2024-394	11 MOD. IFCC	184	INTEGRA	93	ROCHE	19	15.000	0.882	5.88	12.000	18.000	
2024-394	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	31	14.633	0.605	4.13	12.000	18.000	
2024-394	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	34	19.000	2.072	10.91	15.000	23.000	
2024-394	11 MOD. IFCC	203	ROCHE	93	ROCHE	40	15.179	1.217	8.02	12.000	18.000	
2024-394	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	15	19.571	0.728	3.72	16.000	23.000	
2024-394	12 IFCC witho	203	ROCHE	93	ROCHE	12	15.917	1.115	7.00	13.000	19.000	
2024-394	13 ALA &aKETO	165	VITROS	155	ALTV	134	13.586	0.974	7.17	11.000	16.000	
2024-395	5 ENZ. 37 C	194	BIOLIS-24S	154	(IDG)	10	428.200	22.776	5.32	343.000	514.000	
2024-395	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	22	420.909	17.679	4.20	337.000	505.000	
2024-395	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	89	437.205	10.789	2.47	350.000	525.000	
2024-395	11 MOD. IFCC	184	INTEGRA	93	ROCHE	19	405.263	7.853	1.94	324.000	486.000	
2024-395	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	31	374.645	11.625	3.10	300.000	450.000	
2024-395	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	34	460.394	41.850	9.09	368.000	552.000	
2024-395	11 MOD. IFCC	203	ROCHE	93	ROCHE	40	416.350	15.877	3.81	333.000	500.000	
2024-395	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	15	473.667	14.003	2.96	379.000	568.000	
2024-395	12 IFCC witho	203	ROCHE	93	ROCHE	12	412.750	10.183	2.47	330.000	495.000	
2024-395	13 ALA &aKETO	165	VITROS	155	ALTV	134	368.038	9.903	2.69	294.000	442.000	
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-391	3 DYE BI-B.G	165	VITROS	63	KODAK	147	2.323	0.075	3.23	2.100	2.600	
2024-391	3 DYE BI-B.G	184	INTEGRA	93	ROCHE	29	2.554	0.073	2.86	2.300	2.800	
2024-391	3 DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	2.400	0.050	2.08	2.200	2.600	
2024-391	3 DYE BI-B.G	191	RX-SERIES	126	RANDOX	35	2.506	0.106	4.21	2.300	2.800	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-391	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	2.380	0.040	1.68	2.100	2.600
2024-391	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	13	2.331	0.046	1.98	2.100	2.600
2024-391	3	DYE BI-B.G	203	ROCHE	93	ROCHE	51	2.563	0.095	3.70	2.300	2.800
2024-391	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	14	2.457	0.062	2.53	2.200	2.700
2024-391	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	93	2.099	0.087	4.16	1.900	2.300
2024-391	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	2.336	0.048	2.06	2.100	2.600
002	ALBUMIN	CLIA TEST ID #: 265		EVALUATION CRITERIA: TARGET VALUE 10 %								
2024-392	3	DYE BI-B.G	165	VITROS	63	KODAK	147	4.627	0.129	2.79	4.200	5.100
2024-392	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	29	4.507	0.114	2.54	4.100	5.000
2024-392	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	4.409	0.110	2.49	4.000	4.900
2024-392	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	35	4.406	0.125	2.85	4.000	4.800
2024-392	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	4.530	0.100	2.22	4.100	5.000
2024-392	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	13	4.385	0.117	2.66	3.900	4.800
2024-392	3	DYE BI-B.G	203	ROCHE	93	ROCHE	51	4.558	0.118	2.60	4.100	5.000
2024-392	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	14	4.514	0.083	1.85	4.100	5.000
2024-392	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	93	4.161	0.120	2.89	3.700	4.600
2024-392	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	4.400	0.074	1.68	4.000	4.800
2024-393	3	DYE BI-B.G	165	VITROS	63	KODAK	147	3.731	0.113	3.02	3.400	4.100
2024-393	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	29	3.786	0.114	3.00	3.400	4.200
2024-393	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	3.663	0.096	2.62	3.300	4.000
2024-393	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	35	3.706	0.101	2.73	3.300	4.100
2024-393	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	3.740	0.049	1.31	3.400	4.100
2024-393	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	13	3.569	0.099	2.78	3.200	3.900
2024-393	3	DYE BI-B.G	203	ROCHE	93	ROCHE	51	3.814	0.098	2.57	3.400	4.200
2024-393	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	14	3.686	0.099	2.69	3.300	4.100
2024-393	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	93	3.339	0.114	3.40	3.000	3.700
2024-393	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	3.600	0.043	1.18	3.200	4.000
2024-394	3	DYE BI-B.G	165	VITROS	63	KODAK	147	1.792	0.052	2.93	1.600	2.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-394	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	29	2.046	0.082	4.02	1.800	2.300
2024-394	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	1.897	0.068	3.61	1.700	2.100
2024-394	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	35	1.991	0.092	4.62	1.800	2.200
2024-394	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	1.910	0.054	2.82	1.700	2.100
2024-394	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	13	1.831	0.082	4.49	1.600	2.000
2024-394	3	DYE BI-B.G	203	ROCHE	93	ROCHE	51	2.080	0.077	3.72	1.900	2.300
2024-394	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	14	1.954	0.050	2.55	1.800	2.100
2024-394	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	93	1.614	0.081	5.03	1.500	1.800
2024-394	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	1.800	0.000	0.00	1.600	2.000
002 ALBUMIN		CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-395	3	DYE BI-B.G	165	VITROS	63	KODAK	147	5.533	0.158	2.85	5.000	6.100
2024-395	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	29	5.179	0.156	3.02	4.700	5.700
2024-395	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	5.188	0.139	2.67	4.700	5.700
2024-395	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	35	5.182	0.195	3.76	4.700	5.700
2024-395	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	5.340	0.102	1.91	4.800	5.900
2024-395	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	13	5.100	0.088	1.72	4.600	5.600
2024-395	3	DYE BI-B.G	203	ROCHE	93	ROCHE	51	5.288	0.122	2.31	4.800	5.800
2024-395	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	14	5.329	0.088	1.65	4.800	5.900
2024-395	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	93	4.962	0.139	2.80	4.500	5.500
2024-395	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	5.182	0.119	2.30	4.700	5.700
003 ALKALINE PHOSPHATE		CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-391	3	COLORIMET.	184	INTEGRA	93	ROCHE	24	74.583	3.785	5.07	52.000	97.000
2024-391	3	COLORIMET.	203	ROCHE	93	ROCHE	35	74.171	3.299	4.45	52.000	96.000
2024-391	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	70.455	5.298	7.52	49.000	92.000
2024-391	6	KINETIC 37	165	VITROS	63	KODAK	147	87.466	4.432	5.07	61.000	114.000
2024-391	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	32	60.875	7.283	11.96	43.000	79.000
2024-391	10	IFCC	219	ATELLICA	143	SIEMENS	15	74.067	2.351	3.17	52.000	96.000
2024-391	11	Modified I	38	SIEMENS DI	143	SIEMENS	86	77.047	4.147	5.38	54.000	100.000
2024-391	11	Modified I	191	RX-SERIES	126	RANDOX	28	65.536	6.790	10.36	46.000	85.000
2024-391	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	67.250	6.833	10.16	47.000	87.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE	30	%							
2024-392	3	COLORIMET.	184 INTEGRA	93	ROCHE	24	278.792	13.342	4.79	195.000	362.000	
2024-392	3	COLORIMET.	203 ROCHE	93	ROCHE	35	277.257	10.945	3.95	194.000	360.000	
2024-392	5	KINETIC 30	197 ARCHITECT	1	ABBOTT	11	260.091	22.613	8.69	182.000	338.000	
2024-392	6	KINETIC 37	165 VITROS	63	KODAK	147	177.918	9.734	5.47	125.000	231.000	
2024-392	8	BOW. MC-37	186 BECK. COUL	76	AU-BECKMAN	32	225.156	24.439	10.85	158.000	293.000	
2024-392	10	IFCC	219 ATELLICA	143	SIEMENS	15	274.533	6.228	2.27	192.000	357.000	
2024-392	11	Modified I	38 SIEMENS DI	143	SIEMENS	86	291.628	10.869	3.73	204.000	379.000	
2024-392	11	Modified I	191 RX-SERIES	126	RANDOX	28	231.964	21.550	9.29	162.000	302.000	
2024-392	12	P NITRO PH	197 ARCHITECT	1	ABBOTT	12	249.417	21.065	8.45	175.000	324.000	
2024-393	3	COLORIMET.	184 INTEGRA	93	ROCHE	24	197.708	11.219	5.67	138.000	257.000	
2024-393	3	COLORIMET.	203 ROCHE	93	ROCHE	35	195.429	7.976	4.08	137.000	254.000	
2024-393	5	KINETIC 30	197 ARCHITECT	1	ABBOTT	11	183.364	13.766	7.51	128.000	238.000	
2024-393	6	KINETIC 37	165 VITROS	63	KODAK	147	158.055	8.082	5.11	111.000	205.000	
2024-393	8	BOW. MC-37	186 BECK. COUL	76	AU-BECKMAN	32	158.750	16.908	10.65	111.000	206.000	
2024-393	10	IFCC	219 ATELLICA	143	SIEMENS	15	192.733	5.767	2.99	135.000	251.000	
2024-393	11	Modified I	38 SIEMENS DI	143	SIEMENS	86	204.070	8.218	4.03	143.000	265.000	
2024-393	11	Modified I	191 RX-SERIES	126	RANDOX	28	167.357	15.753	9.41	117.000	218.000	
2024-393	12	P NITRO PH	197 ARCHITECT	1	ABBOTT	12	175.417	14.807	8.44	123.000	228.000	
2024-394	3	COLORIMET.	184 INTEGRA	93	ROCHE	24	26.042	1.399	5.37	18.000	34.000	
2024-394	3	COLORIMET.	203 ROCHE	93	ROCHE	35	25.486	1.519	5.96	18.000	33.000	
2024-394	5	KINETIC 30	197 ARCHITECT	1	ABBOTT	11	24.545	2.426	9.88	17.000	32.000	
2024-394	6	KINETIC 37	165 VITROS	63	KODAK	147	42.621	2.075	4.87	30.000	55.000	
2024-394	8	BOW. MC-37	186 BECK. COUL	76	AU-BECKMAN	32	20.000	2.704	13.52	14.000	26.000	
2024-394	10	IFCC	219 ATELLICA	143	SIEMENS	15	25.267	1.526	6.04	18.000	33.000	
2024-394	11	Modified I	38 SIEMENS DI	143	SIEMENS	86	26.581	3.208	12.07	19.000	35.000	
2024-394	11	Modified I	191 RX-SERIES	126	RANDOX	28	23.286	2.889	12.41	16.000	30.000	
2024-394	12	P NITRO PH	197 ARCHITECT	1	ABBOTT	12	22.917	3.353	14.63	16.000	30.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-395	3	COLORIMET.	184 INTEGRA	93	ROCHE	24	365.261	18.090	4.95	256.000	475.000	
2024-395	3	COLORIMET.	203 ROCHE	93	ROCHE	35	362.676	12.179	3.36	254.000	471.000	
2024-395	5	KINETIC 30	197 ARCHITECT	1	ABBOTT	11	334.091	26.753	8.01	234.000	434.000	
2024-395	6	KINETIC 37	165 VITROS	63	KODAK	147	185.966	11.561	6.22	130.000	242.000	
2024-395	8	BOW. MC-37	186 BECK. COUL	76	AU-BECKMAN	32	294.906	33.160	11.24	206.000	383.000	
2024-395	10	IFCC	219 ATELLICA	143	SIEMENS	15	356.467	9.905	2.78	250.000	463.000	
2024-395	11	Modified I	38 SIEMENS DI	143	SIEMENS	86	382.583	11.762	3.07	268.000	497.000	
2024-395	11	Modified I	191 RX-SERIES	126	RANDOX	28	295.821	24.247	8.20	207.000	385.000	
2024-395	12	P NITRO PH	197 ARCHITECT	1	ABBOTT	12	325.083	29.429	9.05	228.000	423.000	
004	AMYLASE	CLIA TEST ID #: 285										
2024-391	3	ENZYM. 37C	165 VITROS	63	KODAK	87	51.523	5.544	10.76	36.000	67.000	
2024-391	4	HYDRO ACT.	38 SIEMENS DI	143	SIEMENS	25	66.920	1.831	2.74	47.000	87.000	
2024-391	9	ENZ/COL.37	203 ROCHE	93	ROCHE	24	67.667	1.748	2.58	47.000	88.000	
2024-391	10	CNPG3	186 BECK. COUL	76	AU-BECKMAN	16	51.313	3.948	7.69	36.000	67.000	
2024-391	11	KINETIC	219 ATELLICA	143	SIEMENS	11	76.182	1.749	2.30	53.000	99.000	
2024-392	3	ENZYM. 37C	165 VITROS	63	KODAK	87	183.966	6.737	3.66	129.000	239.000	
2024-392	4	HYDRO ACT.	38 SIEMENS DI	143	SIEMENS	25	245.520	6.906	2.81	172.000	319.000	
2024-392	9	ENZ/COL.37	203 ROCHE	93	ROCHE	24	246.750	6.273	2.54	173.000	321.000	
2024-392	10	CNPG3	186 BECK. COUL	76	AU-BECKMAN	16	189.125	13.638	7.21	132.000	246.000	
2024-392	11	KINETIC	219 ATELLICA	143	SIEMENS	11	278.455	5.467	1.96	195.000	362.000	
2024-393	3	ENZYM. 37C	165 VITROS	63	KODAK	87	130.337	5.982	4.59	91.000	169.000	
2024-393	4	HYDRO ACT.	38 SIEMENS DI	143	SIEMENS	25	173.320	3.997	2.31	121.000	225.000	
2024-393	9	ENZ/COL.37	203 ROCHE	93	ROCHE	24	173.833	2.939	1.69	122.000	226.000	
2024-393	10	CNPG3	186 BECK. COUL	76	AU-BECKMAN	16	133.063	9.263	6.96	93.000	173.000	
2024-393	11	KINETIC	219 ATELLICA	143	SIEMENS	11	195.600	4.055	2.07	137.000	254.000	
2024-394	3	ENZYM. 37C	165 VITROS	63	KODAK	87	30.037	0.189	0.63	21.000	39.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-394	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	25	24.708	1.172	4.74	17.000 32.000	
2024-394	9	ENZ/COL.37	203	ROCHE	93	ROCHE	24	25.667	0.898	3.50	18.000 33.000	
2024-394	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	18.625	1.364	7.32	13.000 24.000	
2024-394	11	KINETIC	219	ATELLICA	143	SIEMENS	11	28.364	0.481	1.70	20.000 37.000	
004	AMYLASE		CLIA TEST ID #: 285			EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-395	3	ENZYM. 37C	165	VITROS	63	KODAK	87	231.256	7.448	3.22	162.000 301.000	
2024-395	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	25	316.125	6.778	2.14	221.000 411.000	
2024-395	9	ENZ/COL.37	203	ROCHE	93	ROCHE	24	318.750	6.906	2.17	223.000 414.000	
2024-395	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	243.063	17.148	7.06	170.000 316.000	
2024-395	11	KINETIC	219	ATELLICA	143	SIEMENS	11	361.091	5.035	1.39	253.000 469.000	
005	ASP. AMINO AST/SGOT		CLIA TEST ID #: 295			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-391	1	ASPAR&KETO	165	VITROS	63	KODAK	144	115.362	3.691	3.20	92.000 138.000	
2024-391	1	ASPAR&KETO	194	BIOLIS-24S	154	(IDG)	10	104.100	8.467	8.13	83.000 125.000	
2024-391	5	ENZYM. 37C	38	SIEMENS DI	143	SIEMENS	93	98.739	3.176	3.22	79.000 118.000	
2024-391	11	MOD. IFCC	184	INTEGRA	93	ROCHE	21	100.619	2.903	2.88	80.000 121.000	
2024-391	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	89.156	5.032	5.64	71.000 107.000	
2024-391	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	34	114.676	8.950	7.80	92.000 138.000	
2024-391	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	34	106.000	5.354	5.05	85.000 127.000	
2024-391	11	MOD. IFCC	203	ROCHE	93	ROCHE	38	102.026	2.539	2.49	82.000 122.000	
2024-391	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	15	114.733	3.316	2.89	92.000 138.000	
2024-391	12	IFCC witho	203	ROCHE	93	ROCHE	12	102.250	3.631	3.55	82.000 123.000	
2024-391	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	97.714	3.304	3.38	78.000 117.000	
2024-392	1	ASPAR&KETO	165	VITROS	63	KODAK	144	462.657	17.857	3.86	370.000 555.000	
2024-392	1	ASPAR&KETO	194	BIOLIS-24S	154	(IDG)	10	320.000	33.067	10.33	256.000 384.000	
2024-392	5	ENZYM. 37C	38	SIEMENS DI	143	SIEMENS	93	344.108	10.111	2.94	275.000 413.000	
2024-392	11	MOD. IFCC	184	INTEGRA	93	ROCHE	21	350.667	9.301	2.65	281.000 421.000	
2024-392	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	304.355	12.372	4.07	243.000 365.000	
2024-392	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	34	353.667	26.335	7.45	283.000 424.000	
2024-392	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	34	389.273	29.754	7.64	311.000 467.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-392	11 MOD. IFCC	203	ROCHE	93	ROCHE	38	354.368	8.972	2.53	283.000	425.000	
2024-392	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	15	393.667	6.518	1.66	315.000	472.000	
2024-392	12 IFCC witho	203	ROCHE	93	ROCHE	12	354.167	14.559	4.11	283.000	425.000	
2024-392	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	337.571	11.356	3.36	270.000	405.000	
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-393	1 ASPAR&KETO	165	VITROS	63	KODAK	144	310.741	11.632	3.74	249.000	373.000	
2024-393	1 ASPAR&KETO	194	BIOLIS-24S	154	(IDG)	10	236.500	25.307	10.70	189.000	284.000	
2024-393	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	93	245.301	7.242	2.95	196.000	294.000	
2024-393	11 MOD. IFCC	184	INTEGRA	93	ROCHE	21	251.571	4.676	1.86	201.000	302.000	
2024-393	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	220.719	11.015	4.99	177.000	265.000	
2024-393	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	34	285.242	20.923	7.34	228.000	342.000	
2024-393	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	34	261.333	12.472	4.77	209.000	314.000	
2024-393	11 MOD. IFCC	203	ROCHE	93	ROCHE	38	253.763	6.869	2.71	203.000	305.000	
2024-393	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	15	280.800	4.819	1.72	225.000	337.000	
2024-393	12 IFCC witho	203	ROCHE	93	ROCHE	12	254.500	8.539	3.36	204.000	305.000	
2024-393	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	241.143	8.070	3.35	193.000	289.000	
2024-394	1 ASPAR&KETO	165	VITROS	63	KODAK	144	45.901	1.634	3.56	37.000	55.000	
2024-394	1 ASPAR&KETO	194	BIOLIS-24S	154	(IDG)	10	43.000	3.406	7.92	34.000	52.000	
2024-394	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	93	39.774	2.090	5.25	32.000	48.000	
2024-394	11 MOD. IFCC	184	INTEGRA	93	ROCHE	21	39.762	1.925	4.84	32.000	48.000	
2024-394	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	34.935	1.813	5.19	28.000	42.000	
2024-394	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	34	44.333	5.312	11.98	35.000	53.000	
2024-394	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	34	44.636	2.794	6.26	36.000	54.000	
2024-394	11 MOD. IFCC	203	ROCHE	93	ROCHE	38	40.000	1.376	3.44	32.000	48.000	
2024-394	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	15	47.071	1.163	2.47	38.000	56.000	
2024-394	12 IFCC witho	203	ROCHE	93	ROCHE	12	39.833	0.898	2.25	32.000	48.000	
2024-394	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	38.786	1.372	3.54	31.000	47.000	
2024-395	1 ASPAR&KETO	165	VITROS	63	KODAK	144	623.636	26.734	4.29	499.000	748.000	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-395	1	ASPAR&KETO	194	BIOLIS-24S	154	(IDG)	10	391.600	46.682	11.92	313.000 470.000	
2024-395	5	ENZYMAL.37C	38	SIEMENS DI	143	SIEMENS	93	445.739	12.440	2.79	357.000 535.000	
2024-395	11	MOD. IFCC	184	INTEGRA	93	ROCHE	21	447.952	10.974	2.45	358.000 538.000	
2024-395	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	390.258	15.919	4.08	312.000 468.000	
2024-395	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	34	474.212	49.090	10.35	379.000 569.000	
2024-395	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	34	423.333	12.037	2.84	339.000 508.000	
2024-395	11	MOD. IFCC	203	ROCHE	93	ROCHE	38	453.684	11.274	2.49	363.000 544.000	
2024-395	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	15	502.800	10.864	2.16	402.000 603.000	
2024-395	12	IFCC witho	203	ROCHE	93	ROCHE	12	455.583	14.032	3.08	364.000 547.000	
2024-395	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	433.929	22.247	5.13	347.000 521.000	
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-391	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	0.979	0.083	8.51	0.780 1.170	
2024-391	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	91	1.054	0.073	6.90	0.840 1.270	
2024-391	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	30	1.120	0.026	2.29	0.900 1.340	
2024-391	4	J-G WITH B	191	RX-SERIES	126	RANDOX	26	1.053	0.092	8.71	0.840 1.260	
2024-391	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	1.033	0.105	10.14	0.830 1.240	
2024-391	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	1.199	0.066	5.48	0.960 1.440	
2024-391	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	1.089	0.086	7.87	0.870 1.310	
2024-391	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	1.199	0.066	5.48	0.960 1.440	
2024-391	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	0.928	0.081	8.69	0.740 1.110	
2024-391	13	AZOBIL.	203	ROCHE	93	ROCHE	35	0.906	0.039	4.35	0.720 1.090	
2024-391	14	VANADATE	219	ATELLICA	143	SIEMENS	15	1.181	0.046	3.93	0.950 1.420	
2024-391	14	VANADATE	219	ATELLICA	143	SIEMENS	15	1.331	0.119	8.95	1.070 1.600	
2024-391	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	0.936	0.031	3.28	0.750 1.120	
2024-391	18	COLORIMETR	203	ROCHE	93	ROCHE	14	0.909	0.054	5.97	0.730 1.090	
2024-391	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	11	1.101	0.089	8.07	0.880 1.320	
2024-392	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	4.311	0.329	7.64	3.450 5.170	
2024-392	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	91	5.223	0.235	4.51	4.180 6.270	
2024-392	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	30	4.912	0.091	1.85	3.930 5.890	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-392	4	J-G WITH B	191	RX-SERIES	126	RANDOX	26	4.998	0.411	8.22	4.000	6.000
2024-392	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	4.732	0.603	12.74	3.790	5.680
2024-392	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	5.459	0.149	2.72	4.370	6.550
2024-392	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	5.459	0.149	2.72	4.370	6.550
2024-392	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	4.888	0.268	5.48	3.910	5.870
2024-392	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	4.601	0.326	7.08	3.680	5.520
2024-392	13	AZOBIL.	203	ROCHE	93	ROCHE	35	4.476	0.197	4.39	3.580	5.370
2024-392	14	VANADATE	219	ATELLICA	143	SIEMENS	15	6.094	0.569	9.34	4.880	7.310
2024-392	14	VANADATE	219	ATELLICA	143	SIEMENS	15	5.531	0.174	3.15	4.420	6.640
2024-392	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	4.531	0.269	5.93	3.620	5.440
2024-392	18	COLORIMETR	203	ROCHE	93	ROCHE	14	4.451	0.234	5.25	3.560	5.340
2024-392	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	11	4.756	0.291	6.12	3.810	5.710
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-393	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	2.974	0.220	7.38	2.380	3.570
2024-393	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	91	3.574	0.195	5.47	2.860	4.290
2024-393	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	30	3.447	0.082	2.38	2.760	4.140
2024-393	4	J-G WITH B	191	RX-SERIES	126	RANDOX	26	3.448	0.252	7.29	2.760	4.140
2024-393	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	3.233	0.389	12.04	2.590	3.880
2024-393	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	3.808	0.125	3.27	3.050	4.570
2024-393	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	3.396	0.185	5.44	2.720	4.080
2024-393	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	3.808	0.125	3.27	3.050	4.570
2024-393	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	3.105	0.189	6.08	2.480	3.730
2024-393	13	AZOBIL.	203	ROCHE	93	ROCHE	35	3.059	0.130	4.23	2.450	3.670
2024-393	14	VANADATE	219	ATELLICA	143	SIEMENS	15	3.769	0.155	4.11	3.020	4.520
2024-393	14	VANADATE	219	ATELLICA	143	SIEMENS	15	4.235	0.321	7.57	3.390	5.080
2024-393	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	3.143	0.169	5.36	2.510	3.770
2024-393	18	COLORIMETR	203	ROCHE	93	ROCHE	14	3.049	0.122	4.00	2.440	3.660
2024-393	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	11	3.296	0.220	6.67	2.640	3.960
2024-394	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	0.188	0.021	11.36	0.150	0.230

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-394	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	91	0.103	0.022	20.95	0.080	0.120
2024-394	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	30	0.140	0.027	19.22	0.110	0.170
2024-394	4	J-G WITH B	191	RX-SERIES	126	RANDOX	26	0.149	0.060	40.54	0.120	0.180
2024-394	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	0.101	0.003	2.97	0.080	0.120
2024-394	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	0.253	0.073	29.09	0.200	0.300
2024-394	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	0.253	0.073	29.09	0.200	0.300
2024-394	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	0.122	0.036	29.19	0.100	0.150
2024-394	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	0.097	0.042	43.75	0.080	0.120
2024-394	13	AZOBIL.	203	ROCHE	93	ROCHE	35	0.155	0.019	12.25	0.120	0.190
2024-394	14	VANADATE	219	ATELLICA	143	SIEMENS	15	0.164	0.032	19.30	0.130	0.200
2024-394	14	VANADATE	219	ATELLICA	143	SIEMENS	15	0.167	0.024	14.14	0.130	0.200
2024-394	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	0.101	0.030	30.15	0.080	0.120
2024-394	18	COLORIMETR	203	ROCHE	93	ROCHE	14	0.143	0.031	21.65	0.110	0.170
2024-394	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	11	0.100	0.000	0.00	0.080	0.120
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 %							
2024-395	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	5.544	0.372	6.71	4.440	6.650
2024-395	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	91	6.887	0.301	4.37	5.510	8.260
2024-395	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	30	6.387	0.174	2.73	5.110	7.660
2024-395	4	J-G WITH B	191	RX-SERIES	126	RANDOX	26	6.676	0.503	7.53	5.340	8.010
2024-395	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	6.229	0.798	12.80	4.980	7.470
2024-395	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	7.204	0.221	3.07	5.760	8.640
2024-395	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	6.494	0.344	5.30	5.190	7.790
2024-395	7	DIAZO-DYPH	165	VITROS	63	KODAK	145	7.204	0.221	3.07	5.760	8.640
2024-395	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	6.005	0.419	6.97	4.800	7.210
2024-395	13	AZOBIL.	203	ROCHE	93	ROCHE	35	5.957	0.301	5.05	4.770	7.150
2024-395	14	VANADATE	219	ATELLICA	143	SIEMENS	15	7.273	0.238	3.28	5.820	8.730
2024-395	14	VANADATE	219	ATELLICA	143	SIEMENS	15	7.918	0.801	10.12	6.330	9.500
2024-395	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	5.891	0.416	7.06	4.710	7.070
2024-395	18	COLORIMETR	203	ROCHE	93	ROCHE	14	5.931	0.267	4.50	4.750	7.120
2024-395	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	11	6.205	0.368	5.93	4.960	7.450

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
010	CALCIUM, TOTAL	CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE		1.00							
2024-391	3 ARSEN.-III	165 VITROS	63 KODAK	162	6.571	0.145	2.20	5.600	7.600			
2024-391	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	34	6.629	0.177	2.68	5.600	7.600			
2024-391	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	35	6.968	0.319	4.57	6.000	8.000			
2024-391	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	7.000	0.173	2.47	6.000	8.000			
2024-391	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	12	6.642	0.166	2.49	5.600	7.600			
2024-391	3 ARSEN.-III	220 Medica E.	99 STAMBIO	11	6.555	0.235	3.58	5.600	7.600			
2024-391	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	6.610	0.192	2.91	5.600	7.600			
2024-391	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	6.543	0.222	3.39	5.500	7.500			
2024-391	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	6.633	0.262	3.96	5.600	7.600			
2024-391	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	15	6.727	0.144	2.13	5.700	7.700			
2024-391	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	6.600	0.161	2.44	5.600	7.600			
2024-391	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	15	6.420	0.269	4.19	5.400	7.400			
2024-391	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	16	6.638	0.122	1.84	5.600	7.600			
2024-391	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	41	6.715	0.100	1.49	5.700	7.700			
2024-392	3 ARSEN.-III	165 VITROS	63 KODAK	162	10.673	0.191	1.79	9.700	11.700			
2024-392	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	34	10.871	0.209	1.93	9.900	11.900			
2024-392	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	35	10.938	0.373	3.41	9.900	11.900			
2024-392	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	10.990	0.122	1.11	10.000	12.000			
2024-392	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	12	10.675	0.242	2.27	9.700	11.700			
2024-392	3 ARSEN.-III	220 Medica E.	99 STAMBIO	11	10.645	0.375	3.52	9.600	11.600			
2024-392	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	10.840	0.254	2.34	9.800	11.800			
2024-392	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	10.600	0.374	3.53	9.600	11.600			
2024-392	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	10.455	0.282	2.69	9.500	11.500			
2024-392	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	15	10.740	0.203	1.89	9.700	11.700			
2024-392	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	10.460	0.220	2.10	9.500	11.500			
2024-392	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	15	10.647	0.470	4.42	9.600	11.600			
2024-392	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	16	10.669	0.231	2.17	9.700	11.700			
2024-392	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	41	10.680	0.208	1.94	9.700	11.700			

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
010	CALCIUM, TOTAL	CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE		1.00						
2024-393	3 ARSEN.-III	165 VITROS	63 KODAK	162	9.124	0.195	2.14	8.100	10.100		
2024-393	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	34	9.244	0.212	2.29	8.200	10.200		
2024-393	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	35	9.456	0.313	3.31	8.500	10.500		
2024-393	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	9.510	0.170	1.79	8.500	10.500		
2024-393	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	12	8.992	0.222	2.46	8.000	10.000		
2024-393	3 ARSEN.-III	220 Medica E.	99 STAMBIO	11	9.082	0.285	3.14	8.100	10.100		
2024-393	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	9.060	0.180	1.99	8.100	10.100		
2024-393	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	8.898	0.232	2.61	7.900	9.900		
2024-393	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	9.133	0.262	2.87	8.100	10.100		
2024-393	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	15	9.187	0.196	2.14	8.200	10.200		
2024-393	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	8.940	0.229	2.56	7.900	9.900		
2024-393	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	15	8.993	0.259	2.88	8.000	10.000		
2024-393	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	16	9.075	0.179	1.97	8.100	10.100		
2024-393	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	41	9.139	0.148	1.62	8.100	10.100		
2024-394	3 ARSEN.-III	165 VITROS	63 KODAK	162	5.652	0.130	2.30	4.700	6.700		
2024-394	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	34	5.676	0.159	2.80	4.700	6.700		
2024-394	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	35	6.115	0.268	4.38	5.100	7.100		
2024-394	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	6.060	0.206	3.40	5.100	7.100		
2024-394	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	12	5.692	0.144	2.53	4.700	6.700		
2024-394	3 ARSEN.-III	220 Medica E.	99 STAMBIO	11	5.609	0.188	3.35	4.600	6.600		
2024-394	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	5.740	0.174	3.04	4.700	6.700		
2024-394	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	5.700	0.374	6.56	4.700	6.700		
2024-394	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	5.709	0.232	4.06	4.700	6.700		
2024-394	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	15	5.793	0.224	3.86	4.800	6.800		
2024-394	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	5.710	0.114	1.99	4.700	6.700		
2024-394	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	15	5.360	0.218	4.08	4.400	6.400		
2024-394	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	16	5.719	0.118	2.07	4.700	6.700		
2024-394	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	41	5.803	0.111	1.91	4.800	6.800		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
010	CALCIUM, TOTAL	CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE		1.00						
2024-395	3 ARSEN.-III	165 VITROS	63 KODAK	162	12.251	0.217	1.77	11.300	13.300		
2024-395	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	34	12.553	0.289	2.30	11.600	13.600		
2024-395	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	35	12.456	0.410	3.29	11.500	13.500		
2024-395	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	12.530	0.127	1.01	11.500	13.500		
2024-395	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	12	12.258	0.330	2.69	11.300	13.300		
2024-395	3 ARSEN.-III	220 Medica E.	99 STAMBIO	11	12.273	0.374	3.05	11.300	13.300		
2024-395	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	12.450	0.609	4.89	11.500	13.500		
2024-395	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	12.035	0.371	3.08	11.000	13.000		
2024-395	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	94	12.233	0.330	2.70	11.200	13.200		
2024-395	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	15	12.293	0.249	2.02	11.300	13.300		
2024-395	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	12.020	0.282	2.35	11.000	13.000		
2024-395	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	15	12.253	0.447	3.65	11.300	13.300		
2024-395	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	16	12.281	0.313	2.55	11.300	13.300		
2024-395	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	41	12.305	0.255	2.07	11.300	13.300		
011	CHLORIDE	CLIA TEST ID #: 355	EVALUATION CRITERIA: TARGET VALUE		5 %						
2024-391	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	89.031	2.531	2.84	85.000	93.000		
2024-391	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	91.500	0.866	0.95	87.000	96.000		
2024-391	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	32	88.344	1.265	1.43	84.000	93.000		
2024-391	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	14	91.500	0.906	0.99	87.000	96.000		
2024-391	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	85.962	1.682	1.96	82.000	90.000		
2024-391	4 ISE UND-DI	165 VITROS	63 KODAK	65	90.984	1.596	1.75	86.000	96.000		
2024-391	4 ISE UND-DI	165 VITROS	63 KODAK	65	91.500	0.866	0.95	87.000	96.000		
2024-391	4 ISE UND-DI	165 VITROS	156 Kit 32	95	91.213	1.604	1.76	87.000	96.000		
2024-391	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	88.647	2.140	2.41	84.000	93.000		
2024-391	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	91.500	0.866	0.95	87.000	96.000		
2024-391	4 ISE UND-DI	220 Medica E.	130 MEDICA	12	87.250	2.165	2.48	83.000	92.000		
2024-391	5 MER NIT/DI	197 ARCHITECT	1 ABBOTT	10	91.000	1.789	1.97	86.000	96.000		
2024-391	8 IMT	219 ATELLICA	143 SIEMENS	15	92.067	2.081	2.26	87.000	97.000		
2024-391	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	92	86.380	1.292	1.50	82.000	91.000		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
011 CHLORIDE		CLIA TEST ID #: 355	EVALUATION CRITERIA: TARGET VALUE 5 %								
2024-392	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	103.839	2.875	2.77	99.000	109.000		
2024-392	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	107.000	2.236	2.09	102.000	112.000		
2024-392	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	32	100.806	1.281	1.27	96.000	106.000		
2024-392	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	14	103.615	1.273	1.23	98.000	109.000		
2024-392	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	100.113	2.246	2.24	95.000	105.000		
2024-392	4 ISE UND-DI	165 VITROS	63 KODAK	65	107.000	2.236	2.09	102.000	112.000		
2024-392	4 ISE UND-DI	165 VITROS	63 KODAK	65	103.766	2.234	2.15	99.000	109.000		
2024-392	4 ISE UND-DI	165 VITROS	156 Kit 32	95	103.840	1.394	1.34	99.000	109.000		
2024-392	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	107.000	2.236	2.09	102.000	112.000		
2024-392	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	103.706	2.663	2.57	99.000	109.000		
2024-392	4 ISE UND-DI	220 Medica E.	130 MEDICA	12	105.250	1.920	1.82	100.000	111.000		
2024-392	5 MER NIT/DI	197 ARCHITECT	1 ABBOTT	10	103.200	1.887	1.83	98.000	108.000		
2024-392	8 IMT	219 ATELLICA	143 SIEMENS	15	105.400	1.890	1.79	100.000	111.000		
2024-392	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	92	103.505	1.818	1.76	98.000	109.000		
2024-393	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	98.969	2.942	2.97	94.000	104.000		
2024-393	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	101.250	1.639	1.62	96.000	106.000		
2024-393	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	32	96.625	1.269	1.31	92.000	101.000		
2024-393	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	14	99.500	0.982	0.99	95.000	104.000		
2024-393	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	95.000	1.698	1.79	90.000	100.000		
2024-393	4 ISE UND-DI	165 VITROS	63 KODAK	65	99.031	1.811	1.83	94.000	104.000		
2024-393	4 ISE UND-DI	165 VITROS	63 KODAK	65	101.250	1.639	1.62	96.000	106.000		
2024-393	4 ISE UND-DI	165 VITROS	156 Kit 32	95	99.606	1.811	1.82	95.000	105.000		
2024-393	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	98.735	2.671	2.71	94.000	104.000		
2024-393	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	101.250	1.639	1.62	96.000	106.000		
2024-393	4 ISE UND-DI	220 Medica E.	130 MEDICA	12	98.833	2.267	2.29	94.000	104.000		
2024-393	5 MER NIT/DI	197 ARCHITECT	1 ABBOTT	10	98.300	1.735	1.76	93.000	103.000		
2024-393	8 IMT	219 ATELLICA	143 SIEMENS	15	99.933	1.879	1.88	95.000	105.000		
2024-393	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	92	97.174	1.809	1.86	92.000	102.000		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
011 CHLORIDE		CLIA TEST ID #: 355	EVALUATION CRITERIA: TARGET VALUE 5 %									
2024-394	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	85.516	2.576	3.01	81.000	90.000			
2024-394	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	86.250	0.433	0.50	82.000	91.000			
2024-394	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	32	85.688	1.356	1.58	81.000	90.000			
2024-394	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	14	88.714	1.097	1.24	84.000	93.000			
2024-394	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	82.623	2.121	2.57	78.000	87.000			
2024-394	4 ISE UND-DI	165 VITROS	63 KODAK	65	86.250	0.433	0.50	82.000	91.000			
2024-394	4 ISE UND-DI	165 VITROS	63 KODAK	65	88.531	1.489	1.68	84.000	93.000			
2024-394	4 ISE UND-DI	165 VITROS	156 Kit 32	95	88.798	1.441	1.62	84.000	93.000			
2024-394	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	86.250	0.433	0.50	82.000	91.000			
2024-394	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	84.559	2.075	2.45	80.000	89.000			
2024-394	4 ISE UND-DI	220 Medica E.	130 MEDICA	12	83.667	1.700	2.03	79.000	88.000			
2024-394	5 MER NIT/DI	197 ARCHITECT	1 ABBOTT	10	87.900	1.972	2.24	84.000	92.000			
2024-394	8 IMT	219 ATELLICA	143 SIEMENS	15	87.200	2.971	3.41	83.000	92.000			
2024-394	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	92	82.424	1.446	1.75	78.000	87.000			
2024-395	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	111.438	3.708	3.33	106.000	117.000			
2024-395	3 ISE DILUTE	184 INTEGRA	93 ROCHE	32	114.500	1.803	1.57	109.000	120.000			
2024-395	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	32	105.968	1.307	1.23	101.000	111.000			
2024-395	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	14	108.231	1.310	1.21	103.000	114.000			
2024-395	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	105.736	2.164	2.05	100.000	111.000			
2024-395	4 ISE UND-DI	165 VITROS	63 KODAK	65	109.172	2.066	1.89	104.000	115.000			
2024-395	4 ISE UND-DI	165 VITROS	63 KODAK	65	114.500	1.803	1.57	109.000	120.000			
2024-395	4 ISE UND-DI	165 VITROS	156 Kit 32	95	109.621	1.591	1.45	104.000	115.000			
2024-395	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	110.559	3.079	2.79	105.000	116.000			
2024-395	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	34	114.500	1.803	1.57	109.000	120.000			
2024-395	4 ISE UND-DI	220 Medica E.	130 MEDICA	12	112.750	2.385	2.12	107.000	118.000			
2024-395	5 MER NIT/DI	197 ARCHITECT	1 ABBOTT	10	107.600	2.059	1.91	102.000	113.000			
2024-395	8 IMT	219 ATELLICA	143 SIEMENS	15	110.600	2.185	1.98	105.000	116.000			
2024-395	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	92	110.167	1.857	1.69	105.000	116.000			



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365	EVALUATION CRITERIA: TARGET VALUE 10 %									
2024-391	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS	91	126.867	3.967	3.13	114.000	140.000			
2024-391	1 ENZYMATI	165 VITROS	63 KODAK	148	130.952	4.483	3.42	118.000	144.000			
2024-391	1 ENZYMATI	184 INTEGRA	93 ROCHE	11	130.091	2.811	2.16	117.000	143.000			
2024-391	1 ENZYMATI	191 RX-SERIES	126 RANDOX	40	142.718	7.186	5.04	128.000	157.000			
2024-391	1 ENZYMATI	194 BIOLIS-24S	154 (IDG)	10	137.800	3.544	2.57	124.000	152.000			
2024-391	1 ENZYMATI	197 ARCHITECT	1 ABBOTT	11	133.000	1.859	1.40	120.000	146.000			
2024-391	1 ENZYMATI	203 ROCHE	93 ROCHE	21	135.238	3.490	2.58	122.000	149.000			
2024-391	1 ENZYMATI	220 Medica E.	130 MEDICA	11	137.091	2.968	2.17	123.000	151.000			
2024-391	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT	12	132.167	2.267	1.72	119.000	145.000			
2024-391	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN	30	130.500	3.263	2.50	117.000	144.000			
2024-391	8 ENZYMATI	203 ROCHE	93 ROCHE	15	136.400	4.160	3.05	123.000	150.000			
2024-391	9 ENZYMATI	203 ROCHE	93 ROCHE	10	133.400	2.289	1.72	120.000	147.000			
2024-391	9 ENZYMATI	219 ATELLICA	143 SIEMENS	15	135.000	3.225	2.39	122.000	149.000			
2024-392	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS	91	194.231	6.447	3.32	175.000	214.000			
2024-392	1 ENZYMATI	165 VITROS	63 KODAK	148	221.007	7.843	3.55	199.000	243.000			
2024-392	1 ENZYMATI	184 INTEGRA	93 ROCHE	11	203.000	6.688	3.29	183.000	223.000			
2024-392	1 ENZYMATI	191 RX-SERIES	126 RANDOX	40	219.462	9.992	4.55	198.000	241.000			
2024-392	1 ENZYMATI	194 BIOLIS-24S	154 (IDG)	10	215.400	7.088	3.29	194.000	237.000			
2024-392	1 ENZYMATI	197 ARCHITECT	1 ABBOTT	11	206.455	2.536	1.23	186.000	227.000			
2024-392	1 ENZYMATI	203 ROCHE	93 ROCHE	21	210.714	4.702	2.23	190.000	232.000			
2024-392	1 ENZYMATI	220 Medica E.	130 MEDICA	11	210.909	4.907	2.33	190.000	232.000			
2024-392	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT	12	205.250	5.847	2.85	185.000	226.000			
2024-392	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN	30	202.867	4.924	2.43	183.000	223.000			
2024-392	8 ENZYMATI	203 ROCHE	93 ROCHE	15	211.533	5.726	2.71	190.000	233.000			
2024-392	9 ENZYMATI	203 ROCHE	93 ROCHE	10	210.300	8.125	3.86	189.000	231.000			
2024-392	9 ENZYMATI	219 ATELLICA	143 SIEMENS	15	214.143	4.373	2.04	193.000	236.000			
2024-393	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS	91	167.044	5.150	3.08	150.000	184.000			

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2024-393	1	ENZYMATIC	165 VITROS	63	KODAK	148	185.158	6.286	3.40	167.000	204.000	
2024-393	1	ENZYMATIC	184 INTEGRA	93	ROCHE	11	172.545	4.998	2.90	155.000	190.000	
2024-393	1	ENZYMATIC	191 RX-SERIES	126	RANDOX	40	190.436	8.611	4.52	171.000	209.000	
2024-393	1	ENZYMATIC	194 BIOLIS-24S	154	(IDG)	10	185.500	4.544	2.45	167.000	204.000	
2024-393	1	ENZYMATIC	197 ARCHITECT	1	ABBOTT	11	176.545	2.189	1.24	159.000	194.000	
2024-393	1	ENZYMATIC	203 ROCHE	93	ROCHE	21	180.000	4.711	2.62	162.000	198.000	
2024-393	1	ENZYMATIC	220 Medica E.	130	MEDICA	11	183.818	5.686	3.09	165.000	202.000	
2024-393	5	FE-SALTS-N	197 ARCHITECT	1	ABBOTT	12	175.167	4.259	2.43	158.000	193.000	
2024-393	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	30	175.133	4.624	2.64	158.000	193.000	
2024-393	8	ENZYMATIC	203 ROCHE	93	ROCHE	15	181.933	4.892	2.69	164.000	200.000	
2024-393	9	ENZYMATIC	203 ROCHE	93	ROCHE	10	180.800	3.736	2.07	163.000	199.000	
2024-393	9	ENZYMATIC	219 ATELLICA	143	SIEMENS	15	181.429	5.261	2.90	163.000	200.000	
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-394	1	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	91	112.144	4.181	3.73	101.000	123.000	
2024-394	1	ENZYMATIC	165 VITROS	63	KODAK	148	111.138	3.449	3.10	100.000	122.000	
2024-394	1	ENZYMATIC	184 INTEGRA	93	ROCHE	11	115.273	5.259	4.56	104.000	127.000	
2024-394	1	ENZYMATIC	191 RX-SERIES	126	RANDOX	40	123.487	6.437	5.21	111.000	136.000	
2024-394	1	ENZYMATIC	194 BIOLIS-24S	154	(IDG)	10	122.800	2.088	1.70	111.000	135.000	
2024-394	1	ENZYMATIC	197 ARCHITECT	1	ABBOTT	11	118.000	1.477	1.25	106.000	130.000	
2024-394	1	ENZYMATIC	203 ROCHE	93	ROCHE	21	118.714	2.292	1.93	107.000	131.000	
2024-394	1	ENZYMATIC	220 Medica E.	130	MEDICA	11	121.636	4.676	3.84	109.000	134.000	
2024-394	5	FE-SALTS-N	197 ARCHITECT	1	ABBOTT	12	116.833	2.577	2.21	105.000	129.000	
2024-394	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	30	114.567	3.052	2.66	103.000	126.000	
2024-394	8	ENZYMATIC	203 ROCHE	93	ROCHE	15	119.267	3.890	3.26	107.000	131.000	
2024-394	9	ENZYMATIC	203 ROCHE	93	ROCHE	10	118.300	2.410	2.04	106.000	130.000	
2024-394	9	ENZYMATIC	219 ATELLICA	143	SIEMENS	15	116.714	3.149	2.70	105.000	128.000	
2024-395	1	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	91	220.517	7.887	3.58	198.000	243.000	
2024-395	1	ENZYMATIC	165 VITROS	63	KODAK	148	256.347	9.261	3.61	231.000	282.000	
2024-395	1	ENZYMATIC	184 INTEGRA	93	ROCHE	11	228.545	6.358	2.78	206.000	251.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-395	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	40	251.974	15.269	6.06	227.000	277.000
2024-395	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	249.900	5.108	2.04	225.000	275.000
2024-395	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	236.182	2.480	1.05	213.000	260.000
2024-395	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	240.800	6.234	2.59	217.000	265.000
2024-395	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	241.636	4.715	1.95	217.000	266.000
2024-395	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	232.417	10.103	4.35	209.000	256.000
2024-395	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	30	231.700	5.093	2.20	209.000	255.000
2024-395	8	ENZYMATIC	203	ROCHE	93	ROCHE	15	242.267	8.820	3.64	218.000	266.000
2024-395	9	ENZYMATIC	203	ROCHE	93	ROCHE	10	238.200	5.492	2.31	214.000	262.000
2024-395	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	15	242.600	5.135	2.12	218.000	267.000
013 CHOLESTEROL, (HDL)			CLIA TEST ID #: 375			EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-391	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	48.860	2.092	4.28	34.200	63.500
2024-391	11	ENC.-COLO.	165	VITROS	63	KODAK	145	49.804	2.490	5.00	34.900	64.700
2024-391	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	30	59.363	2.661	4.48	41.600	77.200
2024-391	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	31	50.210	2.463	4.91	35.100	65.300
2024-391	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	44.405	5.868	13.22	31.100	57.700
2024-391	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	32.300	2.193	6.79	22.600	42.000
2024-391	11	ENC.-COLO.	203	ROCHE	93	ROCHE	41	58.134	2.715	4.67	40.700	75.600
2024-391	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	14	53.893	2.139	3.97	37.700	70.100
2024-391	11	ENC.-COLO.	220	Medica E.	130	MEDICA	11	44.455	2.675	6.02	31.100	57.800
2024-391	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	14	49.829	1.668	3.35	34.900	64.800
2024-391	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	88	56.127	2.842	5.06	39.300	73.000
2024-392	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	70.550	4.407	6.25	49.400	91.700
2024-392	11	ENC.-COLO.	165	VITROS	63	KODAK	145	75.628	4.384	5.80	52.900	98.300
2024-392	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	30	77.734	3.618	4.65	54.400	101.100
2024-392	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	31	75.871	2.871	3.78	53.100	98.600
2024-392	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	66.542	7.961	11.96	46.600	86.500
2024-392	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	49.100	2.844	5.79	34.400	63.800
2024-392	11	ENC.-COLO.	203	ROCHE	93	ROCHE	41	76.175	3.196	4.20	53.300	99.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2024-392	11 ENC.-COLO.	219 ATELLICA	143 SIEMENS	14	80.479	2.660	3.30	56.300	104.600			
2024-392	11 ENC.-COLO.	220 Medica E.	130 MEDICA	11	68.364	3.549	5.19	47.900	88.900			
2024-392	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT	14	72.736	2.338	3.21	50.900	94.600			
2024-392	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS	88	64.861	3.237	4.99	45.400	84.300			
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375	EVALUATION CRITERIA: TARGET VALUE 30 %									
2024-393	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT	10	62.750	2.639	4.21	43.900	81.600			
2024-393	11 ENC.-COLO.	165 VITROS	63 KODAK	145	64.544	3.299	5.11	45.200	83.900			
2024-393	11 ENC.-COLO.	184 INTEGRA	93 ROCHE	30	71.013	3.453	4.86	49.700	92.300			
2024-393	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN	31	65.826	2.896	4.40	46.100	85.600			
2024-393	11 ENC.-COLO.	191 RX-SERIES	126 RANDOX	39	57.745	6.446	11.16	40.400	75.100			
2024-393	11 ENC.-COLO.	194 BIOLIS-24S	154 (IDG)	10	43.600	2.577	5.91	30.500	56.700			
2024-393	11 ENC.-COLO.	203 ROCHE	93 ROCHE	41	69.612	3.248	4.67	48.700	90.500			
2024-393	11 ENC.-COLO.	219 ATELLICA	143 SIEMENS	14	69.450	2.670	3.84	48.600	90.300			
2024-393	11 ENC.-COLO.	220 Medica E.	130 MEDICA	11	58.273	3.744	6.42	40.800	75.800			
2024-393	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT	14	63.400	2.006	3.16	44.400	82.400			
2024-393	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS	88	62.043	2.837	4.57	43.400	80.700			
2024-394	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT	10	44.890	2.017	4.49	31.400	58.400			
2024-394	11 ENC.-COLO.	165 VITROS	63 KODAK	145	45.915	1.845	4.02	32.100	59.700			
2024-394	11 ENC.-COLO.	184 INTEGRA	93 ROCHE	30	54.493	2.638	4.84	38.100	70.800			
2024-394	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN	31	44.448	2.289	5.15	31.100	57.800			
2024-394	11 ENC.-COLO.	191 RX-SERIES	126 RANDOX	39	39.287	5.552	14.13	27.500	51.100			
2024-394	11 ENC.-COLO.	194 BIOLIS-24S	154 (IDG)	10	28.500	1.803	6.33	20.000	37.100			
2024-394	11 ENC.-COLO.	203 ROCHE	93 ROCHE	41	54.000	2.526	4.68	37.800	70.200			
2024-394	11 ENC.-COLO.	219 ATELLICA	143 SIEMENS	14	47.236	2.950	6.25	33.100	61.400			
2024-394	11 ENC.-COLO.	220 Medica E.	130 MEDICA	11	39.000	2.374	6.09	27.300	50.700			
2024-394	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT	14	44.864	1.996	4.45	31.400	58.300			
2024-394	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS	88	54.324	2.367	4.36	38.000	70.600			
2024-395	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT	10	80.600	2.973	3.69	56.400	104.800			

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-395	11 ENC.-COLO.	165 VITROS	63 KODAK		145	89.223	4.915	5.51	62.500	116.000	
2024-395	11 ENC.-COLO.	184 INTEGRA	93 ROCHE		30	83.183	3.186	3.83	58.200	108.100	
2024-395	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN		31	85.758	4.209	4.91	60.000	111.500	
2024-395	11 ENC.-COLO.	191 RX-SERIES	126 RANDOX		39	74.808	9.475	12.67	52.400	97.300	
2024-395	11 ENC.-COLO.	194 BIOLIS-24S	154 (IDG)		10	55.700	2.002	3.60	39.000	72.400	
2024-395	11 ENC.-COLO.	203 ROCHE	93 ROCHE		41	81.907	3.510	4.28	57.300	106.500	
2024-395	11 ENC.-COLO.	219 ATELLICA	143 SIEMENS		14	90.800	4.022	4.43	63.600	118.000	
2024-395	11 ENC.-COLO.	220 Medica E.	130 MEDICA		11	78.364	6.094	7.78	54.900	101.900	
2024-395	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT		14	81.371	4.017	4.94	57.000	105.800	
2024-395	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS		88	66.974	3.685	5.50	46.900	87.100	
014 CREATINE KINASE (CK)		CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 30 %							
2024-391	3 KINETIC 37	165 VITROS	63 KODAK		72	127.000	8.270	6.51	89.000	165.000	
2024-391	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN		17	124.000	8.444	6.81	87.000	161.000	
2024-391	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS		13	138.846	3.548	2.56	97.000	181.000	
2024-391	8 Hexokinase	203 ROCHE	93 ROCHE		11	134.000	4.805	3.59	94.000	174.000	
2024-391	9 SIEMENS	38 SIEMENS DI	143 SIEMENS		29	133.897	3.845	2.87	94.000	174.000	
2024-391	10 ENZYMATI-	203 ROCHE	93 ROCHE		11	134.727	4.180	3.10	94.000	175.000	
2024-392	3 KINETIC 37	165 VITROS	63 KODAK		72	427.859	21.898	5.12	300.000	556.000	
2024-392	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN		17	498.412	24.447	4.90	349.000	648.000	
2024-392	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS		13	553.692	9.449	1.71	388.000	720.000	
2024-392	8 Hexokinase	203 ROCHE	93 ROCHE		11	533.091	16.790	3.15	373.000	693.000	
2024-392	9 SIEMENS	38 SIEMENS DI	143 SIEMENS		29	537.679	11.282	2.10	376.000	699.000	
2024-392	10 ENZYMATI-	203 ROCHE	93 ROCHE		11	536.000	23.760	4.43	375.000	697.000	
2024-393	3 KINETIC 37	165 VITROS	63 KODAK		72	327.569	18.824	5.75	229.000	426.000	
2024-393	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN		17	348.941	15.895	4.56	244.000	454.000	
2024-393	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS		13	385.615	6.639	1.72	270.000	501.000	
2024-393	8 Hexokinase	203 ROCHE	93 ROCHE		11	373.273	11.694	3.13	261.000	485.000	
2024-393	9 SIEMENS	38 SIEMENS DI	143 SIEMENS		29	378.345	8.515	2.25	265.000	492.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	10 ENZYMATI	203	ROCHE	93	ROCHE	11	376.727	10.288	2.73	264.000	490.000	
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 30 %								
2024-394	3 KINETIC 37	165	VITROS	63	KODAK	72	31.000	4.412	14.23	22.000	40.000	
2024-394	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	27.176	1.790	6.59	19.000	35.000	
2024-394	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	13	33.923	2.674	7.88	24.000	44.000	
2024-394	8 Hexokinase	203	ROCHE	93	ROCHE	11	32.727	3.333	10.18	23.000	43.000	
2024-394	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	29	31.241	1.813	5.80	22.000	41.000	
2024-394	10 ENZYMATI	203	ROCHE	93	ROCHE	11	34.000	1.414	4.16	24.000	44.000	
2024-395	3 KINETIC 37	165	VITROS	63	KODAK	72	508.169	25.696	5.06	356.000	661.000	
2024-395	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	649.471	33.743	5.20	455.000	844.000	
2024-395	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	13	711.769	21.613	3.04	498.000	925.000	
2024-395	8 Hexokinase	203	ROCHE	93	ROCHE	11	685.909	27.658	4.03	480.000	892.000	
2024-395	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	29	697.241	17.459	2.50	488.000	906.000	
2024-395	10 ENZYMATI	203	ROCHE	93	ROCHE	11	688.909	18.293	2.66	482.000	896.000	
016	CREATININE	CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}								
2024-391	2 AK. PIC. N	191	RX-SERIES	126	RANDOX	26	1.636	0.083	5.05	1.340	1.940	
2024-391	2 AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	1.795	0.053	2.96	1.500	2.100	
2024-391	4 ENZYMATI	203	ROCHE	93	ROCHE	11	1.797	0.058	3.22	1.500	2.100	
2024-391	4 ENZYMATI	220	Medica E.	130	MEDICA	12	1.853	0.068	3.67	1.550	2.150	
2024-391	6 KIN. ALK P	184	INTEGRA	93	ROCHE	16	1.788	0.058	3.26	1.490	2.090	
2024-391	6 KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	34	1.736	0.066	3.78	1.440	2.040	
2024-391	6 KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	1.744	0.059	3.37	1.440	2.040	
2024-391	6 KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	1.740	0.047	2.71	1.440	2.040	
2024-391	6 KIN. ALK P	203	ROCHE	93	ROCHE	27	1.772	0.079	4.45	1.470	2.070	
2024-391	8 IDMS-CREA	165	VITROS	63	KODAK	160	1.749	0.062	3.54	1.450	2.050	
2024-391	9 MODIFIED	219	ATELLICA	143	SIEMENS	15	1.669	0.045	2.70	1.370	1.970	
2024-391	10 JAFFE COMP	184	INTEGRA	93	ROCHE	10	1.814	0.055	3.05	1.510	2.110	
2024-391	11 IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	86	1.832	0.072	3.93	1.530	2.130	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
016 CREATININE		CLIA TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}									
2024-392	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	26	4.512	0.234	5.18	4.060	4.960			
2024-392	2 AK. PIC. N	194 BIOLIS-24S	154 (IDG)	10	5.212	0.129	2.48	4.690	5.730			
2024-392	4 ENZYMATIC	203 ROCHE	93 ROCHE	11	5.216	0.151	2.89	4.690	5.740			
2024-392	4 ENZYMATIC	220 Medica E.	130 MEDICA	12	5.470	0.153	2.80	4.920	6.020			
2024-392	6 KIN. ALK P	184 INTEGRA	93 ROCHE	16	5.051	0.158	3.12	4.550	5.560			
2024-392	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	34	5.271	0.163	3.09	4.740	5.800			
2024-392	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	5.913	0.167	2.83	5.320	6.500			
2024-392	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	5.724	0.105	1.83	5.150	6.300			
2024-392	6 KIN. ALK P	203 ROCHE	93 ROCHE	27	5.086	0.180	3.54	4.580	5.590			
2024-392	8 IDMS-CREA	165 VITROS	63 KODAK	160	5.402	0.159	2.95	4.860	5.940			
2024-392	9 MODIFIED	219 ATELLICA	143 SIEMENS	15	5.181	0.111	2.14	4.660	5.700			
2024-392	10 JAFFE COMP	184 INTEGRA	93 ROCHE	10	5.043	0.263	5.21	4.540	5.550			
2024-392	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	86	5.502	0.131	2.38	4.950	6.050			
2024-393	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	26	3.412	0.251	7.36	3.070	3.750			
2024-393	2 AK. PIC. N	194 BIOLIS-24S	154 (IDG)	10	3.852	0.114	2.95	3.470	4.240			
2024-393	4 ENZYMATIC	203 ROCHE	93 ROCHE	11	3.906	0.116	2.96	3.520	4.300			
2024-393	4 ENZYMATIC	220 Medica E.	130 MEDICA	12	4.029	0.086	2.14	3.630	4.430			
2024-393	6 KIN. ALK P	184 INTEGRA	93 ROCHE	16	3.797	0.124	3.26	3.420	4.180			
2024-393	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	34	3.889	0.119	3.06	3.500	4.280			
2024-393	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	4.121	0.072	1.74	3.710	4.530			
2024-393	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	4.189	0.045	1.07	3.770	4.610			
2024-393	6 KIN. ALK P	203 ROCHE	93 ROCHE	27	3.832	0.138	3.60	3.450	4.220			
2024-393	8 IDMS-CREA	165 VITROS	63 KODAK	160	3.967	0.117	2.95	3.570	4.360			
2024-393	9 MODIFIED	219 ATELLICA	143 SIEMENS	15	3.779	0.057	1.51	3.400	4.160			
2024-393	10 JAFFE COMP	184 INTEGRA	93 ROCHE	10	3.796	0.176	4.64	3.420	4.180			
2024-393	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	86	3.997	0.105	2.63	3.600	4.400			
2024-394	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	26	0.922	0.091	9.92	0.620	1.220			

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-394	2	AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	1.037	0.058	5.64	0.740	1.340
2024-394	4	ENZYMATIC	203	ROCHE	93	ROCHE	11	0.886	0.055	6.18	0.590	1.190
2024-394	4	ENZYMATIC	220	Medica E.	130	MEDICA	12	0.972	0.049	5.07	0.670	1.270
2024-394	6	KIN. ALK P	184	INTEGRA	93	ROCHE	16	0.903	0.069	7.64	0.600	1.200
2024-394	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	34	0.859	0.048	5.54	0.560	1.160
2024-394	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	0.800	0.024	3.06	0.500	1.100
2024-394	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	0.804	0.030	3.77	0.500	1.100
2024-394	6	KIN. ALK P	203	ROCHE	93	ROCHE	27	0.865	0.044	5.11	0.570	1.170
2024-394	8	IDMS-CREA	165	VITROS	63	KODAK	160	0.881	0.037	4.24	0.580	1.180
2024-394	9	MODIFIED	219	ATELLICA	143	SIEMENS	15	0.807	0.060	7.47	0.510	1.110
2024-394	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	0.918	0.032	3.44	0.620	1.220
2024-394	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	86	0.849	0.058	6.79	0.550	1.150
016	CREATININE	CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2024-395	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	26	5.587	0.329	5.90	5.030	6.150
2024-395	2	AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	6.616	0.172	2.59	5.950	7.280
2024-395	4	ENZYMATIC	203	ROCHE	93	ROCHE	11	6.450	0.255	3.95	5.810	7.100
2024-395	4	ENZYMATIC	220	Medica E.	130	MEDICA	12	7.005	0.153	2.18	6.300	7.710
2024-395	6	KIN. ALK P	184	INTEGRA	93	ROCHE	16	6.149	0.221	3.60	5.530	6.760
2024-395	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	34	6.620	0.212	3.20	5.960	7.280
2024-395	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	7.385	0.297	4.02	6.650	8.120
2024-395	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	7.516	0.081	1.07	6.760	8.270
2024-395	6	KIN. ALK P	203	ROCHE	93	ROCHE	27	6.315	0.238	3.76	5.680	6.950
2024-395	8	IDMS-CREA	165	VITROS	63	KODAK	160	6.887	0.228	3.31	6.200	7.580
2024-395	9	MODIFIED	219	ATELLICA	143	SIEMENS	15	6.539	0.156	2.38	5.880	7.190
2024-395	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	6.205	0.341	5.49	5.580	6.830
2024-395	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	86	6.998	0.159	2.27	6.300	7.700
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2024-391	3	GL. OXI. C	165	VITROS	63	KODAK	163	56.800	1.532	2.70	51.000	63.000
2024-391	3	GL. OXI. C	214	Envoy 500	150	ELITECH	10	58.900	1.700	2.89	53.000	65.000
2024-391	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	62.699	1.882	3.00	56.000	69.000



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-391	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	58.900	2.300	3.90	53.000	65.000
2024-391	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	34	58.882	1.278	2.17	53.000	65.000
2024-391	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	32	63.355	2.572	4.06	57.000	70.000
2024-391	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	56.800	1.249	2.20	51.000	63.000
2024-391	5	HEXOKINASE	203	ROCHE	93	ROCHE	30	58.433	1.230	2.10	52.000	64.000
2024-391	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	58.100	1.446	2.49	52.000	64.000
2024-391	6	HEXOKI. CO	220	Medica E.	130	MEDICA	12	61.167	2.609	4.26	55.000	67.000
2024-391	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	59.048	1.558	2.64	53.000	65.000
2024-391	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	56.714	0.795	1.40	51.000	63.000
2024-391	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	58.045	1.331	2.29	52.000	64.000
2024-391	12	HEXOKINASE	219	APELLICA	143	SIEMENS	15	58.733	1.436	2.45	53.000	65.000
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2024-392	3	GL. OXI. C	165	VITROS	63	KODAK	163	134.758	3.046	2.26	121.000	148.000
2024-392	3	GL. OXI. C	214	Envoy 500	150	ELITECH	10	133.000	3.376	2.54	120.000	146.000
2024-392	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	140.699	2.850	2.03	127.000	155.000
2024-392	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	132.600	4.128	3.11	119.000	146.000
2024-392	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	34	133.676	2.687	2.01	120.000	147.000
2024-392	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	32	135.645	5.391	3.97	122.000	149.000
2024-392	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	131.800	4.377	3.32	119.000	145.000
2024-392	5	HEXOKINASE	203	ROCHE	93	ROCHE	30	133.000	3.173	2.39	120.000	146.000
2024-392	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	129.200	3.655	2.83	116.000	142.000
2024-392	6	HEXOKI. CO	220	Medica E.	130	MEDICA	12	141.000	3.958	2.81	127.000	155.000
2024-392	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	134.238	3.379	2.52	121.000	148.000
2024-392	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	130.571	2.290	1.75	118.000	144.000
2024-392	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	132.227	3.860	2.92	119.000	145.000
2024-392	12	HEXOKINASE	219	APELLICA	143	SIEMENS	15	130.786	1.372	1.05	118.000	144.000
2024-393	3	GL. OXI. C	165	VITROS	63	KODAK	163	103.758	2.691	2.59	93.000	114.000
2024-393	3	GL. OXI. C	214	Envoy 500	150	ELITECH	10	104.300	3.195	3.06	94.000	115.000
2024-393	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	109.293	2.234	2.04	98.000	120.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	103.700	3.951	3.81	93.000	114.000
2024-393	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	34	104.353	2.460	2.36	94.000	115.000
2024-393	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	32	107.258	4.428	4.13	97.000	118.000
2024-393	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	101.300	2.100	2.07	91.000	111.000
2024-393	5	HEXOKINASE	203	ROCHE	93	ROCHE	30	103.500	2.062	1.99	93.000	114.000
2024-393	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	101.800	2.638	2.59	92.000	112.000
2024-393	6	HEXOKI. CO	220	Medica E.	130	MEDICA	12	109.417	3.475	3.18	98.000	120.000
2024-393	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	104.524	3.018	2.89	94.000	115.000
2024-393	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	101.286	1.221	1.21	91.000	111.000
2024-393	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	102.636	2.805	2.73	92.000	113.000
2024-393	12	HEXOKINASE	219	APELLICA	143	SIEMENS	15	102.133	1.147	1.12	92.000	112.000
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2024-394	3	GL. OXI. C	165	VITROS	63	KODAK	163	37.205	1.211	3.26	31.000	43.000
2024-394	3	GL. OXI. C	214	Envoy 500	150	ELITECH	10	41.100	1.044	2.54	35.000	47.000
2024-394	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	43.925	1.554	3.54	38.000	50.000
2024-394	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	40.900	1.578	3.86	35.000	47.000
2024-394	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	34	40.676	1.277	3.14	35.000	47.000
2024-394	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	32	45.290	1.708	3.77	39.000	51.000
2024-394	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	38.800	0.872	2.25	33.000	45.000
2024-394	5	HEXOKINASE	203	ROCHE	93	ROCHE	30	40.500	0.957	2.36	35.000	47.000
2024-394	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	42.200	1.470	3.48	36.000	48.000
2024-394	6	HEXOKI. CO	220	Medica E.	130	MEDICA	12	43.083	2.060	4.78	37.000	49.000
2024-394	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	40.800	1.030	2.52	35.000	47.000
2024-394	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	38.857	0.639	1.64	33.000	45.000
2024-394	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	40.273	0.914	2.27	34.000	46.000
2024-394	12	HEXOKINASE	219	APELLICA	143	SIEMENS	15	40.667	0.943	2.32	35.000	47.000
2024-395	3	GL. OXI. C	165	VITROS	63	KODAK	163	168.932	3.780	2.24	152.000	186.000
2024-395	3	GL. OXI. C	214	Envoy 500	150	ELITECH	10	164.400	2.691	1.64	148.000	181.000
2024-395	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	171.667	3.688	2.15	155.000	189.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-395	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	162.800	6.400	3.93	147.000	179.000
2024-395	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	34	163.206	4.248	2.60	147.000	180.000
2024-395	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	32	164.968	6.250	3.79	148.000	181.000
2024-395	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	161.000	3.033	1.88	145.000	177.000
2024-395	5	HEXOKINASE	203	ROCHE	93	ROCHE	30	164.000	4.195	2.56	148.000	180.000
2024-395	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	160.300	4.540	2.83	144.000	176.000
2024-395	6	HEXOKI. CO	220	Medica E.	130	MEDICA	12	172.333	5.022	2.91	155.000	190.000
2024-395	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	164.381	3.970	2.42	148.000	181.000
2024-395	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	160.154	2.348	1.47	144.000	176.000
2024-395	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	162.182	5.193	3.20	146.000	178.000
2024-395	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	15	159.400	3.574	2.24	143.000	175.000
018	IRON, TOTAL		CLIA TEST ID #: 425			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-391	4	COULOMETR.	165	VITROS	63	KODAK	17	94.471	6.204	6.57	76.000	113.000
2024-392	4	COULOMETR.	165	VITROS	63	KODAK	17	293.176	9.721	3.32	235.000	352.000
2024-393	4	COULOMETR.	165	VITROS	63	KODAK	17	207.647	7.992	3.85	166.000	249.000
2024-394	4	COULOMETR.	165	VITROS	63	KODAK	17	52.000	4.472	8.60	42.000	62.000
2024-395	4	COULOMETR.	165	VITROS	63	KODAK	17	394.824	10.869	2.75	316.000	474.000
019	LACTASE DEHY. (LDH)		CLIA TEST ID #: 435									
2024-391	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	138.947	11.237	8.09	111.000	167.000
2024-391	6	NADH	203	ROCHE	93	ROCHE	25	174.792	4.848	2.77	140.000	210.000
2024-391	6	NADH	219	ATELLICA	143	SIEMENS	13	173.769	2.665	1.53	139.000	209.000
2024-391	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	163.667	6.839	4.18	131.000	196.000
2024-391	9	LDH1	165	VITROS	63	KODAK	70	217.286	8.252	3.80	174.000	261.000
2024-392	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	491.316	39.850	8.11	393.000	590.000
2024-392	6	NADH	203	ROCHE	93	ROCHE	25	608.583	19.196	3.15	487.000	730.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-392	6	NADH	219	APELLICA	143	SIEMENS	13	587.000	14.353	2.45	470.000	704.000
2024-392	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	586.167	18.667	3.18	469.000	703.000
2024-392	9	LDH1	165	VITROS	63	KODAK	70	753.243	41.254	5.48	603.000	904.000
019 LACTASE DEHY. (LDH)			CLIA TEST ID #: 435			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-393	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	351.474	28.304	8.05	281.000	422.000
2024-393	6	NADH	203	ROCHE	93	ROCHE	25	437.708	14.022	3.20	350.000	525.000
2024-393	6	NADH	219	APELLICA	143	SIEMENS	13	423.462	11.077	2.62	339.000	508.000
2024-393	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	416.528	12.722	3.05	333.000	500.000
2024-393	9	LDH1	165	VITROS	63	KODAK	70	536.188	20.914	3.90	429.000	643.000
2024-394	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	49.684	3.934	7.92	40.000	60.000
2024-394	6	NADH	203	ROCHE	93	ROCHE	25	64.458	3.304	5.13	52.000	77.000
2024-394	6	NADH	219	APELLICA	143	SIEMENS	13	61.167	1.675	2.74	49.000	73.000
2024-394	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	58.861	5.618	9.54	47.000	71.000
2024-394	9	LDH1	165	VITROS	63	KODAK	70	81.536	3.877	4.75	65.000	98.000
2024-395	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	631.158	53.218	8.43	505.000	757.000
2024-395	6	NADH	203	ROCHE	93	ROCHE	25	777.333	21.646	2.78	622.000	933.000
2024-395	6	NADH	219	APELLICA	143	SIEMENS	13	752.462	38.693	5.14	602.000	903.000
2024-395	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	753.222	20.678	2.75	603.000	904.000
2024-395	9	LDH1	165	VITROS	63	KODAK	70	931.956	60.604	6.50	746.000	1118.000
021 MAGNESIUM			CLIA TEST ID #: 455			EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-391	5	COLOR./K E	165	VITROS	63	KODAK	28	2.104	0.063	2.97	1.600	2.600
2024-392	5	COLOR./K E	165	VITROS	63	KODAK	28	5.007	0.128	2.56	3.800	6.300
2024-393	5	COLOR./K E	165	VITROS	63	KODAK	28	3.857	0.094	2.44	2.900	4.800
2024-394	5	COLOR./K E	165	VITROS	63	KODAK	28	1.354	0.057	4.18	1.000	1.700

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
021	MAGNESIUM	CLIA TEST ID #: 455		EVALUATION CRITERIA: TARGET VALUE 25 %								
2024-395	5	COLOR./K E	165 VITROS	63	KODAK	28	6.196	0.123	1.99	4.600	7.700	
022	POTASSIUM	CLIA TEST ID #: 465		EVALUATION CRITERIA: TARGET VALUE 1.00								
2024-391	3	ISE DILUT.	184 INTEGRA	93	ROCHE	30	2.597	0.041	1.59	1.600	3.600	
2024-391	3	ISE DILUT.	186 BECK. COUL	76	AU-BECKMAN	33	2.600	0.055	2.12	1.600	3.600	
2024-391	3	ISE DILUT.	197 ARCHITECT	1	ABBOTT	15	2.587	0.050	1.93	1.600	3.600	
2024-391	3	ISE DILUT.	203 ROCHE	93	ROCHE	54	2.628	0.073	2.78	1.600	3.600	
2024-391	4	ISE UNDIL.	165 VITROS	63	KODAK	66	2.565	0.062	2.41	1.600	3.600	
2024-391	4	ISE UNDIL.	165 VITROS	156	Kit 32	95	2.548	0.060	2.35	1.500	3.500	
2024-391	4	ISE UNDIL.	191 RX-SERIES	126	RANDOX	33	2.709	0.119	4.39	1.700	3.700	
2024-391	4	ISE UNDIL.	220 Medica E.	130	MEDICA	12	2.482	0.039	1.55	1.500	3.500	
2024-391	5	IMT	219 ATELLICA	143	SIEMENS	15	2.533	0.060	2.35	1.500	3.500	
2024-391	6	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	91	2.519	0.047	1.85	1.500	3.500	
2024-392	3	ISE DILUT.	184 INTEGRA	93	ROCHE	30	5.045	0.093	1.85	4.000	6.000	
2024-392	3	ISE DILUT.	186 BECK. COUL	76	AU-BECKMAN	33	4.956	0.061	1.23	4.000	6.000	
2024-392	3	ISE DILUT.	197 ARCHITECT	1	ABBOTT	15	5.067	0.087	1.72	4.100	6.100	
2024-392	3	ISE DILUT.	203 ROCHE	93	ROCHE	54	5.074	0.095	1.88	4.100	6.100	
2024-392	4	ISE UNDIL.	165 VITROS	63	KODAK	66	5.083	0.109	2.14	4.100	6.100	
2024-392	4	ISE UNDIL.	165 VITROS	156	Kit 32	95	5.058	0.098	1.93	4.100	6.100	
2024-392	4	ISE UNDIL.	191 RX-SERIES	126	RANDOX	33	4.948	0.174	3.52	3.900	5.900	
2024-392	4	ISE UNDIL.	220 Medica E.	130	MEDICA	12	4.908	0.155	3.16	3.900	5.900	
2024-392	5	IMT	219 ATELLICA	143	SIEMENS	15	4.940	0.071	1.44	3.900	5.900	
2024-392	6	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	91	5.013	0.079	1.57	4.000	6.000	
2024-393	3	ISE DILUT.	184 INTEGRA	93	ROCHE	30	4.073	0.093	2.28	3.100	5.100	
2024-393	3	ISE DILUT.	186 BECK. COUL	76	AU-BECKMAN	33	4.012	0.069	1.71	3.000	5.000	
2024-393	3	ISE DILUT.	197 ARCHITECT	1	ABBOTT	15	4.033	0.060	1.48	3.000	5.000	
2024-393	3	ISE DILUT.	203 ROCHE	93	ROCHE	54	4.100	0.082	1.99	3.100	5.100	
2024-393	4	ISE UNDIL.	165 VITROS	63	KODAK	66	4.068	0.073	1.78	3.100	5.100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	4	ISE UNLIL.	165	VITROS	156	Kit 32	95	4.067	0.085	2.08	3.100	5.100
2024-393	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	33	4.076	0.126	3.08	3.100	5.100
2024-393	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	3.925	0.101	2.57	2.900	4.900
2024-393	5	IMT	219	ATELLICA	143	SIEMENS	15	3.953	0.050	1.26	3.000	5.000
2024-393	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	4.013	0.067	1.67	3.000	5.000
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 1.00						
2024-394	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	2.007	0.036	1.82	1.000	3.000
2024-394	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	33	2.091	0.045	2.16	1.100	3.100
2024-394	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	2.013	0.034	1.69	1.000	3.000
2024-394	3	ISE DILUT.	203	ROCHE	93	ROCHE	54	2.066	0.085	4.09	1.100	3.100
2024-394	4	ISE UNLIL.	165	VITROS	63	KODAK	66	2.003	0.046	2.31	1.000	3.000
2024-394	4	ISE UNLIL.	165	VITROS	156	Kit 32	95	1.999	0.049	2.47	1.000	3.000
2024-394	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	33	2.179	0.117	5.39	1.200	3.200
2024-394	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	1.992	0.049	2.48	1.000	3.000
2024-394	5	IMT	219	ATELLICA	143	SIEMENS	15	1.986	0.035	1.76	1.000	3.000
2024-394	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	1.942	0.054	2.76	0.900	2.900
2024-395	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	6.045	0.107	1.77	5.000	7.000
2024-395	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	33	5.936	0.101	1.70	4.900	6.900
2024-395	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	6.057	0.105	1.73	5.100	7.100
2024-395	3	ISE DILUT.	203	ROCHE	93	ROCHE	54	6.081	0.102	1.68	5.100	7.100
2024-395	4	ISE UNLIL.	165	VITROS	63	KODAK	66	6.132	0.127	2.06	5.100	7.100
2024-395	4	ISE UNLIL.	165	VITROS	156	Kit 32	95	6.137	0.099	1.61	5.100	7.100
2024-395	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	33	5.927	0.219	3.70	4.900	6.900
2024-395	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	5.933	0.225	3.79	4.900	6.900
2024-395	5	IMT	219	ATELLICA	143	SIEMENS	15	5.907	0.057	0.97	4.900	6.900
2024-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	6.019	0.086	1.43	5.000	7.000
023	SODIUM	CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00						
2024-391	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	127.593	1.910	1.50	124.000	132.000
2024-391	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	127.939	1.705	1.33	124.000	132.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-391	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	127.857	2.100	1.64	124.000	132.000
2024-391	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	128.833	1.462	1.14	125.000	133.000
2024-391	3	ISE DILUTE	203	ROCHE	93	ROCHE	48	128.625	1.932	1.50	125.000	133.000
2024-391	4	ISE UNLIL.	165	VITROS	63	KODAK	61	127.617	1.942	1.52	124.000	132.000
2024-391	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	127.633	2.017	1.58	124.000	132.000
2024-391	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	32	129.219	3.130	2.42	125.000	133.000
2024-391	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	127.182	1.466	1.15	123.000	131.000
2024-391	5	IMT	197	ARCHITECT	1	ABBOTT	12	126.917	1.891	1.49	123.000	131.000
2024-391	5	IMT	219	ATELLICA	143	SIEMENS	15	128.267	1.611	1.26	124.000	132.000
2024-391	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	130.000	1.700	1.31	126.000	134.000
023 SODIUM			CLIA TEST ID #: 475			EVALUATION CRITERIA: TARGET VALUE 4.00						
2024-392	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	147.115	2.207	1.50	143.000	151.000
2024-392	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	141.857	1.726	1.22	138.000	146.000
2024-392	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	147.813	1.960	1.33	144.000	152.000
2024-392	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	149.500	2.102	1.41	146.000	154.000
2024-392	3	ISE DILUTE	203	ROCHE	93	ROCHE	48	148.396	2.187	1.47	144.000	152.000
2024-392	4	ISE UNLIL.	165	VITROS	63	KODAK	61	152.217	3.061	2.01	148.000	156.000
2024-392	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	151.657	2.104	1.39	148.000	156.000
2024-392	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	32	150.125	2.643	1.76	146.000	154.000
2024-392	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	148.636	2.422	1.63	145.000	153.000
2024-392	5	IMT	197	ARCHITECT	1	ABBOTT	12	148.000	1.044	0.71	144.000	152.000
2024-392	5	IMT	219	ATELLICA	143	SIEMENS	15	146.533	1.996	1.36	143.000	151.000
2024-392	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	148.242	2.061	1.39	144.000	152.000
2024-393	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	139.926	3.701	2.65	136.000	144.000
2024-393	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	141.091	2.234	1.58	137.000	145.000
2024-393	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	137.714	2.491	1.81	134.000	142.000
2024-393	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	141.250	1.233	0.87	137.000	145.000
2024-393	3	ISE DILUTE	203	ROCHE	93	ROCHE	48	141.354	2.046	1.45	137.000	145.000
2024-393	4	ISE UNLIL.	165	VITROS	63	KODAK	61	142.750	2.211	1.55	139.000	147.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	143.184	2.042	1.43	139.000	147.000
2024-393	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	32	142.688	2.567	1.80	139.000	147.000
2024-393	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	141.000	2.558	1.81	137.000	145.000
2024-393	5	IMT	197	ARCHITECT	1	ABBOTT	12	139.833	1.908	1.36	136.000	144.000
2024-393	5	IMT	219	ATELLICA	143	SIEMENS	15	139.133	1.408	1.01	135.000	143.000
2024-393	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	141.681	1.944	1.37	138.000	146.000
023	SODIUM		CLIA TEST ID #: 475		EVALUATION CRITERIA: TARGET VALUE 4.00							
2024-394	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	123.154	1.833	1.49	119.000	127.000
2024-394	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	124.429	1.294	1.04	120.000	128.000
2024-394	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	123.576	1.776	1.44	120.000	128.000
2024-394	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	123.667	1.179	0.95	120.000	128.000
2024-394	3	ISE DILUTE	203	ROCHE	93	ROCHE	48	123.813	1.787	1.44	120.000	128.000
2024-394	4	ISE UNLIL.	165	VITROS	63	KODAK	61	122.567	1.995	1.63	119.000	127.000
2024-394	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	122.242	1.652	1.35	118.000	126.000
2024-394	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	32	123.516	1.776	1.44	120.000	128.000
2024-394	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	123.273	1.543	1.25	119.000	127.000
2024-394	5	IMT	197	ARCHITECT	1	ABBOTT	12	121.500	1.756	1.45	118.000	126.000
2024-394	5	IMT	219	ATELLICA	143	SIEMENS	15	123.600	1.583	1.28	120.000	128.000
2024-394	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	125.565	1.569	1.25	122.000	130.000
2024-395	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	155.074	2.788	1.80	151.000	159.000
2024-395	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	155.394	2.674	1.72	151.000	159.000
2024-395	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	148.714	0.881	0.59	145.000	153.000
2024-395	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	157.364	2.144	1.36	153.000	161.000
2024-395	3	ISE DILUTE	203	ROCHE	93	ROCHE	48	156.383	2.208	1.41	152.000	160.000
2024-395	4	ISE UNLIL.	165	VITROS	63	KODAK	61	161.967	2.607	1.61	158.000	166.000
2024-395	4	ISE UNLIL.	165	VITROS	156	Kit 32	100	162.384	2.295	1.41	158.000	166.000
2024-395	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	32	159.500	2.905	1.82	156.000	164.000
2024-395	4	ISE UNLIL.	220	Medica E.	130	MEDICA	12	157.818	3.069	1.94	154.000	162.000
2024-395	5	IMT	197	ARCHITECT	1	ABBOTT	12	155.667	1.106	0.71	152.000	160.000



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-395	5	IMT	219	ATELLICA	143	SIEMENS	15	152.733	1.340	0.88	149.000	157.000
2024-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	155.256	2.142	1.38	151.000	159.000
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-391	1	BIURET	38	SIEMENS DI	143	SIEMENS	92	3.755	0.089	2.37	3.400	4.100
2024-391	1	BIURET	165	VITROS	63	KODAK	146	3.774	0.114	3.01	3.400	4.200
2024-391	1	BIURET	184	INTEGRA	93	ROCHE	18	3.583	0.138	3.86	3.200	3.900
2024-391	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	3.628	0.091	2.51	3.300	4.000
2024-391	1	BIURET	191	RX-SERIES	126	RANDOX	33	3.697	0.153	4.14	3.300	4.100
2024-391	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	3.970	0.127	3.20	3.600	4.400
2024-391	1	BIURET	197	ARCHITECT	1	ABBOTT	21	3.552	0.096	2.69	3.200	3.900
2024-391	1	BIURET	203	ROCHE	93	ROCHE	45	3.716	0.082	2.19	3.300	4.100
2024-391	1	BIURET	219	ATELLICA	143	SIEMENS	15	3.667	0.114	3.10	3.300	4.000
2024-391	1	BIURET	220	Medica E.	130	MEDICA	10	3.500	0.167	4.78	3.200	3.900
2024-391	3	BIURET COL	203	ROCHE	93	ROCHE	10	3.640	0.120	3.30	3.300	4.000
2024-392	1	BIURET	38	SIEMENS DI	143	SIEMENS	92	7.099	0.159	2.24	6.400	7.800
2024-392	1	BIURET	165	VITROS	63	KODAK	146	6.794	0.178	2.62	6.100	7.500
2024-392	1	BIURET	184	INTEGRA	93	ROCHE	18	6.617	0.186	2.82	6.000	7.300
2024-392	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	6.826	0.137	2.00	6.100	7.500
2024-392	1	BIURET	191	RX-SERIES	126	RANDOX	33	6.881	0.201	2.92	6.200	7.600
2024-392	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	7.480	0.232	3.10	6.700	8.200
2024-392	1	BIURET	197	ARCHITECT	1	ABBOTT	21	6.962	0.095	1.36	6.300	7.700
2024-392	1	BIURET	203	ROCHE	93	ROCHE	45	6.840	0.153	2.23	6.200	7.500
2024-392	1	BIURET	219	ATELLICA	143	SIEMENS	15	6.920	0.111	1.60	6.200	7.600
2024-392	1	BIURET	220	Medica E.	130	MEDICA	10	6.600	0.219	3.32	5.900	7.300
2024-392	3	BIURET COL	203	ROCHE	93	ROCHE	10	6.870	0.269	3.91	6.200	7.600
2024-393	1	BIURET	38	SIEMENS DI	143	SIEMENS	92	5.786	0.121	2.09	5.200	6.400
2024-393	1	BIURET	165	VITROS	63	KODAK	146	5.608	0.138	2.46	5.000	6.200
2024-393	1	BIURET	184	INTEGRA	93	ROCHE	18	5.417	0.186	3.44	4.900	6.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	5.565	0.121	2.17	5.000	6.100
2024-393	1	BIURET	191	RX-SERIES	126	RANDOX	33	5.609	0.208	3.71	5.000	6.200
2024-393	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	6.100	0.155	2.54	5.500	6.700
2024-393	1	BIURET	197	ARCHITECT	1	ABBOTT	21	5.581	0.079	1.42	5.000	6.100
2024-393	1	BIURET	203	ROCHE	93	ROCHE	45	5.636	0.098	1.74	5.100	6.200
2024-393	1	BIURET	219	ATELLICA	143	SIEMENS	15	5.587	0.136	2.43	5.000	6.100
2024-393	1	BIURET	220	Medica E.	130	MEDICA	10	5.370	0.190	3.54	4.800	5.900
2024-393	3	BIURET COL	203	ROCHE	93	ROCHE	10	5.670	0.179	3.16	5.100	6.200
024 TOTAL PROTEIN			CLIA TEST ID #: 485			EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-394	1	BIURET	38	SIEMENS DI	143	SIEMENS	92	2.998	0.091	3.03	2.700	3.300
2024-394	1	BIURET	165	VITROS	63	KODAK	146	3.017	0.092	3.07	2.700	3.300
2024-394	1	BIURET	184	INTEGRA	93	ROCHE	18	2.861	0.125	4.38	2.600	3.100
2024-394	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	2.880	0.079	2.75	2.600	3.200
2024-394	1	BIURET	191	RX-SERIES	126	RANDOX	33	2.935	0.093	3.18	2.600	3.200
2024-394	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	3.120	0.098	3.14	2.800	3.400
2024-394	1	BIURET	197	ARCHITECT	1	ABBOTT	21	2.781	0.079	2.86	2.500	3.100
2024-394	1	BIURET	203	ROCHE	93	ROCHE	45	2.964	0.070	2.38	2.700	3.300
2024-394	1	BIURET	219	ATELLICA	143	SIEMENS	15	2.800	0.225	8.04	2.500	3.100
2024-394	1	BIURET	220	Medica E.	130	MEDICA	10	2.840	0.206	7.25	2.600	3.100
2024-394	3	BIURET COL	203	ROCHE	93	ROCHE	10	2.950	0.081	2.73	2.700	3.200
2024-395	1	BIURET	38	SIEMENS DI	143	SIEMENS	92	8.427	0.193	2.29	7.600	9.300
2024-395	1	BIURET	165	VITROS	63	KODAK	146	8.127	0.202	2.48	7.300	8.900
2024-395	1	BIURET	184	INTEGRA	93	ROCHE	18	7.789	0.285	3.65	7.000	8.600
2024-395	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	8.087	0.183	2.26	7.300	8.900
2024-395	1	BIURET	191	RX-SERIES	126	RANDOX	33	8.106	0.286	3.53	7.300	8.900
2024-395	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	8.960	0.174	1.95	8.100	9.900
2024-395	1	BIURET	197	ARCHITECT	1	ABBOTT	21	8.340	0.139	1.67	7.500	9.200
2024-395	1	BIURET	203	ROCHE	93	ROCHE	45	8.093	0.178	2.19	7.300	8.900
2024-395	1	BIURET	219	ATELLICA	143	SIEMENS	15	8.167	0.140	1.71	7.400	9.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-395	1	BIURET	220	Medica E.	130	MEDICA	10	7.710	0.145	1.88	6.900	8.500
2024-395	3	BIURET COL	203	ROCHE	93	ROCHE	10	8.090	0.202	2.50	7.300	8.900
025 TRIGLYCERIDES		CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-391	2	ENZ. COLO.	165	VITROS	63	KODAK	148	115.658	3.741	3.23	87.000	145.000
2024-391	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	14	105.571	2.382	2.26	79.000	132.000
2024-391	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	104.083	2.448	2.35	78.000	130.000
2024-391	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	99.636	5.415	5.43	75.000	125.000
2024-391	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	91	94.429	3.445	3.65	71.000	118.000
2024-391	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	96.417	2.691	2.79	72.000	121.000
2024-391	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	31	105.742	4.008	3.79	79.000	132.000
2024-391	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	33	103.091	6.264	6.08	77.000	129.000
2024-391	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	103.929	2.658	2.56	78.000	130.000
2024-391	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	104.731	2.580	2.46	79.000	131.000
2024-391	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	15	102.800	4.679	4.55	77.000	129.000
2024-391	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	96.000	1.651	1.72	72.000	120.000
2024-392	2	ENZ. COLO.	165	VITROS	63	KODAK	148	226.555	6.568	2.90	170.000	283.000
2024-392	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	14	185.429	4.821	2.60	139.000	232.000
2024-392	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	184.875	5.142	2.78	139.000	231.000
2024-392	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	171.636	6.786	3.95	129.000	215.000
2024-392	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	91	184.824	4.750	2.57	139.000	231.000
2024-392	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	182.667	5.603	3.07	137.000	228.000
2024-392	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	31	196.516	6.554	3.34	147.000	246.000
2024-392	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	33	184.031	9.319	5.06	138.000	230.000
2024-392	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	184.429	5.888	3.19	138.000	231.000
2024-392	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	185.192	3.962	2.14	139.000	231.000
2024-392	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	15	187.333	8.340	4.45	141.000	234.000
2024-392	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	180.273	2.895	1.61	135.000	225.000
2024-393	2	ENZ. COLO.	165	VITROS	63	KODAK	148	183.082	6.072	3.32	137.000	229.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	14	156.500	5.382	3.44	117.000	196.000
2024-393	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	154.042	3.802	2.47	116.000	193.000
2024-393	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	143.364	3.724	2.60	108.000	179.000
2024-393	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	91	149.286	3.861	2.59	112.000	187.000
2024-393	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	147.917	3.378	2.28	111.000	185.000
2024-393	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	31	160.710	5.589	3.48	121.000	201.000
2024-393	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	33	156.656	8.774	5.60	117.000	196.000
2024-393	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	152.929	3.826	2.50	115.000	191.000
2024-393	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	154.800	2.561	1.65	116.000	194.000
2024-393	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	15	154.000	6.011	3.90	116.000	193.000
2024-393	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	147.000	1.595	1.09	110.000	184.000
025 TRIGLYCERIDES			CLIA TEST ID #:	495	EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-394	2	ENZ. COLO.	165	VITROS	63	KODAK	148	90.333	3.204	3.55	68.000	113.000
2024-394	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	14	84.429	3.178	3.76	63.000	106.000
2024-394	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	83.375	1.550	1.86	63.000	104.000
2024-394	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	81.818	3.857	4.71	61.000	102.000
2024-394	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	91	72.267	3.032	4.20	54.000	90.000
2024-394	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	76.250	2.203	2.89	57.000	95.000
2024-394	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	31	83.935	3.464	4.13	63.000	105.000
2024-394	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	33	83.500	5.172	6.19	63.000	104.000
2024-394	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	84.077	2.055	2.44	63.000	105.000
2024-394	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	83.846	2.107	2.51	63.000	105.000
2024-394	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	15	80.600	6.184	7.67	60.000	101.000
2024-394	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	76.091	1.083	1.42	57.000	95.000
2024-395	2	ENZ. COLO.	165	VITROS	63	KODAK	148	272.438	7.524	2.76	204.000	341.000
2024-395	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	14	217.571	6.956	3.20	163.000	272.000
2024-395	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	215.000	6.371	2.96	161.000	269.000
2024-395	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	199.636	6.799	3.41	150.000	250.000
2024-395	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	91	219.456	5.572	2.54	165.000	274.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-395	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	214.583	5.634	2.63	161.000	268.000
2024-395	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	31	233.000	8.238	3.54	175.000	291.000
2024-395	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	33	217.844	13.410	6.16	163.000	272.000
2024-395	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	212.786	5.427	2.55	160.000	266.000
2024-395	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	215.538	5.235	2.43	162.000	269.000
2024-395	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	15	221.400	6.458	2.92	166.000	277.000
2024-395	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	213.636	7.401	3.46	160.000	267.000
026 UREA NITROGEN (BUN)			CLIA TEST ID #: 505			EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2024-391	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	15.596	0.982	6.30	14.000	18.000
2024-391	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	15.667	0.471	3.01	14.000	18.000
2024-391	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	15.250	0.559	3.67	13.000	17.000
2024-391	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	16.750	0.433	2.59	15.000	19.000
2024-391	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	33	15.758	0.605	3.84	14.000	18.000
2024-391	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	15.676	0.865	5.52	14.000	18.000
2024-391	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	16.200	0.872	5.38	14.000	18.000
2024-391	2	UREAS.GLDH	203	ROCHE	93	ROCHE	54	15.528	0.662	4.26	14.000	18.000
2024-391	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	15	15.867	0.499	3.14	14.000	18.000
2024-391	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	15.462	0.843	5.45	13.000	17.000
2024-391	8	UREASE QUI	165	VITROS	63	KODAK	162	13.205	0.591	4.48	11.000	15.000
2024-391	8	UREASE QUI	165	VITROS	63	KODAK	162	14.889	0.737	4.95	13.000	17.000
2024-391	10	UREASE 37	220	Medica E.	130	MEDICA	12	15.250	0.433	2.84	13.000	17.000
2024-392	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	34.000	0.000	0.00	31.000	37.000
2024-392	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	34.204	1.178	3.44	31.000	37.000
2024-392	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	33.813	0.916	2.71	31.000	37.000
2024-392	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	36.000	0.707	1.96	33.000	39.000
2024-392	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	33	34.394	0.983	2.86	31.000	37.000
2024-392	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	32.265	1.686	5.22	29.000	35.000
2024-392	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	34.600	1.200	3.47	31.000	38.000
2024-392	2	UREAS.GLDH	203	ROCHE	93	ROCHE	54	33.815	1.292	3.82	31.000	37.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-392	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	15	33.933	0.998	2.94	31.000	37.000
2024-392	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	35.077	0.997	2.84	32.000	38.000
2024-392	8	UREASE QUI	165	VITROS	63	KODAK	162	33.556	1.499	4.47	31.000	37.000
2024-392	8	UREASE QUI	165	VITROS	63	KODAK	162	30.219	0.811	2.69	27.000	33.000
2024-392	10	UREASE 37	220	Medica E.	130	MEDICA	12	32.750	0.924	2.82	30.000	36.000
026	UREA NITROGEN (BUN)		CLIA TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}							
2024-393	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	26.606	1.248	4.69	24.000	29.000
2024-393	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	27.000	0.000	0.00	25.000	29.000
2024-393	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	26.469	0.865	3.27	24.000	29.000
2024-393	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	28.250	0.433	1.53	26.000	31.000
2024-393	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	33	26.788	1.037	3.87	24.000	29.000
2024-393	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	26.029	1.524	5.86	24.000	28.000
2024-393	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	27.600	0.917	3.32	25.000	30.000
2024-393	2	UREAS.GLDH	203	ROCHE	93	ROCHE	54	26.444	1.066	4.03	24.000	29.000
2024-393	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	15	26.800	0.980	3.66	24.000	29.000
2024-393	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	26.615	0.836	3.14	24.000	29.000
2024-393	8	UREASE QUI	165	VITROS	63	KODAK	162	23.231	0.768	3.31	21.000	25.000
2024-393	8	UREASE QUI	165	VITROS	63	KODAK	162	26.000	0.943	3.63	24.000	28.000
2024-393	10	UREASE 37	220	Medica E.	130	MEDICA	12	25.667	0.943	3.67	23.000	28.000
2024-394	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	11.333	0.471	4.16	9.000	13.000
2024-394	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	11.149	0.785	7.04	9.000	13.000
2024-394	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	11.000	0.433	3.94	9.000	13.000
2024-394	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	12.000	0.000	0.00	10.000	14.000
2024-394	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	33	11.485	0.557	4.85	9.000	13.000
2024-394	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	11.500	0.916	7.96	10.000	14.000
2024-394	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	11.800	0.600	5.08	10.000	14.000
2024-394	2	UREAS.GLDH	203	ROCHE	93	ROCHE	54	11.056	0.558	5.05	9.000	13.000
2024-394	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	15	11.333	0.699	6.17	9.000	13.000
2024-394	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	11.077	0.730	6.59	9.000	13.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-394	8	UREASE QUI	165	VITROS	63	KODAK	162	10.556	0.685	6.49	9.000	13.000
2024-394	8	UREASE QUI	165	VITROS	63	KODAK	162	9.231	0.477	5.17	7.000	11.000
2024-394	10	UREASE 37	220	Medica E.	130	MEDICA	12	11.167	0.373	3.34	9.000	13.000
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2024-395	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	41.957	1.592	3.80	38.000	46.000
2024-395	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	41.667	0.471	1.13	38.000	45.000
2024-395	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	41.594	1.343	3.23	38.000	45.000
2024-395	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	43.250	0.433	1.00	39.000	47.000
2024-395	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	33	42.030	1.193	2.84	38.000	46.000
2024-395	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	38.588	2.658	6.89	35.000	42.000
2024-395	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	42.200	1.166	2.76	38.000	46.000
2024-395	2	UREAS.GLDH	203	ROCHE	93	ROCHE	54	41.170	1.799	4.37	37.000	45.000
2024-395	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	15	40.929	0.593	1.45	37.000	45.000
2024-395	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	42.923	0.615	1.43	39.000	47.000
2024-395	8	UREASE QUI	165	VITROS	63	KODAK	162	37.616	0.976	2.60	34.000	41.000
2024-395	8	UREASE QUI	165	VITROS	63	KODAK	162	41.889	2.767	6.60	38.000	46.000
2024-395	10	UREASE 37	220	Medica E.	130	MEDICA	12	39.583	0.954	2.41	36.000	43.000
027 URIC ACID		CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 17 %						
2024-391	2	URICASE	38	SIEMENS DI	143	SIEMENS	51	3.130	0.139	4.44	2.600	3.700
2024-391	2	URICASE	165	VITROS	63	KODAK	98	3.027	0.098	3.25	2.500	3.500
2024-391	2	URICASE	184	INTEGRA	93	ROCHE	11	3.036	0.098	3.22	2.500	3.600
2024-391	2	URICASE	203	ROCHE	93	ROCHE	33	3.006	0.095	3.17	2.500	3.500
2024-391	2	URICASE	219	ATELLICA	143	SIEMENS	13	3.177	0.058	1.81	2.600	3.700
2024-391	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	3.211	0.107	3.34	2.700	3.800
2024-391	6	ENZY. COL	203	ROCHE	93	ROCHE	13	3.023	0.080	2.64	2.500	3.500
2024-392	2	URICASE	38	SIEMENS DI	143	SIEMENS	51	8.630	0.244	2.82	7.200	10.100
2024-392	2	URICASE	165	VITROS	63	KODAK	98	8.554	0.268	3.14	7.100	10.000
2024-392	2	URICASE	184	INTEGRA	93	ROCHE	11	8.618	0.237	2.75	7.200	10.100
2024-392	2	URICASE	203	ROCHE	93	ROCHE	33	8.506	0.274	3.22	7.100	10.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-392	2	URICASE	219	APELLICA	143	SIEMENS	13	8.900	0.180	2.02	7.400	10.400
2024-392	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	8.700	0.117	1.34	7.200	10.200
2024-392	6	ENZY. COL	203	ROCHE	93	ROCHE	13	8.654	0.285	3.29	7.200	10.100
027	URIC ACID		CLIA TEST ID #: 515			EVALUATION CRITERIA: TARGET VALUE 17 %						
2024-393	2	URICASE	38	SIEMENS DI	143	SIEMENS	51	6.382	0.158	2.48	5.300	7.500
2024-393	2	URICASE	165	VITROS	63	KODAK	98	6.342	0.207	3.26	5.300	7.400
2024-393	2	URICASE	184	INTEGRA	93	ROCHE	11	6.390	0.145	2.26	5.300	7.500
2024-393	2	URICASE	203	ROCHE	93	ROCHE	33	6.291	0.182	2.89	5.200	7.400
2024-393	2	URICASE	219	APELLICA	143	SIEMENS	13	6.577	0.172	2.61	5.500	7.700
2024-393	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	6.526	0.107	1.64	5.400	7.600
2024-393	6	ENZY. COL	203	ROCHE	93	ROCHE	13	6.415	0.151	2.36	5.300	7.500
2024-394	2	URICASE	38	SIEMENS DI	143	SIEMENS	51	1.796	0.109	6.10	1.500	2.100
2024-394	2	URICASE	165	VITROS	63	KODAK	98	1.697	0.078	4.57	1.400	2.000
2024-394	2	URICASE	184	INTEGRA	93	ROCHE	11	1.655	0.123	7.45	1.400	1.900
2024-394	2	URICASE	203	ROCHE	93	ROCHE	33	1.642	0.055	3.38	1.400	1.900
2024-394	2	URICASE	219	APELLICA	143	SIEMENS	13	1.754	0.122	6.93	1.500	2.100
2024-394	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.832	0.057	3.09	1.500	2.100
2024-394	6	ENZY. COL	203	ROCHE	93	ROCHE	13	1.692	0.062	3.64	1.400	2.000
2024-395	2	URICASE	38	SIEMENS DI	143	SIEMENS	51	10.872	0.251	2.31	9.000	12.700
2024-395	2	URICASE	165	VITROS	63	KODAK	98	10.931	0.318	2.91	9.100	12.800
2024-395	2	URICASE	184	INTEGRA	93	ROCHE	11	10.827	0.360	3.32	9.000	12.700
2024-395	2	URICASE	203	ROCHE	93	ROCHE	33	10.652	0.326	3.06	8.800	12.500
2024-395	2	URICASE	219	APELLICA	143	SIEMENS	13	11.138	0.237	2.13	9.200	13.000
2024-395	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	10.932	0.152	1.39	9.100	12.800
2024-395	6	ENZY. COL	203	ROCHE	93	ROCHE	13	10.915	0.199	1.83	9.100	12.800
135	GGT (GAMMA GLU. TRA)		CLIA TEST ID #: 0			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-391	5	KINETIC 37	165	VITROS	63	KODAK	26	137.885	4.317	3.13	110.000	165.000



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-392	5 KINETIC 37	165	VITROS	63	KODAK	26	499.360	15.917	3.19	399.000	599.000	
2024-393	5 KINETIC 37	165	VITROS	63	KODAK	26	376.200	12.202	3.24	301.000	451.000	
2024-394	5 KINETIC 37	165	VITROS	63	KODAK	26	23.000	1.209	5.26	18.000	28.000	
2024-395	5 KINETIC 37	165	VITROS	63	KODAK	26	626.654	36.513	5.83	501.000	752.000	
136	LACTIC ACID											
2024-391	1 LACTATE-P.	165	VITROS	63	KODAK	24	1.258	0.064	5.09	1.000	1.500	
2024-392	1 LACTATE-P.	165	VITROS	63	KODAK	24	4.842	0.129	2.66	3.900	5.800	
2024-393	1 LACTATE-P.	165	VITROS	63	KODAK	24	3.429	0.110	3.20	2.700	4.100	
2024-394	1 LACTATE-P.	165	VITROS	63	KODAK	24	0.517	0.037	7.21	0.400	0.600	
2024-395	1 LACTATE-P.	165	VITROS	63	KODAK	24	6.217	0.172	2.77	5.000	7.500	
137	LIPASE											
2024-391	1 COLORIMET.	203	ROCHE	93	ROCHE	18	27.706	0.956	3.45	22.000	33.000	
2024-391	1 COLORIMET.	219	ATELLICA	143	SIEMENS	11	32.273	1.286	3.98	26.000	39.000	
2024-391	2 ENZIMATIC	165	VITROS	63	KODAK	85	202.459	8.223	4.06	162.000	243.000	
2024-391	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	27.700	0.781	2.82	22.000	33.000	
2024-391	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	27.429	2.921	10.65	22.000	33.000	
2024-391	4 ENZ/COLOR	203	ROCHE	93	ROCHE	11	27.455	0.891	3.24	22.000	33.000	
2024-391	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	28.467	1.258	4.42	23.000	34.000	
2024-392	1 COLORIMET.	203	ROCHE	93	ROCHE	18	75.333	3.621	4.81	60.000	90.000	
2024-392	1 COLORIMET.	219	ATELLICA	143	SIEMENS	11	87.000	2.174	2.50	70.000	104.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-392	2	ENZIMATIC	165	VITROS	63	KODAK	85	641.393	20.718	3.23	513.000	770.000
2024-392	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	72.600	3.747	5.16	58.000	87.000
2024-392	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	80.333	4.482	5.58	64.000	96.000
2024-392	4	ENZ/COLOR	203	ROCHE	93	ROCHE	11	74.727	2.700	3.61	60.000	90.000
2024-392	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	76.067	3.021	3.97	61.000	91.000
137	LIPASE	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-393	1	COLORIMET.	203	ROCHE	93	ROCHE	18	56.278	3.739	6.64	45.000	68.000
2024-393	1	COLORIMET.	219	APELLICA	143	SIEMENS	11	64.727	1.213	1.87	52.000	78.000
2024-393	2	ENZIMATIC	165	VITROS	63	KODAK	85	479.494	18.013	3.76	384.000	575.000
2024-393	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	55.100	2.625	4.76	44.000	66.000
2024-393	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	59.500	4.500	7.56	48.000	71.000
2024-393	4	ENZ/COLOR	203	ROCHE	93	ROCHE	11	55.545	1.437	2.59	44.000	67.000
2024-393	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	56.800	1.759	3.10	45.000	68.000
2024-394	1	COLORIMET.	203	ROCHE	93	ROCHE	18	15.778	1.030	6.53	13.000	19.000
2024-394	1	COLORIMET.	219	APELLICA	143	SIEMENS	11	18.455	1.076	5.83	15.000	22.000
2024-394	2	ENZIMATIC	165	VITROS	63	KODAK	85	74.238	3.487	4.70	59.000	89.000
2024-394	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	16.400	0.800	4.88	13.000	20.000
2024-394	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	14.000	2.066	14.75	11.000	17.000
2024-394	4	ENZ/COLOR	203	ROCHE	93	ROCHE	11	15.545	0.498	3.20	12.000	19.000
2024-394	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	17.400	0.712	4.09	14.000	21.000
2024-395	1	COLORIMET.	203	ROCHE	93	ROCHE	18	92.765	3.797	4.09	74.000	111.000
2024-395	1	COLORIMET.	219	APELLICA	143	SIEMENS	11	107.455	2.742	2.55	86.000	129.000
2024-395	2	ENZIMATIC	165	VITROS	63	KODAK	85	829.847	58.426	7.04	664.000	996.000
2024-395	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	90.300	5.330	5.90	72.000	108.000
2024-395	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	100.714	6.649	6.60	81.000	121.000
2024-395	4	ENZ/COLOR	203	ROCHE	93	ROCHE	11	93.364	3.574	3.83	75.000	112.000
2024-395	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	94.733	3.434	3.63	76.000	114.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
138	PHOSPHORUS	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-391	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	51	2.220	0.112	5.05	1.800	2.700	
2024-391	1	PHOSPHOMO.	165 VITROS	63	KODAK	95	2.407	0.106	4.41	1.900	2.900	
2024-391	1	PHOSPHOMO.	184 INTEGRA	93	ROCHE	16	2.106	0.156	7.41	1.700	2.500	
2024-391	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	2.116	0.074	3.52	1.700	2.500	
2024-391	1	PHOSPHOMO.	203 ROCHE	93	ROCHE	42	2.107	0.105	4.96	1.700	2.500	
2024-391	1	PHOSPHOMO.	219 ATELLICA	143	SIEMENS	13	2.154	0.115	5.35	1.700	2.600	
2024-392	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	51	5.300	0.146	2.75	4.200	6.400	
2024-392	1	PHOSPHOMO.	165 VITROS	63	KODAK	95	5.100	0.167	3.28	4.100	6.100	
2024-392	1	PHOSPHOMO.	184 INTEGRA	93	ROCHE	16	5.000	0.232	4.64	4.000	6.000	
2024-392	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	5.145	0.107	2.08	4.100	6.200	
2024-392	1	PHOSPHOMO.	203 ROCHE	93	ROCHE	42	5.060	0.156	3.08	4.000	6.100	
2024-392	1	PHOSPHOMO.	219 ATELLICA	143	SIEMENS	13	5.246	0.101	1.92	4.200	6.300	
2024-393	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	51	4.092	0.127	3.09	3.300	4.900	
2024-393	1	PHOSPHOMO.	165 VITROS	63	KODAK	95	4.054	0.134	3.30	3.200	4.900	
2024-393	1	PHOSPHOMO.	184 INTEGRA	93	ROCHE	16	3.900	0.203	5.21	3.100	4.700	
2024-393	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	3.955	0.128	3.25	3.200	4.700	
2024-393	1	PHOSPHOMO.	203 ROCHE	93	ROCHE	42	3.910	0.127	3.25	3.100	4.700	
2024-393	1	PHOSPHOMO.	219 ATELLICA	143	SIEMENS	13	3.992	0.100	2.50	3.200	4.800	
2024-394	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	51	1.384	0.090	6.52	1.100	1.700	
2024-394	1	PHOSPHOMO.	165 VITROS	63	KODAK	95	1.591	0.105	6.59	1.300	1.900	
2024-394	1	PHOSPHOMO.	184 INTEGRA	93	ROCHE	16	1.325	0.139	10.51	1.100	1.600	
2024-394	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	1.325	0.070	5.27	1.100	1.600	
2024-394	1	PHOSPHOMO.	203 ROCHE	93	ROCHE	42	1.300	0.071	5.44	1.000	1.600	
2024-394	1	PHOSPHOMO.	219 ATELLICA	143	SIEMENS	13	1.269	0.091	7.17	1.000	1.500	
2024-395	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	51	6.445	0.213	3.30	5.200	7.700	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-395	1	PHOSPHOMO.	165	VITROS	63	KODAK	95	6.239	0.188	3.02	5.000	7.500
2024-395	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	16	6.131	0.310	5.05	4.900	7.400
2024-395	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	6.285	0.124	1.97	5.000	7.500
2024-395	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	42	6.202	0.181	2.93	5.000	7.400
2024-395	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	13	6.354	0.134	2.10	5.100	7.600
169	CO2	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-391	1	Generic Me	184	INTEGRA	93	ROCHE	10	10.800	2.358	21.83	4.000	18.000
2024-391	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	28	9.750	0.950	9.74	7.000	13.000
2024-391	1	Generic Me	203	ROCHE	93	ROCHE	23	8.565	1.313	15.33	5.000	13.000
2024-391	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	77	11.933	1.982	16.61	6.000	18.000
2024-391	2	ENZYMATIC	165	VITROS	63	KODAK	59	7.966	1.562	19.61	3.000	13.000
2024-391	2	ENZYMATIC	165	VITROS	156	Kit 32	84	8.238	1.428	17.33	4.000	13.000
2024-391	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	8.818	1.113	12.63	5.000	12.000
2024-391	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	13	11.538	1.946	16.87	6.000	17.000
2024-392	1	Generic Me	184	INTEGRA	93	ROCHE	10	17.600	3.583	20.36	7.000	28.000
2024-392	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	28	17.500	1.592	9.10	13.000	22.000
2024-392	1	Generic Me	203	ROCHE	93	ROCHE	23	15.957	2.074	13.00	10.000	22.000
2024-392	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	77	19.711	2.327	11.81	13.000	27.000
2024-392	2	ENZYMATIC	165	VITROS	63	KODAK	59	14.847	2.283	15.38	8.000	22.000
2024-392	2	ENZYMATIC	165	VITROS	156	Kit 32	84	15.711	1.767	11.25	10.000	21.000
2024-392	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	17.273	1.135	6.57	14.000	21.000
2024-392	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	13	18.923	1.774	9.38	14.000	24.000
2024-393	1	Generic Me	184	INTEGRA	93	ROCHE	10	14.400	3.412	23.69	4.000	25.000
2024-393	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	28	14.464	1.451	10.03	10.000	19.000
2024-393	1	Generic Me	203	ROCHE	93	ROCHE	23	13.174	1.809	13.74	8.000	19.000
2024-393	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	77	16.671	2.179	13.07	10.000	23.000
2024-393	2	ENZYMATIC	165	VITROS	63	KODAK	59	12.224	1.439	11.77	8.000	17.000
2024-393	2	ENZYMATIC	165	VITROS	156	Kit 32	84	12.639	1.625	12.86	8.000	18.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-393	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	14.182	0.716	5.05	12.000	16.000
2024-393	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	13	15.692	1.814	11.56	10.000	21.000
169	CO2	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-394	1	Generic Me	184	INTEGRA	93	ROCHE	10	8.800	3.311	37.62	0	19.000
2024-394	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	28	8.107	1.047	12.91	5.000	11.000
2024-394	1	Generic Me	203	ROCHE	93	ROCHE	23	7.130	1.623	22.77	2.000	12.000
2024-394	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	77	10.390	1.887	18.17	5.000	16.000
2024-394	2	ENZYMATIC	165	VITROS	63	KODAK	59	6.138	1.008	16.42	3.000	9.000
2024-394	2	ENZYMATIC	165	VITROS	156	Kit 32	84	6.286	1.119	17.80	3.000	10.000
2024-394	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	7.636	1.068	13.98	4.000	11.000
2024-394	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	13	10.083	0.276	2.74	9.000	11.000
2024-395	1	Generic Me	184	INTEGRA	93	ROCHE	10	21.400	4.030	18.83	9.000	33.000
2024-395	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	28	21.750	2.098	9.65	15.000	28.000
2024-395	1	Generic Me	203	ROCHE	93	ROCHE	23	19.217	2.340	12.18	12.000	26.000
2024-395	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	77	24.026	2.395	9.97	17.000	31.000
2024-395	2	ENZYMATIC	165	VITROS	63	KODAK	59	18.542	1.881	10.14	13.000	24.000
2024-395	2	ENZYMATIC	165	VITROS	156	Kit 32	84	18.774	2.026	10.79	13.000	25.000
2024-395	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	19.636	1.150	5.86	16.000	23.000
2024-395	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	13	22.462	1.737	7.73	17.000	28.000
170	DIRECT BILIRUBIN					EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}						
2024-391	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	0.290	0.030	10.45	0.200	0.400
2024-391	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	13	0.485	0.036	7.45	0.400	0.600
2024-391	11	SPECT. WIT	165	VITROS	63	KODAK	71	0.054	0.138	257.11	0	0.500
2024-391	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	18	0.278	0.053	19.18	0.100	0.400
2024-391	14	VANADATE O	219	ATELLICA	143	SIEMENS	14	0.550	0.063	11.40	0.400	0.700
2024-391	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	10	0.370	0.064	17.31	0.200	0.600
2024-392	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	1.167	0.091	7.81	0.900	1.400
2024-392	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	13	1.869	0.099	5.30	1.500	2.200

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2024-392	11	SPECT. WIT	165 VITROS	63	KODAK	71	0.803	0.164	20.41	0.300	1.300	
2024-392	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	18	1.017	0.157	15.47	0.500	1.500	
2024-392	14	VANADATE O	219 ATELLICA	143	SIEMENS	14	2.164	0.149	6.90	1.700	2.600	
2024-392	18	DIAZ. SULF	191 RX-SERIES	126	RANDOX	10	1.620	0.218	13.47	1.000	2.300	
170	DIRECT BILIRUBIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}								
2024-393	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	49	0.859	0.067	7.77	0.700	1.100	
2024-393	5	JEND.-GROG	197 ARCHITECT	1	ABBOTT	13	1.415	0.053	3.77	1.100	1.700	
2024-393	11	SPECT. WIT	165 VITROS	63	KODAK	71	0.483	0.143	29.70	0.100	0.900	
2024-393	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	18	0.772	0.141	18.21	0.400	1.200	
2024-393	14	VANADATE O	219 ATELLICA	143	SIEMENS	14	1.571	0.122	7.77	1.200	1.900	
2024-393	18	DIAZ. SULF	191 RX-SERIES	126	RANDOX	10	1.160	0.136	11.69	0.800	1.600	
2024-394	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	49	0.077	0.042	54.52	0.000	0.200	
2024-394	5	JEND.-GROG	197 ARCHITECT	1	ABBOTT	13	0.100	0.000	0.00	0.100	0.100	
2024-394	11	SPECT. WIT	165 VITROS	63	KODAK	71	0.006	0.024	400.00	0	0.100	
2024-394	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	18	0.200	0.000	0.00	0.200	0.200	
2024-394	14	VANADATE O	219 ATELLICA	143	SIEMENS	14	0.100	0.000	0.00	0.100	0.100	
2024-394	18	DIAZ. SULF	191 RX-SERIES	126	RANDOX	10	0.060	0.080	133.33	0	0.300	
2024-395	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	49	1.438	0.093	6.45	1.200	1.700	
2024-395	5	JEND.-GROG	197 ARCHITECT	1	ABBOTT	13	2.254	0.093	4.12	1.800	2.700	
2024-395	11	SPECT. WIT	165 VITROS	63	KODAK	71	1.103	0.254	22.99	0.300	1.900	
2024-395	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	18	1.244	0.201	16.12	0.600	1.800	
2024-395	14	VANADATE O	219 ATELLICA	143	SIEMENS	14	2.664	0.191	7.18	2.100	3.200	
2024-395	18	DIAZ. SULF	191 RX-SERIES	126	RANDOX	10	2.120	0.289	13.64	1.300	3.000	
SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 15 WHOLE BLOOD GLUCOSE						

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 15 WHOLE BLOOD GLUCOSE				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
157	WHOLE BLOOD GLUCOSE	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	10 % OR 6.00	{GREATER}					
2024-491	23	ABBOTT PRE		24	438.583	33.713	7.69	395.000	482.000	
2024-491	23	ABBOTT PRE		24	418.000	10.873	2.60	376.000	460.000	
2024-491	27	STAT SRIP.		81	299.568	23.063	7.70	270.000	330.000	
2024-491	33	AC.CHEK II		37	459.750	6.942	1.51	414.000	506.000	
2024-491	33	AC.CHEK II		37	449.917	12.054	2.68	405.000	495.000	
2024-491	34	FREE STYL		45	459.750	6.942	1.51	414.000	506.000	
2024-491	34	FREE STYL		45	476.533	32.912	6.91	429.000	524.000	
2024-492	23	ABBOTT PRE		24	78.333	0.471	0.60	71.000	86.000	
2024-492	23	ABBOTT PRE		24	79.583	4.377	5.50	72.000	88.000	
2024-492	27	STAT SRIP.		81	62.111	3.562	5.74	56.000	68.000	
2024-492	33	AC.CHEK II		37	72.139	1.946	2.70	65.000	79.000	
2024-492	33	AC.CHEK II		37	75.250	2.773	3.68	68.000	83.000	
2024-492	34	FREE STYL		45	83.886	5.832	6.95	75.000	92.000	
2024-492	34	FREE STYL		45	75.250	2.773	3.68	68.000	83.000	
2024-493	23	ABBOTT PRE		24	157.167	8.668	5.52	141.000	173.000	
2024-493	23	ABBOTT PRE		24	153.000	3.266	2.13	138.000	168.000	
2024-493	27	STAT SRIP.		81	123.225	7.335	5.95	111.000	136.000	
2024-493	33	AC.CHEK II		37	145.250	4.493	3.09	131.000	160.000	
2024-493	33	AC.CHEK II		37	141.757	4.103	2.89	128.000	156.000	
2024-493	34	FREE STYL		45	176.000	4.493	2.55	158.000	194.000	
2024-493	34	FREE STYL		45	172.273	11.363	6.60	155.000	190.000	
2024-494	23	ABBOTT PRE		24	74.000	1.247	1.69	67.000	81.000	
2024-494	23	ABBOTT PRE		24	79.417	4.856	6.11	71.000	87.000	
2024-494	27	STAT SRIP.		81	61.840	2.971	4.80	56.000	68.000	
2024-494	33	AC.CHEK II		37	72.278	1.967	2.72	65.000	80.000	
2024-494	33	AC.CHEK II		37	73.500	2.062	2.80	66.000	81.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 15 WHOLE BLOOD GLUCOSE					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-494	34	FREE STYL		45	84.295	6.497	7.71	76.000	93.000		
2024-494	34	FREE STYL		45	87.000	2.062	2.37	78.000	96.000		
157 WHOLE BLOOD GLUCOSE			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}							
2024-495	23	ABBOTT PRE		24	418.000	12.472	2.98	376.000	460.000		
2024-495	23	ABBOTT PRE		24	434.708	31.796	7.31	391.000	478.000		
2024-495	27	STAT SRIP.		81	301.367	18.774	6.23	271.000	332.000		
2024-495	33	AC.CHEK II		37	458.750	9.470	2.06	413.000	505.000		
2024-495	33	AC.CHEK II		37	446.861	13.974	3.13	402.000	492.000		
2024-495	34	FREE STYL		45	458.750	9.470	2.06	413.000	505.000		
2024-495	34	FREE STYL		45	478.978	29.102	6.08	431.000	527.000		
SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
007 BLOOD GASES-pCO2			CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}							
2024-441	265	ROCHE COBA		33	66.594	1.989	2.99	61.300	71.900		
2024-442	265	ROCHE COBA		33	43.552	0.772	1.77	38.600	48.600		
2024-443	265	ROCHE COBA		33	21.761	0.741	3.40	16.800	26.800		
2024-444	265	ROCHE COBA		33	43.218	0.706	1.63	38.200	48.200		
2024-445	265	ROCHE COBA		33	67.036	1.555	2.32	61.700	72.400		
008 BLOOD GASES-pH			CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE 0.04							
2024-441	265	ROCHE COBA		33	7.179	0.008	0.11	7.139	7.219		



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
008	BLOOD GASES-pH	CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE		0.04					
2024-442	265 ROCHE COBA			33	7.408	0.006	0.09	7.368	7.448	
2024-443	265 ROCHE COBA			33	7.674	0.009	0.12	7.634	7.714	
2024-444	265 ROCHE COBA			33	7.408	0.006	0.07	7.368	7.448	
2024-445	265 ROCHE COBA			33	7.175	0.008	0.11	7.136	7.216	
009	BLOOD GASES-pO2	CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE		3 SD					
2024-441	265 ROCHE COBA			33	52.187	9.639	18.47	23.300	81.100	
2024-442	265 ROCHE COBA			33	111.830	6.219	5.56	93.200	130.500	
2024-443	265 ROCHE COBA			33	152.688	7.580	4.96	129.900	175.400	
2024-444	265 ROCHE COBA			33	111.328	5.002	4.49	96.300	126.300	
2024-445	265 ROCHE COBA			33	52.250	12.665	24.24	14.300	90.200	

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 0								
2024-421	116 ROCHE COBA			14	11.700	0.592	5.06	9.900	13.500	
2024-421	125 B.C.ACCESS			10	12.690	1.148	9.05	9.200	16.100	
2024-421	149 ARC i2000s			11	10.336	2.334	22.58	3.300	17.300	
2024-422	116 ROCHE COBA			14	34.571	1.704	4.93	29.500	39.700	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-422	125	B.C.ACCESS		10	39.380	3.057	7.76	30.200	48.600		
2024-422	149	ARC i2000s		11	33.564	2.406	7.17	26.300	40.800		
029	FOLL. STIM. HOR.-FSH		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-423	116	ROCHE COBA		14	23.150	1.118	4.83	19.800	26.500		
2024-423	125	B.C.ACCESS		10	24.600	2.177	8.85	18.100	31.100		
2024-423	149	ARC i2000s		11	22.355	1.261	5.64	18.600	26.100		
2024-424	116	ROCHE COBA		14	6.971	0.363	5.21	5.900	8.100		
2024-424	125	B.C.ACCESS		10	7.710	0.351	4.55	6.700	8.800		
2024-424	149	ARC i2000s		11	6.482	0.426	6.57	5.200	7.800		
2024-425	116	ROCHE COBA		14	38.486	1.826	4.74	33.000	44.000		
2024-425	125	B.C.ACCESS		10	42.830	2.736	6.39	34.600	51.000		
2024-425	149	ARC i2000s		11	38.136	2.637	6.91	30.200	46.000		
030	FREE THYROXINE		CLIA TEST ID #: 545								
2024-421	115	VITROS ECI		49	2.540	0.224	8.83	1.900	3.200		
2024-421	116	ROCHE COBA		46	1.211	0.064	5.29	1.000	1.400		
2024-421	125	B.C.ACCESS		47	1.167	0.084	7.16	0.900	1.400		
2024-421	149	ARC i2000s		22	1.076	0.068	6.35	0.900	1.300		
2024-421	160	SIEMENS EX		51	1.206	0.070	5.84	1.000	1.400		
2024-421	169	ATELLICA		12	0.942	0.064	6.80	0.700	1.100		
2024-422	115	VITROS ECI		49	1.480	0.093	6.25	1.200	1.800		
2024-422	116	ROCHE COBA		46	1.454	0.071	4.91	1.200	1.700		
2024-422	125	B.C.ACCESS		47	0.926	0.057	6.14	0.800	1.100		
2024-422	149	ARC i2000s		22	1.205	0.021	1.77	1.100	1.300		
2024-422	160	SIEMENS EX		51	1.140	0.060	5.26	1.000	1.300		
2024-422	169	ATELLICA		12	1.175	0.043	3.69	1.000	1.300		
2024-423	115	VITROS ECI		49	5.044	0.263	5.21	4.300	5.800		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-423	116	ROCHE COBA		46	2.096	0.103	4.92	1.800	2.400
2024-423	125	B.C.ACCESS		47	1.913	0.135	7.04	1.500	2.300
2024-423	149	ARC i2000s		22	1.873	0.101	5.38	1.600	2.200
2024-423	160	SIEMENS EX		51	2.040	0.133	6.50	1.600	2.400
2024-423	169	ATELLICA		12	1.575	0.083	5.26	1.300	1.800
030	FREE THYROXINE		CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-424	115	VITROS ECI		49	1.467	0.117	7.96	1.100	1.800
2024-424	116	ROCHE COBA		46	0.813	0.049	6.07	0.700	1.000
2024-424	125	B.C.ACCESS		47	0.838	0.067	7.99	0.600	1.000
2024-424	149	ARC i2000s		22	0.727	0.045	6.12	0.600	0.900
2024-424	160	SIEMENS EX		51	0.866	0.047	5.47	0.700	1.000
2024-424	169	ATELLICA		12	0.675	0.043	6.42	0.500	0.800
2024-425	115	VITROS ECI		49	6.908	0.102	1.47	6.600	7.200
2024-425	116	ROCHE COBA		46	3.226	0.161	4.98	2.700	3.700
2024-425	125	B.C.ACCESS		47	2.715	0.143	5.26	2.300	3.100
2024-425	149	ARC i2000s		22	2.552	0.230	9.02	1.900	3.200
2024-425	160	SIEMENS EX		51	3.120	0.161	5.16	2.600	3.600
2024-425	169	ATELLICA		12	2.333	0.075	3.19	2.100	2.600
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555						
2024-421	115	VITROS ECI		21	191.629	12.003	6.26	155.600	227.600
2024-421	116	ROCHE COBA		16	134.900	6.598	4.89	115.100	154.700
2024-421	125	B.C.ACCESS		12	126.582	6.060	4.79	108.400	144.800
2024-422	115	VITROS ECI		21	2.400	0.000	0.00	2.400	2.400
2024-422	116	ROCHE COBA		16	1.194	0.097	8.09	0.900	1.500
2024-422	125	B.C.ACCESS		12	1.883	0.128	6.80	1.500	2.300
2024-423	115	VITROS ECI		21	636.048	36.573	5.75	526.300	745.800
2024-423	116	ROCHE COBA		16	465.056	18.188	3.91	410.500	519.600

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-423	125 B.C.ACCESS			12	404.742	19.801	4.89	345.300	464.100	
032 hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-424	115 VITROS ECI			21	2.562	0.215	8.39	1.900	3.200	
2024-424	116 ROCHE COBA			16	1.938	0.111	5.73	1.600	2.300	
2024-424	125 B.C.ACCESS			12	3.075	0.209	6.79	2.400	3.700	
2024-425	115 VITROS ECI			21	1253.114	57.782	4.61	1079.800	1426.500	
2024-425	116 ROCHE COBA			16	934.513	38.702	4.14	818.400	1050.600	
2024-425	125 B.C.ACCESS			12	725.442	29.148	4.02	638.000	812.900	
035 PROLACTIN		CLIA TEST ID #: 0								
2024-421	116 ROCHE COBA			15	7.660	0.307	4.01	6.700	8.600	
2024-421	125 B.C.ACCESS			11	8.055	0.907	11.26	5.300	10.800	
2024-422	116 ROCHE COBA			15	5.120	0.254	4.95	4.400	5.900	
2024-422	125 B.C.ACCESS			11	4.582	0.420	9.16	3.300	5.800	
2024-423	116 ROCHE COBA			15	22.873	1.019	4.45	19.800	25.900	
2024-423	125 B.C.ACCESS			11	22.882	3.030	13.24	13.800	32.000	
2024-424	116 ROCHE COBA			15	1.800	0.097	5.37	1.500	2.100	
2024-424	125 B.C.ACCESS			11	1.618	0.127	7.82	1.200	2.000	
2024-425	116 ROCHE COBA			15	45.547	1.936	4.25	39.700	51.400	
2024-425	125 B.C.ACCESS			11	41.064	6.025	14.67	23.000	59.100	
037 TESTOSTERONE										
2024-421	149 ARC i2000s			10	2.900	0.141	4.88	2.500	3.300	
2024-422	149 ARC i2000s			10	1.789	0.137	7.66	1.400	2.200	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
037	TESTOSTERONE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-423	149 ARC i2000s				10	8.333	0.760	9.12	6.100	10.600	
2024-424	149 ARC i2000s				10	0.767	0.067	8.70	0.600	1.000	
2024-425	149 ARC i2000s				10	14.889	0.314	2.11	13.900	15.800	
039	THYRO. STI. HOR.-TSH		CLIA TEST ID #: 585								
2024-421	106 TOSOH AIA				11	2.336	0.242	10.37	1.600	3.100	
2024-421	115 VITROS ECI				56	2.055	0.095	4.62	1.800	2.300	
2024-421	116 ROCHE COBA				51	1.996	0.087	4.36	1.700	2.300	
2024-421	125 B.C.ACCESS				55	1.600	0.076	4.77	1.400	1.800	
2024-421	149 ARC i2000s				25	1.548	0.117	7.56	1.200	1.900	
2024-421	160 SIEMENS EX				81	1.528	0.088	5.76	1.300	1.800	
2024-421	169 ATELLICA				12	1.875	0.043	2.31	1.700	2.000	
2024-422	106 TOSOH AIA				11	2.045	0.219	10.70	1.400	2.700	
2024-422	115 VITROS ECI				56	1.748	0.096	5.51	1.500	2.000	
2024-422	116 ROCHE COBA				51	2.100	0.091	4.32	1.800	2.400	
2024-422	125 B.C.ACCESS				55	1.965	0.142	7.21	1.500	2.400	
2024-422	149 ARC i2000s				25	1.676	0.180	10.71	1.100	2.200	
2024-422	160 SIEMENS EX				81	1.763	0.117	6.64	1.400	2.100	
2024-422	169 ATELLICA				12	1.950	0.096	4.91	1.700	2.200	
2024-423	106 TOSOH AIA				11	6.309	0.548	8.69	4.700	8.000	
2024-423	115 VITROS ECI				56	5.452	0.212	3.89	4.800	6.100	
2024-423	116 ROCHE COBA				51	4.802	0.192	4.01	4.200	5.400	
2024-423	125 B.C.ACCESS				55	4.138	0.218	5.26	3.500	4.800	
2024-423	149 ARC i2000s				25	4.040	0.290	7.17	3.200	4.900	
2024-423	160 SIEMENS EX				81	3.899	0.223	5.72	3.200	4.600	
2024-423	169 ATELLICA				12	4.833	0.143	2.97	4.400	5.300	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-424	106 TOSOH AIA			11	0.664	0.048	7.25	0.500	0.800	
2024-424	115 VITROS ECI			56	0.500	0.000	0.00	0.500	0.500	
2024-424	116 ROCHE COBA			51	0.714	0.034	4.82	0.600	0.800	
2024-424	125 B.C.ACCESS			55	0.535	0.048	8.90	0.400	0.700	
2024-424	149 ARC i2000s			25	0.488	0.043	8.83	0.400	0.600	
2024-424	160 SIEMENS EX			81	0.531	0.049	9.19	0.400	0.700	
2024-424	169 ATELLICA			12	0.567	0.047	8.32	0.400	0.700	
2024-425	106 TOSOH AIA			11	10.673	0.758	7.10	8.400	12.900	
2024-425	115 VITROS ECI			56	9.675	0.400	4.14	8.500	10.900	
2024-425	116 ROCHE COBA			51	8.248	0.341	4.13	7.200	9.300	
2024-425	125 B.C.ACCESS			55	7.756	0.482	6.21	6.300	9.200	
2024-425	149 ARC i2000s			25	7.396	0.536	7.25	5.800	9.000	
2024-425	160 SIEMENS EX			81	6.905	0.425	6.16	5.600	8.200	
2024-425	169 ATELLICA			12	8.517	0.324	3.80	7.500	9.500	
040	THYROXINE (T4)	CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}							
2024-421	32 SIEM DIME.			48	5.794	0.448	7.74	4.600	7.000	
2024-421	115 VITROS ECI			45	4.666	0.182	3.90	3.700	5.700	
2024-421	116 ROCHE COBA			45	4.931	0.249	5.06	3.900	5.900	
2024-421	116 ROCHE COBA			45	5.833	0.330	5.66	4.700	7.000	
2024-421	125 B.C.ACCESS			45	4.471	0.420	9.40	3.500	5.500	
2024-421	149 ARC i2000s			23	4.204	0.336	7.98	3.200	5.200	
2024-421	169 ATELLICA			12	5.333	0.337	6.33	4.300	6.400	
2024-422	32 SIEM DIME.			48	11.463	0.634	5.53	9.200	13.800	
2024-422	115 VITROS ECI			45	7.802	0.350	4.48	6.200	9.400	
2024-422	116 ROCHE COBA			45	9.753	0.556	5.70	7.800	11.700	
2024-422	116 ROCHE COBA			45	12.367	0.613	4.96	9.900	14.800	
2024-422	125 B.C.ACCESS			45	8.336	0.684	8.20	6.700	10.000	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-422	149	ARC i2000s		23	9.848	0.620	6.29	7.900	11.800	
2024-422	169	APELLICA		12	9.167	0.882	9.62	7.300	11.000	
040	THYROXINE (T4)		CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE	20 %	OR 1.00	{GREATER}		
2024-423	32	SIEM DIME.		48	10.392	0.514	4.95	8.300	12.500	
2024-423	115	VITROS ECI		45	8.222	0.334	4.06	6.600	9.900	
2024-423	116	ROCHE COBA		45	8.891	0.424	4.77	7.100	10.700	
2024-423	116	ROCHE COBA		45	11.167	0.125	1.12	8.900	13.400	
2024-423	125	B.C.ACCESS		45	8.602	0.553	6.43	6.900	10.300	
2024-423	149	ARC i2000s		23	8.813	0.502	5.70	7.100	10.600	
2024-423	169	APELLICA		12	9.433	0.685	7.26	7.500	11.300	
2024-424	32	SIEM DIME.		48	3.643	0.433	11.89	2.600	4.600	
2024-424	115	VITROS ECI		45	3.124	0.142	4.53	2.100	4.100	
2024-424	116	ROCHE COBA		45	3.337	0.183	5.48	2.300	4.300	
2024-424	116	ROCHE COBA		45	3.767	0.573	15.23	2.800	4.800	
2024-424	125	B.C.ACCESS		45	2.598	0.311	11.97	1.600	3.600	
2024-424	149	ARC i2000s		23	2.500	0.323	12.92	1.500	3.500	
2024-424	169	APELLICA		12	3.575	0.421	11.76	2.600	4.600	
2024-425	32	SIEM DIME.		48	17.340	0.731	4.22	13.900	20.800	
2024-425	115	VITROS ECI		45	12.547	0.599	4.78	10.000	15.100	
2024-425	116	ROCHE COBA		45	14.274	0.700	4.90	11.400	17.100	
2024-425	116	ROCHE COBA		45	18.133	0.741	4.09	14.500	21.800	
2024-425	125	B.C.ACCESS		45	13.642	1.049	7.69	10.900	16.400	
2024-425	149	ARC i2000s		23	14.804	1.004	6.78	11.800	17.800	
2024-425	169	APELLICA		12	13.267	0.845	6.37	10.600	15.900	
141	FOLATE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE	25 %				
2024-421	115	VITROS ECI		15	1.388	0.237	17.07	1.000	1.700	
2024-421	115	VITROS ECI		15	1.960	0.285	14.53	1.500	2.500	
2024-421	116	ROCHE COBA		21	2.000	0.000	0.00	1.500	2.500	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-421	125	B.C.ACCESS		12	2.458	0.185	7.51	1.800	3.100	
2024-421	149	ARC i2000s		13	2.500	0.337	13.50	1.900	3.100	
141	FOLATE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %					
2024-422	115	VITROS ECI		15	0.527	0.205	38.89	0.400	0.700	
2024-422	115	VITROS ECI		15	1.538	1.663	108.15	1.200	1.900	
2024-422	116	ROCHE COBA		21	2.000	0.000	0.00	1.500	2.500	
2024-422	125	B.C.ACCESS		12	1.392	0.185	13.27	1.000	1.700	
2024-422	149	ARC i2000s		13	1.231	0.367	29.79	0.900	1.500	
2024-423	115	VITROS ECI		15	5.888	0.575	9.77	4.400	7.400	
2024-423	115	VITROS ECI		15	6.200	0.682	11.00	4.700	7.800	
2024-423	116	ROCHE COBA		21	4.895	0.350	7.15	3.700	6.100	
2024-423	125	B.C.ACCESS		12	7.267	0.359	4.94	5.500	9.100	
2024-423	149	ARC i2000s		13	7.923	0.435	5.49	5.900	9.900	
2024-424	115	VITROS ECI		15	0.588	0.033	5.63	0.400	0.700	
2024-424	115	VITROS ECI		15	0.873	0.195	22.31	0.700	1.100	
2024-424	116	ROCHE COBA		21	2.000	0.000	0.00	1.500	2.500	
2024-424	125	B.C.ACCESS		12	0.767	0.180	23.41	0.600	1.000	
2024-424	149	ARC i2000s		13	1.062	0.399	37.60	0.800	1.300	
2024-425	115	VITROS ECI		15	12.793	1.224	9.57	9.600	16.000	
2024-425	115	VITROS ECI		15	18.238	3.446	18.90	13.700	22.800	
2024-425	116	ROCHE COBA		21	10.545	0.807	7.65	7.900	13.200	
2024-425	125	B.C.ACCESS		12	13.525	0.735	5.43	10.100	16.900	
2024-425	149	ARC i2000s		13	15.354	1.155	7.52	11.500	19.200	
142	hLH (HUMAN LUT. HOR)									
2024-421	116	ROCHE COBA		12	8.925	0.398	4.46	6.700	11.200	
2024-421	125	B.C.ACCESS		10	8.000	0.684	8.55	6.000	10.000	
2024-421	149	ARC i2000s		10	5.140	0.372	7.24	3.900	6.400	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)							
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
142 hLH (HUMAN LUT. HOR)				CLIA TEST ID #: 0						EVALUATION CRITERIA: TARGET VALUE 25 %	
2024-422	116	ROCHE COBA		12	16.542	0.989	5.98	12.400	20.700		
2024-422	125	B.C.ACCESS		10	12.980	1.115	8.59	9.700	16.200		
2024-422	149	ARC i2000s		10	10.600	0.990	9.34	8.000	13.300		
2024-423	116	ROCHE COBA		12	19.017	0.862	4.53	14.300	23.800		
2024-423	125	B.C.ACCESS		10	18.360	1.641	8.94	13.800	23.000		
2024-423	149	ARC i2000s		10	11.810	0.806	6.82	8.900	14.800		
2024-424	116	ROCHE COBA		12	4.375	0.249	5.69	3.300	5.500		
2024-424	125	B.C.ACCESS		10	3.270	0.293	8.97	2.500	4.100		
2024-424	149	ARC i2000s		10	2.340	0.224	9.59	1.800	2.900		
2024-425	116	ROCHE COBA		12	32.375	1.474	4.55	24.300	40.500		
2024-425	125	B.C.ACCESS		10	30.380	3.026	9.96	22.800	38.000		
2024-425	149	ARC i2000s		10	21.470	1.965	9.15	16.100	26.800		

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)								
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART #	LABS #	"SF"	Score	
SAMPLE	RESULT	RESULT	RESULT	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
031 hCG-QUALITATIVE												
2024-421	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	23	23	23	100
2024-421	142	INSTANT VI		002	002	002	002	002 - POSITIVE	32	32	32	100
2024-421	150	AIM STEP		002	002	002	002	002 - POSITIVE	108	108	108	100
2024-421	164	HCG Alere		002	002	002	002	002 - POSITIVE	72	72	72	100
2024-421	165	Osom HCG C		002	002	002	002	002 - POSITIVE	13	13	13	100
2024-421	166	FaStep		002	002	002	002	002 - POSITIVE	17	17	17	100
2024-421	168	STANBIO 20		002	002	002	002	002 - POSITIVE	14	14	14	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
031 hCG-QUALITATIVE													
2024-422	113	BIO-SIGN		001	001	001	001	001 - NEGATIVE	23	23	23	100	
2024-422	142	INSTANT VI		001	001	001	001	001 - NEGATIVE	32	32	32	100	
2024-422	150	AIM STEP		001	001	001	001	002 - POSITIVE	108	5	103	0	
2024-422	150	AIM STEP		001	001	001	001	001 - NEGATIVE	108	103	103	100	
2024-422	164	HCG Alere		001	001	001	001	001 - NEGATIVE	72	72	72	100	
2024-422	165	Osom HCG C		001	001	001	001	001 - NEGATIVE	13	13	13	100	
2024-422	166	FaStep		001	001	001	001	001 - NEGATIVE	17	17	17	100	
2024-422	168	STANBIO 20		001	001	001	001	001 - NEGATIVE	14	14	14	100	
2024-423	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	23	23	23	100	
2024-423	142	INSTANT VI		002	002	002	002	002 - POSITIVE	32	32	32	100	
2024-423	150	AIM STEP		002	002	002	002	002 - POSITIVE	108	108	108	100	
2024-423	164	HCG Alere		002	002	002	002	002 - POSITIVE	72	72	72	100	
2024-423	165	Osom HCG C		002	002	002	002	002 - POSITIVE	13	13	13	100	
2024-423	166	FaStep		002	002	002	002	002 - POSITIVE	17	17	17	100	
2024-423	168	STANBIO 20		002	002	002	002	002 - POSITIVE	14	14	14	100	
2024-424	113	BIO-SIGN		001	001	001	001	001 - NEGATIVE	23	23	23	100	
2024-424	142	INSTANT VI		001	001	001	001	001 - NEGATIVE	32	32	32	100	
2024-424	150	AIM STEP		001	001	001	001	001 - NEGATIVE	108	101	101	100	
2024-424	150	AIM STEP		001	001	001	001	002 - POSITIVE	108	7	101	0	
2024-424	164	HCG Alere		001	001	001	001	001 - NEGATIVE	72	72	72	100	
2024-424	165	Osom HCG C		001	001	001	001	001 - NEGATIVE	13	13	13	100	
2024-424	166	FaStep		001	001	001	001	001 - NEGATIVE	17	17	17	100	
2024-424	168	STANBIO 20		001	001	001	001	001 - NEGATIVE	14	14	14	100	
2024-425	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	23	23	23	100	
2024-425	142	INSTANT VI		002	002	002	002	002 - POSITIVE	32	32	32	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-425	150	AIM STEP		002 002	002 002		002 - POSITIVE	108	108	108	100	
2024-425	164	HCG Alere		002 002	002 002		002 - POSITIVE	72	72	72	100	
2024-425	165	Osom HCG C		002 002	002 002		002 - POSITIVE	13	13	13	100	
2024-425	166	FaStep		002 002	002 002		002 - POSITIVE	17	17	17	100	
2024-425	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100	

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE												
2024-411	018	BIO SIGN		002 002	002 002		002 - POSITIVE	24	24	24	100	
2024-411	114	INSTANT VI		002 002	002 002		002 - POSITIVE	69	69	69	100	
2024-411	118	AIM STEP		002 002	002 002		002 - POSITIVE	217	217	217	100	
2024-411	130	ALERE HCG		002 002	002 002		002 - POSITIVE	96	96	96	100	
2024-411	131	OSOM HCG		002 002	002 002		002 - POSITIVE	28	28	28	100	
2024-411	133	FaStep		002 002	002 002		002 - POSITIVE	34	34	34	100	
2024-411	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	54	54	54	100	
2024-411	136	CLARITY		002 002	002 002		002 - POSITIVE	20	20	20	100	
2024-412	018	BIO SIGN		002 002	002 002		002 - POSITIVE	24	24	24	100	
2024-412	114	INSTANT VI		002 002	002 002		002 - POSITIVE	69	69	69	100	
2024-412	118	AIM STEP		002 002	002 002		002 - POSITIVE	217	217	217	100	
2024-412	130	ALERE HCG		002 002	002 002		002 - POSITIVE	96	96	96	100	
2024-412	131	OSOM HCG		002 002	002 002		002 - POSITIVE	28	28	28	100	
2024-412	133	FaStep		002 002	002 002		002 - POSITIVE	34	34	34	100	
2024-412	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	54	54	54	100	
2024-412	136	CLARITY		002 002	002 002		002 - POSITIVE	20	20	20	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
151 hCG ONLY QUALITATIVE													
2024-413	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	24	24	24	100		
2024-413	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	69	69	69	100		
2024-413	118	AIM STEP		001 001	001 001		001 - NEGATIVE	217	217	217	100		
2024-413	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	96	96	96	100		
2024-413	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	28	28	28	100		
2024-413	133	FaStep		001 001	001 001		001 - NEGATIVE	34	34	34	100		
2024-413	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	54	54	54	100		
2024-413	136	CLARITY		001 001	001 001		001 - NEGATIVE	20	20	20	100		
2024-414	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	24	24	24	100		
2024-414	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	69	69	69	100		
2024-414	118	AIM STEP		001 001	001 001		001 - NEGATIVE	217	217	217	100		
2024-414	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	96	96	96	100		
2024-414	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	28	28	28	100		
2024-414	133	FaStep		001 001	001 001		001 - NEGATIVE	34	34	34	100		
2024-414	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	54	54	54	100		
2024-414	136	CLARITY		001 001	001 001		001 - NEGATIVE	20	20	20	100		
2024-415	018	BIO SIGN		002 002	002 002		002 - POSITIVE	24	24	24	100		
2024-415	114	INSTANT VI		002 002	002 002		002 - POSITIVE	69	69	69	100		
2024-415	118	AIM STEP		002 002	002 002		002 - POSITIVE	217	217	217	100		
2024-415	130	ALERE HCG		002 002	002 002		002 - POSITIVE	96	96	96	100		
2024-415	131	OSOM HCG		002 002	002 002		002 - POSITIVE	28	28	28	100		
2024-415	133	FaStep		002 002	002 002		002 - POSITIVE	34	34	34	100		
2024-415	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	54	54	54	100		
2024-415	136	CLARITY		002 002	002 002		002 - POSITIVE	20	20	20	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY      SUB: 30 ENDOCRINOLOGY      GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
173 T3 UPTAKE		CLIA TEST ID #: 565	EVALUATION CRITERIA: TARGET VALUE 3 SD									
2024-421	1 %U	84 VITROS ECI	1	25-35	44	56.571	2.744	4.85	48.340	64.800		
2024-421	1 %U	91 B.C.ACCESS	2	35-45	32	49.332	2.889	5.86	40.660	58.000		
2024-421	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	0.748	0.034	4.50	0.650	0.850		
2024-421	4 %	32 DIMENSION	2	35-45	46	37.700	1.160	3.08	34.220	41.180		
2024-421	4 %	91 B.C.ACCESS	2	35-45	11	50.155	2.765	5.51	41.860	58.450		
2024-421	4 %	106 ATELLICA	1	25-35	10	46.076	3.524	7.65	35.500	56.650		
2024-421	5 TBI	98 ROCHE COBA	4	0.8-1.3	41	0.875	0.047	5.38	0.730	1.020		
2024-422	1 %U	84 VITROS ECI	1	25-35	44	26.489	3.211	12.12	16.860	36.120		
2024-422	1 %U	91 B.C.ACCESS	2	35-45	32	32.763	2.201	6.72	26.160	39.370		
2024-422	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	1.362	0.053	3.92	1.200	1.520		
2024-422	4 %	32 DIMENSION	2	35-45	46	29.061	1.031	3.55	25.970	32.150		
2024-422	4 %	91 B.C.ACCESS	2	35-45	11	33.600	1.706	5.08	28.480	38.720		
2024-422	4 %	106 ATELLICA	1	25-35	10	19.312	1.284	6.65	15.460	23.160		
2024-422	5 TBI	98 ROCHE COBA	4	0.8-1.3	41	1.133	0.042	3.73	1.010	1.260		
2024-423	1 %U	84 VITROS ECI	1	25-35	44	51.252	2.981	5.82	42.310	60.200		
2024-423	1 %U	91 B.C.ACCESS	2	35-45	32	47.269	2.532	5.36	39.670	54.860		
2024-423	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	0.951	0.045	4.75	0.820	1.090		
2024-423	4 %	32 DIMENSION	2	35-45	46	37.862	1.401	3.70	33.660	42.060		
2024-423	4 %	91 B.C.ACCESS	2	35-45	11	46.791	3.769	8.05	35.480	58.100		
2024-423	4 %	106 ATELLICA	1	25-35	10	38.199	2.657	6.96	30.230	46.170		
2024-423	5 TBI	98 ROCHE COBA	4	0.8-1.3	41	0.753	0.051	6.75	0.600	0.910		
2024-424	1 %U	84 VITROS ECI	1	25-35	44	57.964	3.346	5.77	47.930	68.000		
2024-424	1 %U	91 B.C.ACCESS	2	35-45	32	51.194	2.784	5.44	42.840	59.550		
2024-424	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	0.645	0.039	6.06	0.530	0.760		
2024-424	4 %	32 DIMENSION	2	35-45	46	37.469	1.422	3.79	33.200	41.730		
2024-424	4 %	91 B.C.ACCESS	2	35-45	11	51.673	2.423	4.69	44.400	58.940		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-424	4	%	106	APELLICA	1	25-35	10	49.762	4.422	8.89	36.500	63.030	
2024-424	5	TBI	98	ROCHE COBA	4	0.8-1.3	41	0.939	0.046	4.87	0.800	1.080	
173 T3 UPTAKE			CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-425	1	%U	84	VITROS ECI	1	25-35	44	46.239	3.606	7.80	35.420	57.060	
2024-425	1	%U	91	B.C.ACCESS	2	35-45	32	44.906	2.927	6.52	36.120	53.690	
2024-425	2	TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.159	0.057	4.93	0.990	1.330	
2024-425	4	%	32	DIMENSION	2	35-45	46	38.474	1.255	3.26	34.710	42.240	
2024-425	4	%	91	B.C.ACCESS	2	35-45	11	45.218	2.412	5.33	37.980	52.450	
2024-425	4	%	106	APELLICA	1	25-35	10	31.877	2.279	7.15	25.040	38.710	
2024-425	5	TBI	98	ROCHE COBA	4	0.8-1.3	41	0.611	0.055	8.96	0.450	0.780	

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY				GRP: 60 TOXICOLOGY						
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
043 DIGOXIN			CLIA TEST ID #: 645				EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2024-421	50	VITROS					16	0.575	0.103	17.93	0.400	0.800	
2024-422	50	VITROS					16	0.400	0.000	0.00	0.200	0.600	
2024-423	50	VITROS					16	1.050	0.146	13.88	0.800	1.300	
2024-424	50	VITROS					16	0.433	0.070	16.14	0.200	0.600	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
043 DIGOXIN		CLIA TEST ID #: 645	EVALUATION CRITERIA: TARGET VALUE	20	% OR 0.20	{GREATER}				
2024-425	50 VITROS			16	1.831	0.157	8.57	1.500	2.200	
045 FERRITIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	%					
2024-421	50 VITROS			20	35.935	1.668	4.64	27.000	44.900	
2024-421	90 ROCHE COBA			13	62.800	2.725	4.34	47.100	78.500	
2024-421	98 ARC i200sr			10	67.350	4.791	7.11	50.500	84.200	
2024-421	105 ATELLICA			10	40.670	2.286	5.62	30.500	50.800	
2024-422	50 VITROS			20	54.325	3.224	5.93	40.700	67.900	
2024-422	90 ROCHE COBA			13	89.146	5.227	5.86	66.900	111.400	
2024-422	98 ARC i200sr			10	79.190	6.901	8.71	59.400	99.000	
2024-422	105 ATELLICA			10	59.390	2.459	4.14	44.500	74.200	
2024-423	50 VITROS			20	89.790	4.773	5.32	67.300	112.200	
2024-423	90 ROCHE COBA			13	153.638	6.386	4.16	115.200	192.000	
2024-423	98 ARC i200sr			10	172.360	14.330	8.31	129.300	215.500	
2024-423	105 ATELLICA			10	105.570	4.723	4.47	79.200	132.000	
2024-424	50 VITROS			20	16.330	0.458	2.81	12.200	20.400	
2024-424	90 ROCHE COBA			13	26.685	1.251	4.69	20.000	33.400	
2024-424	98 ARC i200sr			10	24.760	2.812	11.36	18.600	31.000	
2024-424	105 ATELLICA			10	15.740	0.745	4.73	11.800	19.700	
2024-425	50 VITROS			20	166.390	7.248	4.36	124.800	208.000	
2024-425	90 ROCHE COBA			13	278.708	11.867	4.26	209.000	348.400	
2024-425	98 ARC i200sr			10	313.880	26.373	8.40	235.400	392.400	
2024-425	105 ATELLICA			10	195.530	6.435	3.29	146.600	244.400	
046 GENTAMICIN		CLIA TEST ID #: 665								
2024-421	50 VITROS			17	2.082	0.062	2.96	1.600	2.600	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
046 GENTAMICIN		CLIA TEST ID #: 665	EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-422	50 VITROS			17	0.994	0.064	6.43	0.700	1.200	
2024-423	50 VITROS			17	7.012	0.325	4.64	5.300	8.800	
2024-424	50 VITROS			17	0.600	0.000	0.00	0.500	0.800	
2024-425	50 VITROS			17	14.153	0.766	5.41	10.600	17.700	
050 PHENYTOIN		CLIA TEST ID #: 695								
2024-421	50 VITROS			16	4.363	0.483	11.08	3.300	5.500	
2024-422	50 VITROS			16	8.331	0.568	6.81	6.200	10.400	
2024-423	50 VITROS			16	14.813	0.933	6.30	11.100	18.500	
2024-424	50 VITROS			16	2.688	1.029	38.28	2.000	3.400	
2024-425	50 VITROS			16	30.256	2.033	6.72	22.700	37.800	
054 THEOPHYLLINE		CLIA TEST ID #: 735								
2024-421	50 VITROS			12	13.942	0.581	4.17	10.500	17.400	
2024-422	50 VITROS			12	16.775	1.043	6.22	12.600	21.000	
2024-423	50 VITROS			12	37.767	1.280	3.39	28.300	47.200	
2024-424	50 VITROS			12	3.283	0.479	14.60	2.500	4.100	
2024-425	50 VITROS			12	70.533	2.144	3.04	52.900	88.200	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
127	VANCOMYCIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-421	50	VITROS		21	7.967	0.372	4.67	6.000	10.000		
2024-422	50	VITROS		21	5.000	0.000	0.00	3.800	6.300		
2024-423	50	VITROS		21	25.533	1.119	4.38	19.200	31.900		
2024-424	50	VITROS		21	5.000	0.000	0.00	3.800	6.300		
2024-425	50	VITROS		21	52.419	2.548	4.86	39.300	65.500		
<hr/>											
SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
065	URINA-PROTEIN QUANT.			EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2024-451	58	VITROS		42	180.317	11.919	6.61	135.200	225.400		
2024-451	62	SIEM DIM.		48	118.655	3.030	2.55	89.000	148.300		
2024-451	79	BECK. COUL		20	100.889	3.668	3.64	75.700	126.100		
2024-451	93	ARCHITECT		18	99.372	4.122	4.15	74.500	124.200		
2024-451	113	ROCHE COBA		36	95.639	2.687	2.81	71.700	119.500		
2024-451	146	ATELLICA		11	114.045	2.999	2.63	85.500	142.600		
2024-452	58	VITROS		42	5.390	0.694	12.88	0.400	10.400		
2024-452	62	SIEM DIM.		48	23.549	2.803	11.90	17.700	29.400		
2024-452	79	BECK. COUL		20	5.558	0.599	10.77	0.600	10.600		
2024-452	93	ARCHITECT		18	6.859	0.261	3.81	1.900	11.900		
2024-452	113	ROCHE COBA		36	4.011	0.638	15.91	0	9.000		
2024-452	146	ATELLICA		11	24.130	1.396	5.79	18.100	30.200		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
065	URINA-PROTEIN QUANT.	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2024-453	58 VITROS			42	5.000	0.000	0.00	0.000	10.000	
2024-453	62 SIEM DIM.			48	14.726	2.991	20.31	9.700	19.700	
2024-453	79 BECK. COUL			20	4.150	0.642	15.48	0	9.200	
2024-453	93 ARCHITECT			18	6.806	0.054	0.79	1.800	11.800	
2024-453	113 ROCHE COBA			36	3.918	0.263	6.72	0	8.900	
2024-453	146 ATELLICA			11	13.082	2.430	18.58	8.100	18.100	
2024-454	58 VITROS			42	148.286	16.229	10.94	111.200	185.400	
2024-454	62 SIEM DIM.			48	109.936	2.247	2.04	82.500	137.400	
2024-454	79 BECK. COUL			20	101.442	5.047	4.98	76.100	126.800	
2024-454	93 ARCHITECT			18	97.178	3.936	4.05	72.900	121.500	
2024-454	113 ROCHE COBA			36	90.639	2.283	2.52	68.000	113.300	
2024-454	146 ATELLICA			11	103.518	5.520	5.33	77.600	129.400	
2024-455	58 VITROS			42	170.805	11.223	6.57	128.100	213.500	
2024-455	62 SIEM DIM.			48	117.072	2.170	1.85	87.800	146.300	
2024-455	79 BECK. COUL			20	104.847	3.788	3.61	78.600	131.100	
2024-455	93 ARCHITECT			18	98.906	4.256	4.30	74.200	123.600	
2024-455	113 ROCHE COBA			36	92.017	2.467	2.68	69.000	115.000	
2024-455	146 ATELLICA			11	114.100	3.236	2.84	85.600	142.600	
067	URI-SPECIFIC GRAVITY		EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-451	11 AMES NM10S			39	1.018	0.003	0.31	1.009	1.028	
2024-451	13 BAYER CLI			23	1.018	0.002	0.24	1.010	1.025	
2024-451	67 URISCAN			56	1.013	0.004	0.36	1.002	1.024	
2024-451	72 URS-9-TECO			52	1.017	0.004	0.37	1.006	1.029	
2024-451	80 ROCHE (CHE			37	1.011	0.002	0.22	1.004	1.017	
2024-451	89 AIMSTRIP			147	1.017	0.004	0.35	1.006	1.027	
2024-451	94 CLINITEK			106	1.018	0.003	0.27	1.010	1.027	
2024-451	102 ACON LAB			125	1.016	0.003	0.34	1.006	1.027	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-451	131	iCHEM VELO		32	1.028	0.001	0.12	1.024	1.032
2024-451	138	URS-10T		19	1.016	0.005	0.45	1.002	1.029
2024-451	140	MISSION A		44	1.017	0.004	0.36	1.006	1.028
2024-451	145	CLINITEK		36	1.031	0.001	0.05	1.030	1.033
2024-451	147	Mission120		42	1.019	0.002	0.17	1.014	1.025
2024-451	148	Mission500		123	1.017	0.003	0.25	1.010	1.025
2024-451	151	Clari. Uro		20	1.013	0.002	0.24	1.006	1.020
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-452	11	AMES NM10S		39	1.013	0.004	0.38	1.002	1.025
2024-452	13	BAYER CLI		23	1.013	0.003	0.28	1.005	1.022
2024-452	67	URISCAN		56	1.008	0.004	0.37	0.997	1.020
2024-452	72	URS-9-TECO		52	1.014	0.004	0.37	1.003	1.025
2024-452	80	ROCHE (CHE		37	1.012	0.003	0.26	1.004	1.020
2024-452	89	AIMSTRIP		147	1.012	0.004	0.38	1.000	1.023
2024-452	94	CLINITEK		106	1.013	0.003	0.28	1.005	1.022
2024-452	102	ACON LAB		125	1.013	0.004	0.40	1.001	1.025
2024-452	131	iCHEM VELO		32	1.026	0.001	0.08	1.023	1.028
2024-452	138	URS-10T		19	1.013	0.004	0.40	1.001	1.025
2024-452	140	MISSION A		44	1.013	0.004	0.43	1.000	1.027
2024-452	145	CLINITEK		36	1.031	0.001	0.05	1.030	1.033
2024-452	147	Mission120		42	1.016	0.003	0.28	1.007	1.024
2024-452	148	Mission500		123	1.015	0.004	0.37	1.004	1.027
2024-452	151	Clari. Uro		20	1.011	0.002	0.20	1.005	1.017
2024-453	11	AMES NM10S		39	1.023	0.003	0.29	1.014	1.032
2024-453	13	BAYER CLI		23	1.021	0.004	0.39	1.009	1.033
2024-453	67	URISCAN		56	1.020	0.004	0.35	1.010	1.031
2024-453	72	URS-9-TECO		52	1.020	0.005	0.49	1.005	1.035
2024-453	80	ROCHE (CHE		37	1.016	0.002	0.21	1.010	1.023
2024-453	89	AIMSTRIP		147	1.021	0.003	0.32	1.011	1.031

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-453	94	CLINITEK		106	1.022	0.004	0.34	1.012	1.033
2024-453	102	ACON LAB		125	1.022	0.003	0.29	1.013	1.031
2024-453	131	iCHEM VELO		32	1.027	0.001	0.07	1.024	1.029
2024-453	138	URS-10T		19	1.021	0.005	0.51	1.005	1.036
2024-453	140	MISSION A		44	1.022	0.004	0.35	1.012	1.033
2024-453	145	CLINITEK		36	1.033	0.001	0.09	1.030	1.035
2024-453	147	Mission120		42	1.022	0.002	0.23	1.015	1.029
2024-453	148	Mission500		123	1.022	0.003	0.25	1.015	1.030
2024-453	151	Clari. Uro		20	1.025	0.004	0.34	1.014	1.035
067 URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-454	11	AMES NM10S		39	1.024	0.003	0.25	1.017	1.032
2024-454	13	BAYER CLI		23	1.023	0.002	0.22	1.017	1.030
2024-454	67	URISCAN		56	1.020	0.005	0.45	1.007	1.034
2024-454	72	URS-9-TECO		52	1.022	0.004	0.38	1.010	1.033
2024-454	80	ROCHE (CHE		37	1.015	0.000	0.00	1.015	1.015
2024-454	89	AIMSTRIP		147	1.021	0.002	0.22	1.014	1.028
2024-454	94	CLINITEK		106	1.024	0.002	0.23	1.017	1.031
2024-454	102	ACON LAB		125	1.021	0.002	0.22	1.014	1.027
2024-454	131	iCHEM VELO		32	1.025	0.001	0.10	1.022	1.028
2024-454	138	URS-10T		19	1.022	0.002	0.24	1.015	1.029
2024-454	140	MISSION A		44	1.021	0.003	0.32	1.012	1.031
2024-454	145	CLINITEK		36	1.030	0.001	0.06	1.028	1.032
2024-454	147	Mission120		42	1.024	0.003	0.28	1.015	1.032
2024-454	148	Mission500		123	1.020	0.001	0.13	1.016	1.024
2024-454	151	Clari. Uro		20	1.022	0.002	0.22	1.015	1.028
2024-455	11	AMES NM10S		39	1.022	0.003	0.32	1.012	1.031
2024-455	13	BAYER CLI		23	1.021	0.003	0.30	1.012	1.030
2024-455	67	URISCAN		56	1.016	0.003	0.29	1.007	1.025
2024-455	72	URS-9-TECO		52	1.020	0.004	0.38	1.008	1.031

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-455	80	ROCHE (CHE		37	1.012	0.002	0.25	1.005	1.020
2024-455	89	AIMSTRIP		147	1.018	0.003	0.27	1.010	1.026
2024-455	94	CLINITEK		106	1.021	0.003	0.27	1.013	1.030
2024-455	102	ACON LAB		125	1.018	0.003	0.29	1.010	1.027
2024-455	131	iCHEM VELO		32	1.025	0.001	0.10	1.022	1.028
2024-455	138	URS-10T		19	1.020	0.005	0.48	1.005	1.035
2024-455	140	MISSION A		44	1.019	0.003	0.31	1.009	1.028
2024-455	145	CLINITEK		36	1.027	0.001	0.08	1.025	1.030
2024-455	147	Mission120		42	1.021	0.002	0.24	1.014	1.028
2024-455	148	Mission500		123	1.019	0.002	0.20	1.013	1.025
2024-455	151	Clari. Uro		20	1.016	0.002	0.20	1.010	1.022
166	MICROALBUMIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}				
2024-451	58	VITROS		54	835.194	47.340	5.67	626.400	1044.000
2024-451	62	SIEM DIM.		81	848.271	43.579	5.14	636.200	1060.300
2024-451	79	BECK. COUL		20	784.555	97.039	12.37	588.400	980.700
2024-451	85	Rx DAYTONA		14	781.523	77.396	9.90	586.100	976.900
2024-451	93	ARCHITECT		22	845.623	17.888	2.12	634.200	1057.000
2024-451	95	INTEGRA		19	836.668	24.238	2.90	627.500	1045.800
2024-451	113	ROCHE COBA		43	802.205	49.557	6.18	601.700	1002.800
2024-451	146	ATELLICA		13	713.846	21.370	2.99	535.400	892.300
2024-452	58	VITROS		54	6.030	0.157	2.61	1.000	11.000
2024-452	62	SIEM DIM.		81	2.743	1.617	58.94	0	7.700
2024-452	79	BECK. COUL		20	2.415	2.864	118.58	0	7.400
2024-452	85	Rx DAYTONA		14	2.107	2.233	105.97	0	7.100
2024-452	93	ARCHITECT		22	4.995	0.021	0.43	0.000	10.000
2024-452	95	INTEGRA		19	3.005	1.184	39.41	0	8.000
2024-452	113	ROCHE COBA		43	12.000	0.000	0.00	7.000	17.000
2024-452	146	ATELLICA		13	3.000	0.000	0.00	0	8.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
166	MICROALBUMIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}			
2024-453	58	VITROS		54	6.019	0.137	2.28	1.000	11.000
2024-453	62	SIEM DIM.		81	3.250	2.572	79.14	0	8.300
2024-453	79	BECK. COUL		20	2.450	2.877	117.42	0	7.500
2024-453	85	Rx DAYTONA		14	2.386	2.297	96.29	0	7.400
2024-453	93	ARCHITECT		22	4.995	0.021	0.43	0.000	10.000
2024-453	95	INTEGRA		19	2.826	1.050	37.14	0	7.800
2024-453	113	ROCHE COBA		43	12.000	0.000	0.00	7.000	17.000
2024-453	146	APELLICA		13	3.000	0.000	0.00	0	8.000
2024-454	58	VITROS		54	840.804	45.857	5.45	630.600	1051.000
2024-454	62	SIEM DIM.		81	844.338	52.168	6.18	633.300	1055.400
2024-454	79	BECK. COUL		20	773.755	95.327	12.32	580.300	967.200
2024-454	85	Rx DAYTONA		14	835.893	128.485	15.37	626.900	1044.900
2024-454	93	ARCHITECT		22	854.162	22.265	2.61	640.600	1067.700
2024-454	95	INTEGRA		19	843.979	34.871	4.13	633.000	1055.000
2024-454	113	ROCHE COBA		43	808.452	49.325	6.10	606.300	1010.600
2024-454	146	APELLICA		13	712.238	18.998	2.67	534.200	890.300
2024-455	58	VITROS		54	860.498	46.976	5.46	645.400	1075.600
2024-455	62	SIEM DIM.		81	861.349	49.617	5.76	646.000	1076.700
2024-455	79	BECK. COUL		20	791.315	102.006	12.89	593.500	989.100
2024-455	85	Rx DAYTONA		14	819.323	65.495	7.99	614.500	1024.200
2024-455	93	ARCHITECT		22	882.968	24.567	2.78	662.200	1103.700
2024-455	95	INTEGRA		19	856.189	26.966	3.15	642.100	1070.200
2024-455	113	ROCHE COBA		43	823.638	49.894	6.06	617.700	1029.500
2024-455	146	APELLICA		13	726.877	17.488	2.41	545.200	908.600
167	CREATININE								
2024-451	58	VITROS		57	242.318	9.556	3.94	181.700	302.900
2024-451	62	SIEM DIM.		77	239.280	7.924	3.31	179.500	299.100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-451	79	BECK. COUL		21	198.124	14.922	7.53	148.600	247.700
2024-451	85	Rx DAYTONA		12	226.392	22.120	9.77	169.800	283.000
2024-451	93	ARCHITECT		20	235.385	5.053	2.15	176.500	294.200
2024-451	95	INTEGRA		19	248.905	8.141	3.27	186.700	311.100
2024-451	113	ROCHE COBA		43	244.653	9.263	3.79	183.500	305.800
2024-451	146	ATELLICA		13	222.100	4.803	2.16	166.600	277.600
167	CREATININE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}				
2024-452	58	VITROS		57	250.467	13.275	5.30	187.900	313.100
2024-452	62	SIEM DIM.		77	246.697	9.476	3.84	185.000	308.400
2024-452	79	BECK. COUL		21	217.352	13.866	6.38	163.000	271.700
2024-452	85	Rx DAYTONA		12	227.667	23.131	10.16	170.800	284.600
2024-452	93	ARCHITECT		20	242.380	5.591	2.31	181.800	303.000
2024-452	95	INTEGRA		19	256.616	7.973	3.11	192.500	320.800
2024-452	113	ROCHE COBA		43	252.902	10.551	4.17	189.700	316.100
2024-452	146	ATELLICA		13	231.538	6.176	2.67	173.700	289.400
2024-453	58	VITROS		57	3.205	0.115	3.59	0	8.200
2024-453	62	SIEM DIM.		77	8.855	5.602	63.26	3.900	13.900
2024-453	79	BECK. COUL		21	0.770	1.664	216.15	0	5.800
2024-453	85	Rx DAYTONA		12	1.142	1.215	106.41	0	6.100
2024-453	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000
2024-453	95	INTEGRA		19	0.372	0.478	128.47	0	5.400
2024-453	113	ROCHE COBA		43	3.880	0.837	21.56	0	8.900
2024-453	146	ATELLICA		13	3.000	0.000	0.00	0	8.000
2024-454	58	VITROS		57	3.205	0.114	3.56	0	8.200
2024-454	62	SIEM DIM.		77	8.914	5.577	62.56	3.900	13.900
2024-454	79	BECK. COUL		21	0.910	1.635	179.63	0	5.900
2024-454	85	Rx DAYTONA		12	0.775	0.608	78.51	0	5.800
2024-454	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS			LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-454	95	INTEGRA				19	0.567	0.281	49.57	0	5.600
2024-454	113	ROCHE COBA				43	3.793	0.997	26.29	0	8.800
2024-454	146	ATELLICA				13	3.000	0.000	0.00	0	8.000
167 CREATININE			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2024-455	58	VITROS				57	242.916	10.305	4.24	182.200	303.600
2024-455	62	SIEM DIM.				77	249.368	9.979	4.00	187.000	311.700
2024-455	79	BECK. COUL				21	218.610	13.702	6.27	164.000	273.300
2024-455	85	Rx DAYTONA				12	233.933	28.379	12.13	175.500	292.400
2024-455	93	ARCHITECT				20	242.555	5.562	2.29	181.900	303.200
2024-455	95	INTEGRA				19	255.737	6.964	2.72	191.800	319.700
2024-455	113	ROCHE COBA				43	253.281	8.798	3.47	190.000	316.600
2024-455	146	ATELLICA				13	229.408	4.030	1.76	172.100	286.800

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS	
057 URINALYSIS-BILIRUBIN											
2024-451	011	AMES NM10S		058 060	057 059		060 - 3+	40	4	40	100
2024-451	011	AMES NM10S		058 060	057 059		058 - TRACES,1+	40	7	40	100
2024-451	011	AMES NM10S		058 060	057 059		059 - 2+	40	29	40	100
2024-451	013	BAYER CLI		058 060	057 059		060 - 3+	23	1	23	100
2024-451	013	BAYER CLI		058 060	057 059		058 - TRACES,1+	23	5	23	100
2024-451	013	BAYER CLI		058 060	057 059		059 - 2+	23	17	23	100
2024-451	067	URISCAN		057 059	057 059		057 - NEGATIVE	55	15	55	100
2024-451	067	URISCAN		057 059	057 059		058 - TRACES,1+	55	36	55	100
2024-451	067	URISCAN		057 059	057 059		059 - 2+	55	4	55	100
2024-451	072	URS-9-TECO		058 060	057 059		058 - TRACES,1+	53	11	53	100
2024-451	072	URS-9-TECO		058 060	057 059		059 - 2+	53	32	53	100
2024-451	072	URS-9-TECO		058 060	057 059		060 - 3+	53	9	53	100



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-451	072	URS-9-TECO		058 060	057 059		057 - NEGATIVE	53	1	53	100	
2024-451	080	ROCHE (CHE		057 059	057 059		059 - 2+	36	1	35	100	
2024-451	080	ROCHE (CHE		057 059	057 059		060 - 3+	36	1	35	0	
2024-451	080	ROCHE (CHE		057 059	057 059		058 - TRACES,1+	36	34	35	100	
2024-451	089	AIMSTRIP		057 059	057 059		059 - 2+	145	43	136	100	
2024-451	089	AIMSTRIP		057 059	057 059		058 - TRACES,1+	145	81	136	100	
2024-451	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	145	12	136	100	
2024-451	089	AIMSTRIP		057 059	057 059		060 - 3+	145	9	136	0	
2024-451	094	CLINITEK		058 060	057 059		059 - 2+	106	91	106	100	
2024-451	094	CLINITEK		058 060	057 059		058 - TRACES,1+	106	14	106	100	
2024-451	094	CLINITEK		058 060	057 059		060 - 3+	106	1	106	100	
2024-451	102	ACON LAB		057 059	057 059		059 - 2+	117	32	115	100	
2024-451	102	ACON LAB		057 059	057 059		058 - TRACES,1+	117	82	115	100	
2024-451	102	ACON LAB		057 059	057 059		060 - 3+	117	2	115	0	
2024-451	102	ACON LAB		057 059	057 059		057 - NEGATIVE	117	1	115	100	
2024-451	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	32	32	32	100	
2024-451	138	URS-10T		058 060	057 059		058 - TRACES,1+	21	6	21	100	
2024-451	138	URS-10T		058 060	057 059		060 - 3+	21	4	21	100	
2024-451	138	URS-10T		058 060	057 059		059 - 2+	21	11	21	100	
2024-451	140	MISSION A		057 059	057 059		058 - TRACES,1+	40	33	40	100	
2024-451	140	MISSION A		057 059	057 059		059 - 2+	40	7	40	100	
2024-451	145	CLINITEK		057 057	057 059		057 - NEGATIVE	37	37	37	100	
2024-451	147	Mission120		057 059	057 059		057 - NEGATIVE	44	2	44	100	
2024-451	147	Mission120		057 059	057 059		058 - TRACES,1+	44	33	44	100	
2024-451	147	Mission120		057 059	057 059		059 - 2+	44	9	44	100	
2024-451	148	Mission500		057 059	057 059		059 - 2+	126	8	126	100	
2024-451	148	Mission500		057 059	057 059		058 - TRACES,1+	126	118	126	100	
2024-451	151	Clari. Uro		057 059	057 059		060 - 3+	21	1	20	0	
2024-451	151	Clari. Uro		057 059	057 059		059 - 2+	21	5	20	100	
2024-451	151	Clari. Uro		057 059	057 059		058 - TRACES,1+	21	15	20	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
057 URINALYSIS-BILIRUBIN													
2024-452	011	AMES NMI0S		057	057	057	057	057 - NEGATIVE	40	40	40	100	
2024-452	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	23	23	23	100	
2024-452	067	URISCAN		057	057	057	057	057 - NEGATIVE	55	55	55	100	
2024-452	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	53	53	53	100	
2024-452	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2024-452	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	145	145	145	100	
2024-452	094	CLINITEK		057	057	057	057	057 - NEGATIVE	106	106	106	100	
2024-452	102	ACON LAB		057	057	057	057	057 - NEGATIVE	117	117	117	100	
2024-452	131	iCHEM VELO		057	057	057	057	057 - NEGATIVE	32	32	32	100	
2024-452	138	URS-10T		057	057	057	057	057 - NEGATIVE	21	21	21	100	
2024-452	140	MISSION A		057	057	057	057	057 - NEGATIVE	40	40	40	100	
2024-452	145	CLINITEK		057	057	057	057	057 - NEGATIVE	37	37	37	100	
2024-452	147	Mission120		057	057	057	057	057 - NEGATIVE	44	44	44	100	
2024-452	148	Mission500		057	057	057	057	057 - NEGATIVE	126	126	126	100	
2024-452	151	Clari. Uro		057	057	057	057	057 - NEGATIVE	21	21	21	100	
2024-453	011	AMES NMI0S		057	057	057	057	057 - NEGATIVE	40	40	40	100	
2024-453	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	23	23	23	100	
2024-453	067	URISCAN		057	057	057	057	057 - NEGATIVE	55	55	55	100	
2024-453	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	53	53	53	100	
2024-453	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2024-453	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	145	145	145	100	
2024-453	094	CLINITEK		057	057	057	057	057 - NEGATIVE	106	106	106	100	
2024-453	102	ACON LAB		057	057	057	057	057 - NEGATIVE	117	117	117	100	
2024-453	131	iCHEM VELO		057	057	057	057	057 - NEGATIVE	32	32	32	100	
2024-453	138	URS-10T		057	057	057	057	057 - NEGATIVE	21	21	21	100	
2024-453	140	MISSION A		057	057	057	057	057 - NEGATIVE	40	40	40	100	
2024-453	145	CLINITEK		057	057	057	057	057 - NEGATIVE	37	37	37	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-453	147	Mission120		057 057	057 057		057 - NEGATIVE	44	44	44	100	
2024-453	148	Mission500		057 057	057 057		057 - NEGATIVE	126	126	126	100	
2024-453	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	21	21	21	100	
057 URINALYSIS-BILIRUBIN												
2024-454	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	40	40	40	100	
2024-454	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	23	23	23	100	
2024-454	067	URISCAN		057 057	057 057		057 - NEGATIVE	55	55	55	100	
2024-454	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	53	53	53	100	
2024-454	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-454	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	145	145	145	100	
2024-454	094	CLINITEK		057 057	057 057		057 - NEGATIVE	106	106	106	100	
2024-454	102	ACON LAB		057 057	057 057		057 - NEGATIVE	117	117	117	100	
2024-454	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	32	32	32	100	
2024-454	138	URS-10T		057 057	057 057		057 - NEGATIVE	21	21	21	100	
2024-454	140	MISSION A		057 057	057 057		057 - NEGATIVE	40	40	40	100	
2024-454	145	CLINITEK		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2024-454	147	Mission120		057 057	057 057		057 - NEGATIVE	44	44	44	100	
2024-454	148	Mission500		057 057	057 057		057 - NEGATIVE	126	126	126	100	
2024-454	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	21	21	21	100	
2024-455	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	40	40	40	100	
2024-455	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	23	23	23	100	
2024-455	067	URISCAN		057 057	057 057		057 - NEGATIVE	55	55	55	100	
2024-455	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	53	53	53	100	
2024-455	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-455	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	145	145	145	100	
2024-455	094	CLINITEK		057 057	057 057		057 - NEGATIVE	106	106	106	100	
2024-455	102	ACON LAB		057 057	057 057		057 - NEGATIVE	117	117	117	100	
2024-455	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	32	32	32	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-455	138	URS-10T		057 057	057 057		057 - NEGATIVE	21	21	21	100		
2024-455	140	MISSION A		057 057	057 057		057 - NEGATIVE	40	40	40	100		
2024-455	145	CLINITEK		057 057	057 057		057 - NEGATIVE	37	37	37	100		
2024-455	147	Mission120		057 057	057 057		057 - NEGATIVE	44	44	44	100		
2024-455	148	Mission500		057 057	057 057		057 - NEGATIVE	126	126	126	100		
2024-455	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	21	21	21	100		
058 URINALYSIS-GLUCOSE													
2024-451	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	40	40	40	100		
2024-451	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	23	23	23	100		
2024-451	067	URISCAN		073 073	073 073		073 - NEGATIVE	55	55	55	100		
2024-451	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	52	52	52	100		
2024-451	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	37	37	37	100		
2024-451	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	146	146	146	100		
2024-451	094	CLINITEK		073 073	073 073	073 073	073 - NEGATIVE	106	106	106	100		
2024-451	102	ACON LAB		073 073	073 073	073 073	073 - NEGATIVE	123	123	123	100		
2024-451	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	32	32	32	100		
2024-451	138	URS-10T		073 073	073 073		073 - NEGATIVE	21	21	21	100		
2024-451	140	MISSION A		073 073	073 073		073 - NEGATIVE	42	42	42	100		
2024-451	145	CLINITEK		073 073	073 073		073 - NEGATIVE	37	37	37	100		
2024-451	147	Mission120		073 073	073 073		073 - NEGATIVE	42	42	42	100		
2024-451	148	Mission500		073 073	073 073		073 - NEGATIVE	124	124	124	100		
2024-451	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	21	21	21	100		
2024-452	011	AMES NM10S		076 078	075 077		078 - 2000mg/dl	40	3	39	100		
2024-452	011	AMES NM10S		076 078	075 077		076 - 500mg/dl2+	40	10	39	100		
2024-452	011	AMES NM10S		076 078	075 077		074 - TRACES	40	1	39	0		
2024-452	011	AMES NM10S		076 078	075 077		077 - 1000mg/dl	40	26	39	100		
2024-452	013	BAYER CLI		076 078	075 077		077 - 1000mg/dl	23	11	23	100		
2024-452	013	BAYER CLI		076 078	075 077		078 - 2000mg/dl	23	1	23	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-452	013	BAYER CLI		076 078	075 077		076 - 500mg/dl2+	23	11	23	100	
2024-452	067	URISCAN		077 078	075 077		076 - 500mg/dl2+	55	3	55	100	
2024-452	067	URISCAN		077 078	075 077		078 - 2000mg/dl	55	36	55	100	
2024-452	067	URISCAN		077 078	075 077		077 - 1000mg/dl	55	16	55	100	
2024-452	072	URS-9-TECO		076 078	075 077		076 - 500mg/dl2+	52	19	52	100	
2024-452	072	URS-9-TECO		076 078	075 077		077 - 1000mg/dl	52	31	52	100	
2024-452	072	URS-9-TECO		076 078	075 077		078 - 2000mg/dl	52	2	52	100	
2024-452	080	ROCHE (CHE		076 078	075 077		077 - 1000mg/dl	37	31	37	100	
2024-452	080	ROCHE (CHE		076 078	075 077		075 - 250mg/dl-+	37	2	37	100	
2024-452	080	ROCHE (CHE		076 078	075 077		078 - 2000mg/dl	37	3	37	100	
2024-452	080	ROCHE (CHE		076 078	075 077		076 - 500mg/dl2+	37	1	37	100	
2024-452	089	AIMSTRIP		076 078	075 077		075 - 250mg/dl-+	146	2	146	100	
2024-452	089	AIMSTRIP		076 078	075 077		078 - 2000mg/dl	146	1	146	100	
2024-452	089	AIMSTRIP		076 078	075 077		076 - 500mg/dl2+	146	49	146	100	
2024-452	089	AIMSTRIP		076 078	075 077		077 - 1000mg/dl	146	94	146	100	
2024-452	094	CLINITEK		076 078	075 077	075 077	077 - 1000mg/dl	106	69	106	100	
2024-452	094	CLINITEK		076 078	075 077	075 077	075 - 250mg/dl-+	106	3	106	100	
2024-452	094	CLINITEK		076 078	075 077	075 077	078 - 2000mg/dl	106	2	106	100	
2024-452	094	CLINITEK		076 078	075 077	075 077	076 - 500mg/dl2+	106	32	106	100	
2024-452	102	ACON LAB		075 077	075 077	075 077	076 - 500mg/dl2+	123	57	117	100	
2024-452	102	ACON LAB		075 077	075 077	075 077	075 - 250mg/dl-+	123	5	117	100	
2024-452	102	ACON LAB		075 077	075 077	075 077	078 - 2000mg/dl	123	4	117	0	
2024-452	102	ACON LAB		075 077	075 077	075 077	074 - TRACES	123	2	117	0	
2024-452	102	ACON LAB		075 077	075 077	075 077	077 - 1000mg/dl	123	55	117	100	
2024-452	131	iCHEM VELO		075 077	075 077		077 - 1000mg/dl	32	5	32	100	
2024-452	131	iCHEM VELO		075 077	075 077		076 - 500mg/dl2+	32	27	32	100	
2024-452	138	URS-10T		076 078	075 077		077 - 1000mg/dl	21	12	21	100	
2024-452	138	URS-10T		076 078	075 077		076 - 500mg/dl2+	21	9	21	100	
2024-452	140	MISSION A		076 078	075 077		078 - 2000mg/dl	42	6	42	100	
2024-452	140	MISSION A		076 078	075 077		076 - 500mg/dl2+	42	15	42	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-452	140	MISSION A		076 078	075 077		077 - 1000mg/dl	42	21	42	100	
2024-452	145	CLINITEK		075 077	075 077		076 - 500mg/dl2+	37	24	35	100	
2024-452	145	CLINITEK		075 077	075 077		077 - 1000mg/dl	37	9	35	100	
2024-452	145	CLINITEK		075 077	075 077		075 - 250mg/dl-+	37	2	35	100	
2024-452	145	CLINITEK		075 077	075 077		078 - 2000mg/dl	37	2	35	0	
2024-452	147	Mission120		076 078	075 077		073 - NEGATIVE	42	1	41	0	
2024-452	147	Mission120		076 078	075 077		076 - 500mg/dl2+	42	8	41	100	
2024-452	147	Mission120		076 078	075 077		078 - 2000mg/dl	42	9	41	100	
2024-452	147	Mission120		076 078	075 077		077 - 1000mg/dl	42	24	41	100	
2024-452	148	Mission500		076 078	075 077		074 - TRACES	124	1	123	0	
2024-452	148	Mission500		076 078	075 077		077 - 1000mg/dl	124	57	123	100	
2024-452	148	Mission500		076 078	075 077		076 - 500mg/dl2+	124	56	123	100	
2024-452	148	Mission500		076 078	075 077		075 - 250mg/dl-+	124	1	123	100	
2024-452	148	Mission500		076 078	075 077		078 - 2000mg/dl	124	9	123	100	
2024-452	151	Clari. Uro		076 078	075 077		077 - 1000mg/dl	21	15	21	100	
2024-452	151	Clari. Uro		076 078	075 077		076 - 500mg/dl2+	21	6	21	100	
058 URINALYSIS-GLUCOSE												
2024-453	011	AMES NM10S		074 076	074 076		075 - 250mg/dl-+	40	26	40	100	
2024-453	011	AMES NM10S		074 076	074 076		076 - 500mg/dl2+	40	1	40	100	
2024-453	011	AMES NM10S		074 076	074 076		074 - TRACES	40	13	40	100	
2024-453	013	BAYER CLI		074 076	074 076		074 - TRACES	23	5	23	100	
2024-453	013	BAYER CLI		074 076	074 076		075 - 250mg/dl-+	23	18	23	100	
2024-453	067	URISCAN		075 077	074 076		077 - 1000mg/dl	55	11	52	100	
2024-453	067	URISCAN		075 077	074 076		074 - TRACES	55	4	52	100	
2024-453	067	URISCAN		075 077	074 076		076 - 500mg/dl2+	55	27	52	100	
2024-453	067	URISCAN		075 077	074 076		075 - 250mg/dl-+	55	10	52	100	
2024-453	067	URISCAN		075 077	074 076		078 - 2000mg/dl	55	3	52	0	
2024-453	072	URS-9-TECO		074 076	074 076		076 - 500mg/dl2+	52	1	48	100	
2024-453	072	URS-9-TECO		074 076	074 076		074 - TRACES	52	13	48	100	
2024-453	072	URS-9-TECO		074 076	074 076		073 - NEGATIVE	52	4	48	0	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-453	072	URS-9-TECO		074 076	074 076		075 - 250mg/dl-+	52	34	48	100		
2024-453	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	37	3	37	100		
2024-453	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	37	34	37	100		
2024-453	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	146	124	144	100		
2024-453	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	146	2	144	0		
2024-453	089	AIMSTRIP		074 076	074 076		074 - TRACES	146	17	144	100		
2024-453	089	AIMSTRIP		074 076	074 076		076 - 500mg/dl2+	146	3	144	100		
2024-453	094	CLINITEK		074 076	074 076	074 076	074 - TRACES	106	31	105	100		
2024-453	094	CLINITEK		074 076	074 076	074 076	073 - NEGATIVE	106	1	105	0		
2024-453	094	CLINITEK		074 076	074 076	074 076	075 - 250mg/dl-+	106	74	105	100		
2024-453	102	ACON LAB		074 076	074 076	075 077	074 - TRACES	123	26	121	100		
2024-453	102	ACON LAB		074 076	074 076	075 077	073 - NEGATIVE	123	2	121	0		
2024-453	102	ACON LAB		074 076	074 076	075 077	077 - 1000mg/dl	123	1	121	100		
2024-453	102	ACON LAB		074 076	074 076	075 077	075 - 250mg/dl-+	123	94	121	100		
2024-453	131	iCHEM VELO		075 077	074 076		075 - 250mg/dl-+	32	1	32	100		
2024-453	131	iCHEM VELO		075 077	074 076		076 - 500mg/dl2+	32	26	32	100		
2024-453	131	iCHEM VELO		075 077	074 076		077 - 1000mg/dl	32	5	32	100		
2024-453	138	URS-10T		073 075	074 076		076 - 500mg/dl2+	21	1	21	100		
2024-453	138	URS-10T		073 075	074 076		075 - 250mg/dl-+	21	6	21	100		
2024-453	138	URS-10T		073 075	074 076		074 - TRACES	21	14	21	100		
2024-453	140	MISSION A		074 076	074 076		076 - 500mg/dl2+	42	2	42	100		
2024-453	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	42	36	42	100		
2024-453	140	MISSION A		074 076	074 076		074 - TRACES	42	4	42	100		
2024-453	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	37	31	37	100		
2024-453	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	37	4	37	100		
2024-453	145	CLINITEK		076 078	074 076		075 - 250mg/dl-+	37	1	37	100		
2024-453	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	37	1	37	100		
2024-453	147	Mission120		074 076	074 076		074 - TRACES	42	10	42	100		
2024-453	147	Mission120		074 076	074 076		075 - 250mg/dl-+	42	32	42	100		
2024-453	148	Mission500		074 076	074 076		074 - TRACES	124	9	124	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-453	148	Mission500		074 076	074 076		075 - 250mg/dl-+	124	115	124	100	
2024-453	151	Clari. Uro		074 076	074 076		075 - 250mg/dl-+	21	15	21	100	
2024-453	151	Clari. Uro		074 076	074 076		074 - TRACES	21	6	21	100	
058 URINALYSIS-GLUCOSE												
2024-454	011	AMES NM10S		076 078	076 078		077 - 1000mg/dl	40	31	40	100	
2024-454	011	AMES NM10S		076 078	076 078		076 - 500mg/dl2+	40	8	40	100	
2024-454	011	AMES NM10S		076 078	076 078		078 - 2000mg/dl	40	1	40	100	
2024-454	013	BAYER CLI		076 078	076 078		076 - 500mg/dl2+	23	11	23	100	
2024-454	013	BAYER CLI		076 078	076 078		078 - 2000mg/dl	23	1	23	100	
2024-454	013	BAYER CLI		076 078	076 078		077 - 1000mg/dl	23	11	23	100	
2024-454	067	URISCAN		077 078	076 078		078 - 2000mg/dl	55	39	55	100	
2024-454	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	55	2	55	100	
2024-454	067	URISCAN		077 078	076 078		077 - 1000mg/dl	55	14	55	100	
2024-454	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	52	5	52	100	
2024-454	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	52	15	52	100	
2024-454	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	52	32	52	100	
2024-454	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	37	34	37	100	
2024-454	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	37	3	37	100	
2024-454	089	AIMSTRIP		076 078	076 078		077 - 1000mg/dl	146	76	146	100	
2024-454	089	AIMSTRIP		076 078	076 078		076 - 500mg/dl2+	146	70	146	100	
2024-454	094	CLINITEK		076 078	076 078	075 077	078 - 2000mg/dl	106	2	106	100	
2024-454	094	CLINITEK		076 078	076 078	075 077	075 - 250mg/dl-+	106	1	106	100	
2024-454	094	CLINITEK		076 078	076 078	075 077	077 - 1000mg/dl	106	72	106	100	
2024-454	094	CLINITEK		076 078	076 078	075 077	076 - 500mg/dl2+	106	31	106	100	
2024-454	102	ACON LAB		075 077	076 078	075 077	077 - 1000mg/dl	123	35	123	100	
2024-454	102	ACON LAB		075 077	076 078	075 077	078 - 2000mg/dl	123	2	123	100	
2024-454	102	ACON LAB		075 077	076 078	075 077	075 - 250mg/dl-+	123	5	123	100	
2024-454	102	ACON LAB		075 077	076 078	075 077	076 - 500mg/dl2+	123	81	123	100	
2024-454	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	32	5	32	100	
2024-454	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	32	27	32	100	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-454	138	URS-10T		076 078	076 078		077 - 1000mg/dl	21	13	21	100
2024-454	138	URS-10T		076 078	076 078		078 - 2000mg/dl	21	1	21	100
2024-454	138	URS-10T		076 078	076 078		076 - 500mg/dl2+	21	7	21	100
2024-454	140	MISSION A		076 078	076 078		077 - 1000mg/dl	42	21	42	100
2024-454	140	MISSION A		076 078	076 078		078 - 2000mg/dl	42	9	42	100
2024-454	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	42	12	42	100
2024-454	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	37	32	37	100
2024-454	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	37	4	37	100
2024-454	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	37	1	37	100
2024-454	147	Mission120		076 078	076 078		078 - 2000mg/dl	42	4	42	100
2024-454	147	Mission120		076 078	076 078		076 - 500mg/dl2+	42	10	42	100
2024-454	147	Mission120		076 078	076 078		077 - 1000mg/dl	42	28	42	100
2024-454	148	Mission500		075 077	076 078		076 - 500mg/dl2+	124	62	124	100
2024-454	148	Mission500		075 077	076 078		078 - 2000mg/dl	124	5	124	100
2024-454	148	Mission500		075 077	076 078		075 - 250mg/dl-+	124	2	124	100
2024-454	148	Mission500		075 077	076 078		077 - 1000mg/dl	124	55	124	100
2024-454	151	Clari. Uro		076 078	076 078		076 - 500mg/dl2+	21	8	21	100
2024-454	151	Clari. Uro		076 078	076 078		077 - 1000mg/dl	21	13	21	100
058 URINALYSIS-GLUCOSE											
2024-455	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	40	40	40	100
2024-455	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	23	22	22	100
2024-455	013	BAYER CLI		073 073	073 073		074 - TRACES	23	1	22	0
2024-455	067	URISCAN		073 073	073 073		073 - NEGATIVE	55	55	55	100
2024-455	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	52	52	52	100
2024-455	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	37	37	37	100
2024-455	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	146	146	146	100
2024-455	094	CLINITEK		073 073	073 073	073 073	073 - NEGATIVE	106	106	106	100
2024-455	102	ACON LAB		073 073	073 073	073 073	073 - NEGATIVE	123	122	122	100
2024-455	102	ACON LAB		073 073	073 073	073 073	074 - TRACES	123	1	122	0
2024-455	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	32	31	31	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-455	131	iCHEM VELO		073 073	073 073		074 - TRACES	32	1	31	0
2024-455	138	URS-10T		073 073	073 073		073 - NEGATIVE	21	21	21	100
2024-455	140	MISSION A		073 073	073 073		073 - NEGATIVE	42	41	41	100
2024-455	140	MISSION A		073 073	073 073		077 - 1000mg/dl	42	1	41	0
2024-455	145	CLINITEK		073 073	073 073		073 - NEGATIVE	37	37	37	100
2024-455	147	Mission120		073 073	073 073		073 - NEGATIVE	42	41	41	100
2024-455	147	Mission120		073 073	073 073		074 - TRACES	42	1	41	0
2024-455	148	Mission500		073 073	073 073		074 - TRACES	124	1	123	0
2024-455	148	Mission500		073 073	073 073		073 - NEGATIVE	124	123	123	100
2024-455	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	21	21	21	100
059 URINALYS.HG.OR BLOOD											
2024-451	011	AMES NM10S		068 069	067 069		069 - POS.(3+ )	40	33	40	100
2024-451	011	AMES NM10S		068 069	067 069		068 - POS.(1-2+)	40	7	40	100
2024-451	013	BAYER CLI		068 069	067 069		068 - POS.(1-2+)	23	2	23	100
2024-451	013	BAYER CLI		068 069	067 069		069 - POS.(3+ )	23	21	23	100
2024-451	067	URISCAN		068 069	067 069		068 - POS.(1-2+)	55	13	55	100
2024-451	067	URISCAN		068 069	067 069		069 - POS.(3+ )	55	42	55	100
2024-451	072	URS-9-TECO		068 069	067 069		068 - POS.(1-2+)	52	11	52	100
2024-451	072	URS-9-TECO		068 069	067 069		069 - POS.(3+ )	52	41	52	100
2024-451	080	ROCHE (CHE		068 069	067 069		068 - POS.(1-2+)	37	1	37	100
2024-451	080	ROCHE (CHE		068 069	067 069		069 - POS.(3+ )	37	36	37	100
2024-451	089	AIMSTRIP		068 069	067 069		068 - POS.(1-2+)	145	2	145	100
2024-451	089	AIMSTRIP		068 069	067 069		069 - POS.(3+ )	145	143	145	100
2024-451	094	CLINITEK		068 069	067 069		068 - POS.(1-2+)	106	15	106	100
2024-451	094	CLINITEK		068 069	067 069		069 - POS.(3+ )	106	91	106	100
2024-451	102	ACON LAB		068 069	067 069		069 - POS.(3+ )	125	123	125	100
2024-451	102	ACON LAB		068 069	067 069		068 - POS.(1-2+)	125	2	125	100
2024-451	131	iCHEM VELO		067 069	067 069		068 - POS.(1-2+)	32	30	32	100
2024-451	131	iCHEM VELO		067 069	067 069		067 - TRACES	32	1	32	100
2024-451	131	iCHEM VELO		067 069	067 069		069 - POS.(3+ )	32	1	32	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-451	138	URS-10T		068 069	067 069		069 - POS.(3+) )	21	15	21	100		
2024-451	138	URS-10T		068 069	067 069		068 - POS.(1-2+)	21	6	21	100		
2024-451	140	MISSION A		068 069	067 069		069 - POS.(3+) )	40	38	40	100		
2024-451	140	MISSION A		068 069	067 069		068 - POS.(1-2+)	40	2	40	100		
2024-451	145	CLINITEK		067 069	067 069		069 - POS.(3+) )	37	15	37	100		
2024-451	145	CLINITEK		067 069	067 069		068 - POS.(1-2+)	37	22	37	100		
2024-451	147	Mission120		068 069	067 069		069 - POS.(3+) )	43	43	43	100		
2024-451	148	Mission500		068 069	067 069		069 - POS.(3+) )	124	123	124	100		
2024-451	148	Mission500		068 069	067 069		068 - POS.(1-2+)	124	1	124	100		
2024-451	151	Clari. Uro		068 069	067 069		069 - POS.(3+) )	21	21	21	100		
059 URINALYS.HG.OR BLOOD													
2024-452	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	40	40	40	100		
2024-452	013	BAYER CLI		066 066	066 066		067 - TRACES	23	1	22	0		
2024-452	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	23	22	22	100		
2024-452	067	URISCAN		066 066	066 066		066 - NEGATIVE	55	55	55	100		
2024-452	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	52	52	52	100		
2024-452	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	37	37	37	100		
2024-452	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	145	145	145	100		
2024-452	094	CLINITEK		066 066	066 066		066 - NEGATIVE	106	106	106	100		
2024-452	102	ACON LAB		066 066	066 066		066 - NEGATIVE	125	124	124	100		
2024-452	102	ACON LAB		066 066	066 066		068 - POS.(1-2+)	125	1	124	0		
2024-452	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	32	32	32	100		
2024-452	138	URS-10T		066 066	066 066		066 - NEGATIVE	21	21	21	100		
2024-452	140	MISSION A		066 066	066 066		066 - NEGATIVE	40	40	40	100		
2024-452	145	CLINITEK		066 066	066 066		066 - NEGATIVE	37	37	37	100		
2024-452	147	Mission120		066 066	066 066		066 - NEGATIVE	43	43	43	100		
2024-452	148	Mission500		066 066	066 066		066 - NEGATIVE	124	124	124	100		
2024-452	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	21	21	21	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
059 URINALYS.HG.OR BLOOD													
2024-453	011	AMES NM10S		066	066	066	066	066 - NEGATIVE	40	40	40	100	
2024-453	013	BAYER CLI		066	066	066	066	066 - NEGATIVE	23	23	23	100	
2024-453	067	URISCAN		066	066	066	066	066 - NEGATIVE	55	55	55	100	
2024-453	072	URS-9-TECO		066	066	066	066	066 - NEGATIVE	52	52	52	100	
2024-453	080	ROCHE (CHE		066	066	066	066	066 - NEGATIVE	37	36	36	100	
2024-453	080	ROCHE (CHE		066	066	066	066	068 - POS.(1-2+)	37	1	36	0	
2024-453	089	AIMSTRIP		066	066	066	066	066 - NEGATIVE	145	144	144	100	
2024-453	089	AIMSTRIP		066	066	066	066	067 - TRACES	145	1	144	0	
2024-453	094	CLINITEK		066	066	066	066	066 - NEGATIVE	106	106	106	100	
2024-453	102	ACON LAB		066	066	066	066	066 - NEGATIVE	125	125	125	100	
2024-453	131	iCHEM VELO		066	066	066	066	066 - NEGATIVE	32	32	32	100	
2024-453	138	URS-10T		066	066	066	066	066 - NEGATIVE	21	21	21	100	
2024-453	140	MISSION A		066	066	066	066	066 - NEGATIVE	40	40	40	100	
2024-453	145	CLINITEK		066	066	066	066	066 - NEGATIVE	37	37	37	100	
2024-453	147	Mission120		066	066	066	066	066 - NEGATIVE	43	42	42	100	
2024-453	147	Mission120		066	066	066	066	067 - TRACES	43	1	42	0	
2024-453	148	Mission500		066	066	066	066	066 - NEGATIVE	124	124	124	100	
2024-453	151	Clari. Uro		066	066	066	066	066 - NEGATIVE	21	21	21	100	
2024-454	011	AMES NM10S		068	069	068	069	068 - POS.(1-2+)	40	2	40	100	
2024-454	011	AMES NM10S		068	069	068	069	069 - POS.(3+)	40	38	40	100	
2024-454	013	BAYER CLI		068	069	068	069	069 - POS.(3+)	23	23	23	100	
2024-454	067	URISCAN		068	069	068	069	069 - POS.(3+)	55	49	54	100	
2024-454	067	URISCAN		068	069	068	069	068 - POS.(1-2+)	55	5	54	100	
2024-454	067	URISCAN		068	069	068	069	067 - TRACES	55	1	54	0	
2024-454	072	URS-9-TECO		068	069	068	069	069 - POS.(3+)	52	48	50	100	
2024-454	072	URS-9-TECO		068	069	068	069	067 - TRACES	52	2	50	0	
2024-454	072	URS-9-TECO		068	069	068	069	068 - POS.(1-2+)	52	2	50	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-454	080 ROCHE (CHE			068 069	068 069		066 - NEGATIVE	37	1	36	0
2024-454	080 ROCHE (CHE			068 069	068 069		068 - POS.(1-2+)	37	1	36	100
2024-454	080 ROCHE (CHE			068 069	068 069		069 - POS.(3+ )	37	35	36	100
2024-454	089 AIMSTRIP			068 069	068 069		068 - POS.(1-2+)	145	2	145	100
2024-454	089 AIMSTRIP			068 069	068 069		069 - POS.(3+ )	145	143	145	100
2024-454	094 CLINITEK			068 069	068 069		069 - POS.(3+ )	106	104	106	100
2024-454	094 CLINITEK			068 069	068 069		068 - POS.(1-2+)	106	2	106	100
2024-454	102 ACON LAB			068 069	068 069		069 - POS.(3+ )	125	121	125	100
2024-454	102 ACON LAB			068 069	068 069		068 - POS.(1-2+)	125	4	125	100
2024-454	131 iCHEM VELO			068 069	068 069		068 - POS.(1-2+)	32	2	32	100
2024-454	131 iCHEM VELO			068 069	068 069		069 - POS.(3+ )	32	30	32	100
2024-454	138 URS-10T			068 069	068 069		069 - POS.(3+ )	21	20	21	100
2024-454	138 URS-10T			068 069	068 069		068 - POS.(1-2+)	21	1	21	100
2024-454	140 MISSION A			068 069	068 069		069 - POS.(3+ )	40	38	40	100
2024-454	140 MISSION A			068 069	068 069		068 - POS.(1-2+)	40	2	40	100
2024-454	145 CLINITEK			068 069	068 069		068 - POS.(1-2+)	37	2	37	100
2024-454	145 CLINITEK			068 069	068 069		069 - POS.(3+ )	37	35	37	100
2024-454	147 Mission120			068 069	068 069		069 - POS.(3+ )	43	41	43	100
2024-454	147 Mission120			068 069	068 069		068 - POS.(1-2+)	43	2	43	100
2024-454	148 Mission500			068 069	068 069		069 - POS.(3+ )	124	124	124	100
2024-454	151 Clari. Uro			068 069	068 069		069 - POS.(3+ )	21	21	21	100
059 URINALYS.HG.OR BLOOD											
2024-455	011 AMES NM10S			068 069	068 069		069 - POS.(3+ )	40	39	40	100
2024-455	011 AMES NM10S			068 069	068 069		068 - POS.(1-2+)	40	1	40	100
2024-455	013 BAYER CLI			068 069	068 069		069 - POS.(3+ )	23	23	23	100
2024-455	067 URISCAN			068 069	068 069		069 - POS.(3+ )	55	51	55	100
2024-455	067 URISCAN			068 069	068 069		068 - POS.(1-2+)	55	4	55	100
2024-455	072 URS-9-TECO			068 069	068 069		069 - POS.(3+ )	52	46	52	100
2024-455	072 URS-9-TECO			068 069	068 069		068 - POS.(1-2+)	52	6	52	100
2024-455	080 ROCHE (CHE			068 069	068 069		069 - POS.(3+ )	37	36	37	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-455	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	37	1	37	100	
2024-455	089	AIMSTRIP		068 069	068 069		066 - NEGATIVE	145	3	142	0	
2024-455	089	AIMSTRIP		068 069	068 069		069 - POS.(3+ )	145	141	142	100	
2024-455	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	145	1	142	100	
2024-455	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	106	5	106	100	
2024-455	094	CLINITEK		068 069	068 069		069 - POS.(3+ )	106	101	106	100	
2024-455	102	ACON LAB		068 069	068 069		069 - POS.(3+ )	125	123	124	100	
2024-455	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	125	1	124	100	
2024-455	102	ACON LAB		068 069	068 069		066 - NEGATIVE	125	1	124	0	
2024-455	131	iCHEM VELO		068 069	068 069		069 - POS.(3+ )	32	29	32	100	
2024-455	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	32	3	32	100	
2024-455	138	URS-10T		068 069	068 069		069 - POS.(3+ )	21	17	21	100	
2024-455	138	URS-10T		068 069	068 069		068 - POS.(1-2+)	21	4	21	100	
2024-455	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	40	2	40	100	
2024-455	140	MISSION A		068 069	068 069		069 - POS.(3+ )	40	38	40	100	
2024-455	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	37	2	37	100	
2024-455	145	CLINITEK		068 069	068 069		069 - POS.(3+ )	37	35	37	100	
2024-455	147	Mission120		068 069	068 069		069 - POS.(3+ )	43	43	43	100	
2024-455	148	Mission500		068 069	068 069		069 - POS.(3+ )	124	124	124	100	
2024-455	151	Clari. Uro		068 069	068 069		069 - POS.(3+ )	21	21	21	100	
060 URINALYSIS-KETONES												
2024-451	011	AMES NM10S		093 094	093 094		093 - MOD. (2+)	40	1	40	100	
2024-451	011	AMES NM10S		093 094	093 094		094 - LARGE-3-4+	40	39	40	100	
2024-451	013	BAYER CLI		093 094	093 094		093 - MOD. (2+)	23	1	23	100	
2024-451	013	BAYER CLI		093 094	093 094		094 - LARGE-3-4+	23	22	23	100	
2024-451	067	URISCAN		093 094	093 094		094 - LARGE-3-4+	55	35	54	100	
2024-451	067	URISCAN		093 094	093 094		090 - NEGATIVE	55	1	54	0	
2024-451	067	URISCAN		093 094	093 094		093 - MOD. (2+)	55	19	54	100	
2024-451	072	URS-9-TECO		093 094	093 094		094 - LARGE-3-4+	51	48	51	100	
2024-451	072	URS-9-TECO		093 094	093 094		093 - MOD. (2+)	51	3	51	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-451	080	ROCHE (CHE		093 094	093 094		094 - LARGE-3-4+	37	31	37	100
2024-451	080	ROCHE (CHE		093 094	093 094		093 - MOD. (2+)	37	6	37	100
2024-451	089	AIMSTRIP		093 094	093 094		094 - LARGE-3-4+	146	142	145	100
2024-451	089	AIMSTRIP		093 094	093 094		093 - MOD. (2+)	146	3	145	100
2024-451	089	AIMSTRIP		093 094	093 094		092 - SMALL (1+)	146	1	145	0
2024-451	094	CLINITEK		093 094	093 094		093 - MOD. (2+)	106	2	106	100
2024-451	094	CLINITEK		093 094	093 094		094 - LARGE-3-4+	106	104	106	100
2024-451	102	ACON LAB		093 094	093 094		094 - LARGE-3-4+	123	119	123	100
2024-451	102	ACON LAB		093 094	093 094		093 - MOD. (2+)	123	4	123	100
2024-451	131	iCHEM VELO		093 094	093 094		094 - LARGE-3-4+	32	16	32	100
2024-451	131	iCHEM VELO		093 094	093 094		093 - MOD. (2+)	32	16	32	100
2024-451	138	URS-10T		093 094	093 094		094 - LARGE-3-4+	21	21	21	100
2024-451	140	MISSION A		093 094	093 094		090 - NEGATIVE	43	1	42	0
2024-451	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	43	42	42	100
2024-451	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	37	37	37	100
2024-451	147	Mission120		093 094	093 094		094 - LARGE-3-4+	42	42	42	100
2024-451	148	Mission500		093 094	093 094		094 - LARGE-3-4+	124	124	124	100
2024-451	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	21	21	21	100
060 URINALYSIS-KETONES											
2024-452	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	40	40	40	100
2024-452	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	23	23	23	100
2024-452	067	URISCAN		090 090	090 090		090 - NEGATIVE	55	55	55	100
2024-452	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	51	51	51	100
2024-452	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100
2024-452	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	146	146	146	100
2024-452	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100
2024-452	102	ACON LAB		090 090	090 090		090 - NEGATIVE	123	123	123	100
2024-452	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	32	32	32	100
2024-452	138	URS-10T		090 090	090 090		090 - NEGATIVE	21	21	21	100
2024-452	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	43	43	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-452	145	CLINITEK		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-452	147	Mission120		090 090	090 090		090 - NEGATIVE	42	42	42	100	
2024-452	148	Mission500		090 090	090 090		090 - NEGATIVE	124	124	124	100	
2024-452	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	21	21	21	100	
060 URINALYSIS-KETONES												
2024-453	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	40	8	40	100	
2024-453	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	40	3	40	100	
2024-453	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	40	29	40	100	
2024-453	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	23	8	23	100	
2024-453	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	23	15	23	100	
2024-453	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	55	7	55	100	
2024-453	067	URISCAN		092 094	092 094		093 - MOD. (2+)	55	40	55	100	
2024-453	067	URISCAN		092 094	092 094		092 - SMALL (1+)	55	8	55	100	
2024-453	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	51	9	51	100	
2024-453	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	51	10	51	100	
2024-453	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	51	32	51	100	
2024-453	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	37	26	37	100	
2024-453	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	37	8	37	100	
2024-453	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	37	3	37	100	
2024-453	089	AIMSTRIP		092 094	092 094		091 - TRACE	146	2	144	0	
2024-453	089	AIMSTRIP		092 094	092 094		094 - LARGE-3-4+	146	30	144	100	
2024-453	089	AIMSTRIP		092 094	092 094		093 - MOD. (2+)	146	94	144	100	
2024-453	089	AIMSTRIP		092 094	092 094		092 - SMALL (1+)	146	20	144	100	
2024-453	094	CLINITEK		092 094	092 094		094 - LARGE-3-4+	106	4	104	100	
2024-453	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	106	75	104	100	
2024-453	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	106	25	104	100	
2024-453	094	CLINITEK		092 094	092 094		091 - TRACE	106	2	104	0	
2024-453	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	123	14	122	100	
2024-453	102	ACON LAB		092 094	092 094		091 - TRACE	123	1	122	0	
2024-453	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	123	14	122	100	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-453	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	123	94	122	100	
2024-453	131	iCHEM VELO		091 093	092 094		093 - MOD. (2+)	32	10	32	100	
2024-453	131	iCHEM VELO		091 093	092 094		092 - SMALL (1+)	32	18	32	100	
2024-453	131	iCHEM VELO		091 093	092 094		094 - LARGE-3-4+	32	4	32	100	
2024-453	138	URS-10T		092 094	092 094		094 - LARGE-3-4+	21	2	21	100	
2024-453	138	URS-10T		092 094	092 094		092 - SMALL (1+)	21	4	21	100	
2024-453	138	URS-10T		092 094	092 094		093 - MOD. (2+)	21	15	21	100	
2024-453	140	MISSION A		092 094	092 094		093 - MOD. (2+)	43	24	43	100	
2024-453	140	MISSION A		092 094	092 094		092 - SMALL (1+)	43	2	43	100	
2024-453	140	MISSION A		092 094	092 094		094 - LARGE-3-4+	43	17	43	100	
2024-453	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	37	32	37	100	
2024-453	145	CLINITEK		092 094	092 094		092 - SMALL (1+)	37	5	37	100	
2024-453	147	Mission120		092 094	092 094		093 - MOD. (2+)	42	27	42	100	
2024-453	147	Mission120		092 094	092 094		094 - LARGE-3-4+	42	15	42	100	
2024-453	148	Mission500		092 094	092 094		094 - LARGE-3-4+	124	7	124	100	
2024-453	148	Mission500		092 094	092 094		092 - SMALL (1+)	124	1	124	100	
2024-453	148	Mission500		092 094	092 094		093 - MOD. (2+)	124	116	124	100	
2024-453	151	Clari. Uro		092 094	092 094		093 - MOD. (2+)	21	16	21	100	
2024-453	151	Clari. Uro		092 094	092 094		094 - LARGE-3-4+	21	5	21	100	
060 URINALYSIS-KETONES												
2024-454	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	40	40	40	100	
2024-454	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	23	23	23	100	
2024-454	067	URISCAN		090 090	090 090		090 - NEGATIVE	55	55	55	100	
2024-454	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	51	51	51	100	
2024-454	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-454	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	146	146	146	100	
2024-454	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100	
2024-454	102	ACON LAB		090 090	090 090		090 - NEGATIVE	123	123	123	100	
2024-454	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	32	32	32	100	
2024-454	138	URS-10T		090 090	090 090		090 - NEGATIVE	21	21	21	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-454	140	MISSION A		090 090	090 090		094 - LARGE-3-4+	43	1	42	0	
2024-454	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	42	42	100	
2024-454	145	CLINITEK		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-454	147	Mission120		090 090	090 090		094 - LARGE-3-4+	42	1	41	0	
2024-454	147	Mission120		090 090	090 090		090 - NEGATIVE	42	41	41	100	
2024-454	148	Mission500		090 090	090 090		090 - NEGATIVE	124	124	124	100	
2024-454	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	21	21	21	100	
060 URINALYSIS-KETONES												
2024-455	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	40	40	40	100	
2024-455	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	23	23	23	100	
2024-455	067	URISCAN		090 090	090 090		090 - NEGATIVE	55	55	55	100	
2024-455	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	51	51	51	100	
2024-455	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-455	089	AIMSTRIP		090 090	090 090		094 - LARGE-3-4+	146	1	145	0	
2024-455	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	146	145	145	100	
2024-455	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100	
2024-455	102	ACON LAB		090 090	090 090		090 - NEGATIVE	123	123	123	100	
2024-455	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	32	32	32	100	
2024-455	138	URS-10T		090 090	090 090		090 - NEGATIVE	21	21	21	100	
2024-455	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-455	145	CLINITEK		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-455	147	Mission120		090 090	090 090		090 - NEGATIVE	42	42	42	100	
2024-455	148	Mission500		090 090	090 090		090 - NEGATIVE	124	124	124	100	
2024-455	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	21	21	21	100	
061 URINALYSIS-NITRATE												
2024-451	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-451	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	23	23	23	100	
2024-451	067	URISCAN		070 070	070 070		070 - NEGATIVE	55	55	55	100	
2024-451	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	52	52	52	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-451	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100		
2024-451	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	146	146	146	100		
2024-451	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100		
2024-451	102	ACON LAB		070 070	070 070		070 - NEGATIVE	123	123	123	100		
2024-451	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	32	32	32	100		
2024-451	138	URS-10T		070 070	070 070		070 - NEGATIVE	21	21	21	100		
2024-451	140	MISSION A		070 070	070 070		070 - NEGATIVE	42	42	42	100		
2024-451	145	CLINITEK		070 070	070 070		070 - NEGATIVE	37	37	37	100		
2024-451	147	Mission120		070 070	070 070		070 - NEGATIVE	43	43	43	100		
2024-451	148	Mission500		070 070	070 070		070 - NEGATIVE	124	124	124	100		
2024-451	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	20	20	20	100		
061 URINALYSIS-NITRATE													
2024-452	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	40	40	40	100		
2024-452	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	23	23	23	100		
2024-452	067	URISCAN		070 070	070 070		070 - NEGATIVE	55	55	55	100		
2024-452	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	52	52	52	100		
2024-452	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100		
2024-452	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	146	146	146	100		
2024-452	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100		
2024-452	102	ACON LAB		070 070	070 070		070 - NEGATIVE	123	123	123	100		
2024-452	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	32	32	32	100		
2024-452	138	URS-10T		070 070	070 070		070 - NEGATIVE	21	21	21	100		
2024-452	140	MISSION A		070 070	070 070		070 - NEGATIVE	42	42	42	100		
2024-452	145	CLINITEK		070 070	070 070		070 - NEGATIVE	37	37	37	100		
2024-452	147	Mission120		070 070	070 070		070 - NEGATIVE	43	43	43	100		
2024-452	148	Mission500		070 070	070 070		070 - NEGATIVE	124	124	124	100		
2024-452	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	20	20	20	100		
2024-453	011	AMES NM10S		071 072	071 072		072 - POSITIVE	40	40	40	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-453	013	BAYER CLI		071 072	071 072		072 - POSITIVE	23	23	23	100	
2024-453	067	URISCAN		071 072	071 072		072 - POSITIVE	55	55	55	100	
2024-453	072	URS-9-TECO		071 072	071 072		072 - POSITIVE	52	52	52	100	
2024-453	080	ROCHE (CHE		071 072	071 072		072 - POSITIVE	37	37	37	100	
2024-453	089	AIMSTRIP		071 072	071 072		072 - POSITIVE	146	144	146	100	
2024-453	089	AIMSTRIP		071 072	071 072		071 - WEAK POS.	146	2	146	100	
2024-453	094	CLINITEK		071 072	071 072		072 - POSITIVE	106	106	106	100	
2024-453	102	ACON LAB		071 072	071 072		071 - WEAK POS.	123	1	123	100	
2024-453	102	ACON LAB		071 072	071 072		072 - POSITIVE	123	122	123	100	
2024-453	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	32	32	32	100	
2024-453	138	URS-10T		071 072	071 072		072 - POSITIVE	21	21	21	100	
2024-453	140	MISSION A		071 072	071 072		072 - POSITIVE	42	42	42	100	
2024-453	145	CLINITEK		071 072	071 072		072 - POSITIVE	37	37	37	100	
2024-453	147	Mission120		071 072	071 072		072 - POSITIVE	43	43	43	100	
2024-453	148	Mission500		071 072	071 072		072 - POSITIVE	124	124	124	100	
2024-453	151	Clari. Uro		071 072	071 072		072 - POSITIVE	20	20	20	100	
061 URINALYSIS-NITRATE												
2024-454	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-454	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	23	23	23	100	
2024-454	067	URISCAN		070 070	070 070		070 - NEGATIVE	55	55	55	100	
2024-454	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	52	52	52	100	
2024-454	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-454	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	146	146	146	100	
2024-454	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100	
2024-454	102	ACON LAB		070 070	070 070		070 - NEGATIVE	123	123	123	100	
2024-454	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	32	32	32	100	
2024-454	138	URS-10T		070 070	070 070		070 - NEGATIVE	21	21	21	100	
2024-454	140	MISSION A		070 070	070 070		070 - NEGATIVE	42	42	42	100	
2024-454	145	CLINITEK		070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-454	147	Mission120		070 070	070 070		070 - NEGATIVE	43	43	43	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-454	148	Mission500		070 070	070 070		070 - NEGATIVE	124	124	124	100		
2024-454	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	20	20	20	100		
061 URINALYSIS-NITRATE													
2024-455	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	40	40	40	100		
2024-455	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	23	23	23	100		
2024-455	067	URISCAN		070 070	070 070		070 - NEGATIVE	55	55	55	100		
2024-455	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	52	52	52	100		
2024-455	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100		
2024-455	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	146	146	146	100		
2024-455	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100		
2024-455	102	ACON LAB		070 070	070 070		070 - NEGATIVE	123	123	123	100		
2024-455	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	32	32	32	100		
2024-455	138	URS-10T		070 070	070 070		070 - NEGATIVE	21	21	21	100		
2024-455	140	MISSION A		070 070	070 070		070 - NEGATIVE	42	42	42	100		
2024-455	145	CLINITEK		070 070	070 070		070 - NEGATIVE	37	37	37	100		
2024-455	147	Mission120		070 070	070 070		070 - NEGATIVE	43	43	43	100		
2024-455	148	Mission500		070 070	070 070		070 - NEGATIVE	124	124	124	100		
2024-455	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	20	20	20	100		
062 URINALYSIS-pH													
2024-451	011	AMES NM10S		086 088	085 088		088 - 8.0OR MORE	40	25	40	100		
2024-451	011	AMES NM10S		086 088	085 088		087 - 7.5	40	15	40	100		
2024-451	013	BAYER CLI		086 088	085 088		087 - 7.5	23	9	23	100		
2024-451	013	BAYER CLI		086 088	085 088		088 - 8.0OR MORE	23	14	23	100		
2024-451	067	URISCAN		085 088	085 088		086 - 7.0	55	2	55	100		
2024-451	067	URISCAN		085 088	085 088		088 - 8.0OR MORE	55	9	55	100		
2024-451	067	URISCAN		085 088	085 088		087 - 7.5	55	44	55	100		
2024-451	072	URS-9-TECO		085 088	085 088		086 - 7.0	52	8	52	100		
2024-451	072	URS-9-TECO		085 088	085 088		088 - 8.0OR MORE	52	9	52	100		
2024-451	072	URS-9-TECO		085 088	085 088		087 - 7.5	52	35	52	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-451	080	ROCHE (CHE		084 088	085 088		085 - 6.5	37	1	37	100	
2024-451	080	ROCHE (CHE		084 088	085 088		088 - 8.0OR MORE	37	16	37	100	
2024-451	080	ROCHE (CHE		084 088	085 088		086 - 7.0	37	20	37	100	
2024-451	089	AIMSTRIP		086 088	085 088		087 - 7.5	146	38	146	100	
2024-451	089	AIMSTRIP		086 088	085 088		088 - 8.0OR MORE	146	107	146	100	
2024-451	089	AIMSTRIP		086 088	085 088		086 - 7.0	146	1	146	100	
2024-451	094	CLINITEK		086 088	085 088		088 - 8.0OR MORE	106	80	106	100	
2024-451	094	CLINITEK		086 088	085 088		087 - 7.5	106	26	106	100	
2024-451	102	ACON LAB		085 088	085 088		087 - 7.5	124	80	124	100	
2024-451	102	ACON LAB		085 088	085 088		086 - 7.0	124	3	124	100	
2024-451	102	ACON LAB		085 088	085 088		088 - 8.0OR MORE	124	41	124	100	
2024-451	131	iCHEM VELO		084 088	085 088		086 - 7.0	32	32	32	100	
2024-451	138	URS-10T		085 088	085 088		086 - 7.0	21	2	21	100	
2024-451	138	URS-10T		085 088	085 088		087 - 7.5	21	19	21	100	
2024-451	140	MISSION A		085 088	085 088		087 - 7.5	43	29	43	100	
2024-451	140	MISSION A		085 088	085 088		088 - 8.0OR MORE	43	13	43	100	
2024-451	140	MISSION A		085 088	085 088		086 - 7.0	43	1	43	100	
2024-451	145	CLINITEK		085 088	085 088		088 - 8.0OR MORE	36	3	36	100	
2024-451	145	CLINITEK		085 088	085 088		087 - 7.5	36	33	36	100	
2024-451	147	Mission120		085 088	085 088		088 - 8.0OR MORE	42	11	42	100	
2024-451	147	Mission120		085 088	085 088		087 - 7.5	42	31	42	100	
2024-451	148	Mission500		085 088	085 088		086 - 7.0	124	1	124	100	
2024-451	148	Mission500		085 088	085 088		088 - 8.0OR MORE	124	34	124	100	
2024-451	148	Mission500		085 088	085 088		087 - 7.5	124	89	124	100	
2024-451	151	Clari. Uro		085 088	085 088		087 - 7.5	20	11	20	100	
2024-451	151	Clari. Uro		085 088	085 088		088 - 8.0OR MORE	20	9	20	100	
062 URINALYSIS-pH												
2024-452	011	AMES NM10S		086 088	086 088		087 - 7.5	40	6	39	100	
2024-452	011	AMES NM10S		086 088	086 088		084 - 6.0	40	1	39	0	
2024-452	011	AMES NM10S		086 088	086 088		088 - 8.0OR MORE	40	33	39	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-452	013	BAYER CLI		086 088	086 088		087 - 7.5	23	7	23	100	
2024-452	013	BAYER CLI		086 088	086 088		088 - 8.0OR MORE	23	16	23	100	
2024-452	067	URISCAN		085 088	086 088		088 - 8.0OR MORE	55	27	55	100	
2024-452	067	URISCAN		085 088	086 088		087 - 7.5	55	27	55	100	
2024-452	067	URISCAN		085 088	086 088		086 - 7.0	55	1	55	100	
2024-452	072	URS-9-TECO		085 088	086 088		084 - 6.0	52	1	51	0	
2024-452	072	URS-9-TECO		085 088	086 088		087 - 7.5	52	34	51	100	
2024-452	072	URS-9-TECO		085 088	086 088		088 - 8.0OR MORE	52	15	51	100	
2024-452	072	URS-9-TECO		085 088	086 088		086 - 7.0	52	2	51	100	
2024-452	080	ROCHE (CHE		086 088	086 088		088 - 8.0OR MORE	37	26	36	100	
2024-452	080	ROCHE (CHE		086 088	086 088		086 - 7.0	37	10	36	100	
2024-452	080	ROCHE (CHE		086 088	086 088		085 - 6.5	37	1	36	0	
2024-452	089	AIMSTRIP		086 088	086 088		088 - 8.0OR MORE	146	127	146	100	
2024-452	089	AIMSTRIP		086 088	086 088		086 - 7.0	146	1	146	100	
2024-452	089	AIMSTRIP		086 088	086 088		087 - 7.5	146	18	146	100	
2024-452	094	CLINITEK		086 088	086 088		087 - 7.5	106	18	106	100	
2024-452	094	CLINITEK		086 088	086 088		086 - 7.0	106	1	106	100	
2024-452	094	CLINITEK		086 088	086 088		088 - 8.0OR MORE	106	87	106	100	
2024-452	102	ACON LAB		086 088	086 088		088 - 8.0OR MORE	124	72	124	100	
2024-452	102	ACON LAB		086 088	086 088		087 - 7.5	124	49	124	100	
2024-452	102	ACON LAB		086 088	086 088		086 - 7.0	124	3	124	100	
2024-452	131	iCHEM VELO		086 088	086 088		086 - 7.0	32	9	32	100	
2024-452	131	iCHEM VELO		086 088	086 088		088 - 8.0OR MORE	32	23	32	100	
2024-452	138	URS-10T		085 088	086 088		088 - 8.0OR MORE	21	4	21	100	
2024-452	138	URS-10T		085 088	086 088		085 - 6.5	21	1	21	100	
2024-452	138	URS-10T		085 088	086 088		087 - 7.5	21	13	21	100	
2024-452	138	URS-10T		085 088	086 088		086 - 7.0	21	3	21	100	
2024-452	140	MISSION A		086 088	086 088		088 - 8.0OR MORE	43	25	43	100	
2024-452	140	MISSION A		086 088	086 088		087 - 7.5	43	18	43	100	
2024-452	145	CLINITEK		086 088	086 088		088 - 8.0OR MORE	36	30	36	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-452	145	CLINITEK		086 088	086 088		087 - 7.5	36	6	36	100	
2024-452	147	Mission120		085 088	086 088		087 - 7.5	42	26	42	100	
2024-452	147	Mission120		085 088	086 088		088 - 8.0OR MORE	42	16	42	100	
2024-452	148	Mission500		086 088	086 088		086 - 7.0	124	1	124	100	
2024-452	148	Mission500		086 088	086 088		088 - 8.0OR MORE	124	91	124	100	
2024-452	148	Mission500		086 088	086 088		087 - 7.5	124	32	124	100	
2024-452	151	Clari. Uro		086 088	086 088		087 - 7.5	20	7	20	100	
2024-452	151	Clari. Uro		086 088	086 088		088 - 8.0OR MORE	20	13	20	100	
062 URINALYSIS-pH												
2024-453	011	AMES NM10S		081 085	081 085		084 - 6.0	40	14	40	100	
2024-453	011	AMES NM10S		081 085	081 085		083 - 5.5	40	18	40	100	
2024-453	011	AMES NM10S		081 085	081 085		082 - 5.0	40	8	40	100	
2024-453	013	BAYER CLI		081 085	081 085		084 - 6.0	23	4	23	100	
2024-453	013	BAYER CLI		081 085	081 085		082 - 5.0	23	6	23	100	
2024-453	013	BAYER CLI		081 085	081 085		083 - 5.5	23	13	23	100	
2024-453	067	URISCAN		080 084	081 085		083 - 5.5	55	6	55	100	
2024-453	067	URISCAN		080 084	081 085		082 - 5.0	55	49	55	100	
2024-453	072	URS-9-TECO		082 086	081 085		082 - 5.0	52	10	52	100	
2024-453	072	URS-9-TECO		082 086	081 085		083 - 5.5	52	9	52	100	
2024-453	072	URS-9-TECO		082 086	081 085		084 - 6.0	52	33	52	100	
2024-453	080	ROCHE (CHE		080 084	081 085		082 - 5.0	37	35	37	100	
2024-453	080	ROCHE (CHE		080 084	081 085		084 - 6.0	37	2	37	100	
2024-453	089	AIMSTRIP		082 086	081 085		082 - 5.0	146	43	146	100	
2024-453	089	AIMSTRIP		082 086	081 085		083 - 5.5	146	39	146	100	
2024-453	089	AIMSTRIP		082 086	081 085		084 - 6.0	146	64	146	100	
2024-453	094	CLINITEK		081 085	081 085		082 - 5.0	106	13	106	100	
2024-453	094	CLINITEK		081 085	081 085		084 - 6.0	106	38	106	100	
2024-453	094	CLINITEK		081 085	081 085		083 - 5.5	106	55	106	100	
2024-453	102	ACON LAB		082 086	081 085		082 - 5.0	124	20	124	100	
2024-453	102	ACON LAB		082 086	081 085		083 - 5.5	124	21	124	100	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-453	102	ACON LAB		082 086	081 085		084 - 6.0	124	83	124	100	
2024-453	131	iCHEM VELO		080 084	081 085		082 - 5.0	32	32	32	100	
2024-453	138	URS-10T		080 084	081 085		085 - 6.5	21	1	21	100	
2024-453	138	URS-10T		080 084	081 085		082 - 5.0	21	11	21	100	
2024-453	138	URS-10T		080 084	081 085		083 - 5.5	21	1	21	100	
2024-453	138	URS-10T		080 084	081 085		084 - 6.0	21	8	21	100	
2024-453	140	MISSION A		082 086	081 085		083 - 5.5	43	19	43	100	
2024-453	140	MISSION A		082 086	081 085		084 - 6.0	43	20	43	100	
2024-453	140	MISSION A		082 086	081 085		082 - 5.0	43	4	43	100	
2024-453	145	CLINITEK		081 085	081 085		083 - 5.5	36	35	36	100	
2024-453	145	CLINITEK		081 085	081 085		082 - 5.0	36	1	36	100	
2024-453	147	Mission120		081 085	081 085		083 - 5.5	42	33	42	100	
2024-453	147	Mission120		081 085	081 085		084 - 6.0	42	3	42	100	
2024-453	147	Mission120		081 085	081 085		082 - 5.0	42	6	42	100	
2024-453	148	Mission500		082 086	081 085		083 - 5.5	124	3	124	100	
2024-453	148	Mission500		082 086	081 085		084 - 6.0	124	120	124	100	
2024-453	148	Mission500		082 086	081 085		082 - 5.0	124	1	124	100	
2024-453	151	Clari. Uro		081 085	081 085		082 - 5.0	20	4	20	100	
2024-453	151	Clari. Uro		081 085	081 085		084 - 6.0	20	8	20	100	
2024-453	151	Clari. Uro		081 085	081 085		083 - 5.5	20	8	20	100	
062 URINALYSIS-pH												
2024-454	011	AMES NM10S		084 088	084 088		086 - 7.0	40	32	40	100	
2024-454	011	AMES NM10S		084 088	084 088		085 - 6.5	40	8	40	100	
2024-454	013	BAYER CLI		084 088	084 088		086 - 7.0	23	23	23	100	
2024-454	067	URISCAN		083 087	084 088		084 - 6.0	55	5	55	100	
2024-454	067	URISCAN		083 087	084 088		086 - 7.0	55	4	55	100	
2024-454	067	URISCAN		083 087	084 088		085 - 6.5	55	46	55	100	
2024-454	072	URS-9-TECO		083 087	084 088		085 - 6.5	52	33	52	100	
2024-454	072	URS-9-TECO		083 087	084 088		086 - 7.0	52	18	52	100	
2024-454	072	URS-9-TECO		083 087	084 088		084 - 6.0	52	1	52	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-454	080	ROCHE (CHE		083 087	084 088		086 - 7.0	37	10	37	100	
2024-454	080	ROCHE (CHE		083 087	084 088		085 - 6.5	37	27	37	100	
2024-454	089	AIMSTRIP		083 087	084 088		086 - 7.0	146	53	146	100	
2024-454	089	AIMSTRIP		083 087	084 088		085 - 6.5	146	91	146	100	
2024-454	089	AIMSTRIP		083 087	084 088		084 - 6.0	146	2	146	100	
2024-454	094	CLINITEK		084 088	084 088		086 - 7.0	106	100	106	100	
2024-454	094	CLINITEK		084 088	084 088		085 - 6.5	106	6	106	100	
2024-454	102	ACON LAB		083 087	084 088		086 - 7.0	124	26	124	100	
2024-454	102	ACON LAB		083 087	084 088		085 - 6.5	124	91	124	100	
2024-454	102	ACON LAB		083 087	084 088		087 - 7.5	124	1	124	100	
2024-454	102	ACON LAB		083 087	084 088		084 - 6.0	124	6	124	100	
2024-454	131	iCHEM VELO		084 088	084 088		086 - 7.0	32	16	32	100	
2024-454	131	iCHEM VELO		084 088	084 088		084 - 6.0	32	16	32	100	
2024-454	138	URS-10T		084 088	084 088		085 - 6.5	21	7	21	100	
2024-454	138	URS-10T		084 088	084 088		086 - 7.0	21	14	21	100	
2024-454	140	MISSION A		083 087	084 088		084 - 6.0	43	2	43	100	
2024-454	140	MISSION A		083 087	084 088		086 - 7.0	43	1	43	100	
2024-454	140	MISSION A		083 087	084 088		085 - 6.5	43	40	43	100	
2024-454	145	CLINITEK		083 087	084 088		085 - 6.5	36	26	36	100	
2024-454	145	CLINITEK		083 087	084 088		086 - 7.0	36	10	36	100	
2024-454	147	Mission120		083 087	084 088		085 - 6.5	42	42	42	100	
2024-454	148	Mission500		083 087	084 088		086 - 7.0	124	8	124	100	
2024-454	148	Mission500		083 087	084 088		085 - 6.5	124	116	124	100	
2024-454	151	Clari. Uro		083 087	084 088		086 - 7.0	20	1	20	100	
2024-454	151	Clari. Uro		083 087	084 088		085 - 6.5	20	16	20	100	
2024-454	151	Clari. Uro		083 087	084 088		084 - 6.0	20	3	20	100	
062 URINALYSIS-pH												
2024-455	011	AMES NM10S		085 088	084 088		087 - 7.5	40	21	40	100	
2024-455	011	AMES NM10S		085 088	084 088		086 - 7.0	40	19	40	100	
2024-455	013	BAYER CLI		085 088	084 088		087 - 7.5	23	13	23	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-455	013	BAYER CLI		085 088	084 088		086 - 7.0	23	10	23	100	
2024-455	067	URISCAN		084 088	084 088		086 - 7.0	55	49	55	100	
2024-455	067	URISCAN		084 088	084 088		088 - 8.0OR MORE	55	1	55	100	
2024-455	067	URISCAN		084 088	084 088		087 - 7.5	55	1	55	100	
2024-455	067	URISCAN		084 088	084 088		085 - 6.5	55	4	55	100	
2024-455	072	URS-9-TECO		084 088	084 088		086 - 7.0	52	43	52	100	
2024-455	072	URS-9-TECO		084 088	084 088		085 - 6.5	52	3	52	100	
2024-455	072	URS-9-TECO		084 088	084 088		087 - 7.5	52	6	52	100	
2024-455	080	ROCHE (CHE		084 088	084 088		086 - 7.0	37	37	37	100	
2024-455	089	AIMSTRIP		084 088	084 088		087 - 7.5	146	26	146	100	
2024-455	089	AIMSTRIP		084 088	084 088		086 - 7.0	146	120	146	100	
2024-455	094	CLINITEK		085 088	084 088		086 - 7.0	106	37	106	100	
2024-455	094	CLINITEK		085 088	084 088		087 - 7.5	106	69	106	100	
2024-455	102	ACON LAB		084 088	084 088		086 - 7.0	124	113	124	100	
2024-455	102	ACON LAB		084 088	084 088		087 - 7.5	124	9	124	100	
2024-455	102	ACON LAB		084 088	084 088		085 - 6.5	124	2	124	100	
2024-455	131	iCHEM VELO		084 088	084 088		086 - 7.0	32	32	32	100	
2024-455	138	URS-10T		084 088	084 088		086 - 7.0	21	13	21	100	
2024-455	138	URS-10T		084 088	084 088		087 - 7.5	21	8	21	100	
2024-455	140	MISSION A		084 088	084 088		085 - 6.5	43	1	43	100	
2024-455	140	MISSION A		084 088	084 088		086 - 7.0	43	42	43	100	
2024-455	145	CLINITEK		084 088	084 088		086 - 7.0	36	36	36	100	
2024-455	147	Mission120		084 088	084 088		086 - 7.0	42	42	42	100	
2024-455	148	Mission500		084 088	084 088		086 - 7.0	124	124	124	100	
2024-455	151	Clari. Uro		084 088	084 088		086 - 7.0	20	20	20	100	
064 URIN-PROTEIN QUALI.												
2024-451	011	AMES NM10S		053 055	053 055		056 - 4+	40	1	39	0	
2024-451	011	AMES NM10S		053 055	053 055		054 - 2+	40	19	39	100	
2024-451	011	AMES NM10S		053 055	053 055		053 - 1+	40	2	39	100	
2024-451	011	AMES NM10S		053 055	053 055		055 - 3+	40	18	39	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-451	013	BAYER CLI		053 055	053 055		055 - 3+	23	7	23	100
2024-451	013	BAYER CLI		053 055	053 055		054 - 2+	23	16	23	100
2024-451	067	URISCAN		053 055	053 055		055 - 3+	55	5	55	100
2024-451	067	URISCAN		053 055	053 055		054 - 2+	55	45	55	100
2024-451	067	URISCAN		053 055	053 055		053 - 1+	55	5	55	100
2024-451	072	URS-9-TECO		054 056	053 055		055 - 3+	52	28	52	100
2024-451	072	URS-9-TECO		054 056	053 055		053 - 1+	52	4	52	100
2024-451	072	URS-9-TECO		054 056	053 055		054 - 2+	52	20	52	100
2024-451	080	ROCHE (CHE		053 055	053 055		053 - 1+	37	2	37	100
2024-451	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	23	37	100
2024-451	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100
2024-451	089	AIMSTRIP		053 055	053 055		054 - 2+	145	72	142	100
2024-451	089	AIMSTRIP		053 055	053 055		053 - 1+	145	1	142	100
2024-451	089	AIMSTRIP		053 055	053 055		056 - 4+	145	3	142	0
2024-451	089	AIMSTRIP		053 055	053 055		055 - 3+	145	69	142	100
2024-451	094	CLINITEK		053 055	053 055		054 - 2+	106	86	104	100
2024-451	094	CLINITEK		053 055	053 055		053 - 1+	106	2	104	100
2024-451	094	CLINITEK		053 055	053 055		056 - 4+	106	2	104	0
2024-451	094	CLINITEK		053 055	053 055		055 - 3+	106	16	104	100
2024-451	102	ACON LAB		053 055	053 055		053 - 1+	125	4	124	100
2024-451	102	ACON LAB		053 055	053 055		054 - 2+	125	81	124	100
2024-451	102	ACON LAB		053 055	053 055		056 - 4+	125	1	124	0
2024-451	102	ACON LAB		053 055	053 055		055 - 3+	125	39	124	100
2024-451	131	iCHEM VELO		054 056	053 055		054 - 2+	32	10	32	100
2024-451	131	iCHEM VELO		054 056	053 055		056 - 4+	32	3	32	100
2024-451	131	iCHEM VELO		054 056	053 055		055 - 3+	32	19	32	100
2024-451	138	URS-10T		053 055	053 055		053 - 1+	21	2	21	100
2024-451	138	URS-10T		053 055	053 055		054 - 2+	21	11	21	100
2024-451	138	URS-10T		053 055	053 055		055 - 3+	21	8	21	100
2024-451	140	MISSION A		053 055	053 055		055 - 3+	42	6	42	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-451	140	MISSION A		053 055	053 055		054 - 2+	42	34	42	100	
2024-451	140	MISSION A		053 055	053 055		053 - 1+	42	2	42	100	
2024-451	145	CLINITEK		053 055	053 055		054 - 2+	37	30	36	100	
2024-451	145	CLINITEK		053 055	053 055		056 - 4+	37	1	36	0	
2024-451	145	CLINITEK		053 055	053 055		055 - 3+	37	6	36	100	
2024-451	147	Mission120		053 055	053 055		054 - 2+	43	40	43	100	
2024-451	147	Mission120		053 055	053 055		053 - 1+	43	3	43	100	
2024-451	148	Mission500		053 055	053 055		053 - 1+	123	6	121	100	
2024-451	148	Mission500		053 055	053 055		054 - 2+	123	74	121	100	
2024-451	148	Mission500		053 055	053 055		052 - TRACES	123	1	121	0	
2024-451	148	Mission500		053 055	053 055		056 - 4+	123	1	121	0	
2024-451	148	Mission500		053 055	053 055		055 - 3+	123	41	121	100	
2024-451	151	Clari. Uro		053 055	053 055		055 - 3+	20	8	20	100	
2024-451	151	Clari. Uro		053 055	053 055		054 - 2+	20	12	20	100	
064 URIN-PROTEIN QUALI.												
2024-452	011	AMES NM10S		051 051	051 051		052 - TRACES	40	1	39	0	
2024-452	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	40	39	39	100	
2024-452	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	23	23	23	100	
2024-452	067	URISCAN		051 051	051 051		051 - NEGATIVE	55	54	54	100	
2024-452	067	URISCAN		051 051	051 051		052 - TRACES	55	1	54	0	
2024-452	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	52	52	52	100	
2024-452	080	ROCHE (CHE		051 051	051 051		052 - TRACES	37	1	36	0	
2024-452	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	37	36	36	100	
2024-452	089	AIMSTRIP		051 051	051 051		052 - TRACES	145	7	138	0	
2024-452	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	145	138	138	100	
2024-452	094	CLINITEK		051 051	051 051		051 - NEGATIVE	106	104	104	100	
2024-452	094	CLINITEK		051 051	051 051		052 - TRACES	106	2	104	0	
2024-452	102	ACON LAB		051 051	051 051		052 - TRACES	125	7	118	0	
2024-452	102	ACON LAB		051 051	051 051		051 - NEGATIVE	125	118	118	100	
2024-452	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	32	32	32	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-452	138	URS-10T		051 051	051 051		051 - NEGATIVE	21	21	21	100
2024-452	140	MISSION A		051 051	051 051		052 - TRACES	42	1	41	0
2024-452	140	MISSION A		051 051	051 051		051 - NEGATIVE	42	41	41	100
2024-452	145	CLINITEK		051 051	051 051		051 - NEGATIVE	37	37	37	100
2024-452	147	Mission120		051 051	051 051		051 - NEGATIVE	43	43	43	100
2024-452	148	Mission500		051 051	051 051		052 - TRACES	123	12	111	0
2024-452	148	Mission500		051 051	051 051		051 - NEGATIVE	123	111	111	100
2024-452	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	20	19	19	100
2024-452	151	Clari. Uro		051 051	051 051		052 - TRACES	20	1	19	0
064 URIN-PROTEIN QUALI.											
2024-453	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	40	40	40	100
2024-453	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	23	23	23	100
2024-453	067	URISCAN		051 051	051 051		051 - NEGATIVE	55	55	55	100
2024-453	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	52	52	52	100
2024-453	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	37	37	37	100
2024-453	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	145	144	144	100
2024-453	089	AIMSTRIP		051 051	051 051		052 - TRACES	145	1	144	0
2024-453	094	CLINITEK		051 051	051 051		051 - NEGATIVE	106	106	106	100
2024-453	102	ACON LAB		051 051	051 051		051 - NEGATIVE	125	125	125	100
2024-453	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	32	32	32	100
2024-453	138	URS-10T		051 051	051 051		051 - NEGATIVE	21	21	21	100
2024-453	140	MISSION A		051 051	051 051		051 - NEGATIVE	42	42	42	100
2024-453	145	CLINITEK		051 051	051 051		051 - NEGATIVE	37	37	37	100
2024-453	147	Mission120		051 051	051 051		051 - NEGATIVE	43	43	43	100
2024-453	148	Mission500		051 051	051 051		051 - NEGATIVE	123	123	123	100
2024-453	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	20	20	20	100
2024-454	011	AMES NM10S		053 055	053 055		055 - 3+	40	6	40	100
2024-454	011	AMES NM10S		053 055	053 055		054 - 2+	40	31	40	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-454	011	AMES NM10S		053 055	053 055		053 - 1+	40	3	40	100	
2024-454	013	BAYER CLI		053 055	053 055		054 - 2+	23	17	23	100	
2024-454	013	BAYER CLI		053 055	053 055		053 - 1+	23	1	23	100	
2024-454	013	BAYER CLI		053 055	053 055		055 - 3+	23	5	23	100	
2024-454	067	URISCAN		053 055	053 055		054 - 2+	55	37	55	100	
2024-454	067	URISCAN		053 055	053 055		053 - 1+	55	17	55	100	
2024-454	067	URISCAN		053 055	053 055		055 - 3+	55	1	55	100	
2024-454	072	URS-9-TECO		053 055	053 055		055 - 3+	52	10	52	100	
2024-454	072	URS-9-TECO		053 055	053 055		054 - 2+	52	41	52	100	
2024-454	072	URS-9-TECO		053 055	053 055		053 - 1+	52	1	52	100	
2024-454	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100	
2024-454	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	22	37	100	
2024-454	080	ROCHE (CHE		053 055	053 055		053 - 1+	37	3	37	100	
2024-454	089	AIMSTRIP		053 055	053 055		056 - 4+	145	1	144	0	
2024-454	089	AIMSTRIP		053 055	053 055		055 - 3+	145	28	144	100	
2024-454	089	AIMSTRIP		053 055	053 055		054 - 2+	145	113	144	100	
2024-454	089	AIMSTRIP		053 055	053 055		053 - 1+	145	3	144	100	
2024-454	094	CLINITEK		053 055	053 055		054 - 2+	106	100	105	100	
2024-454	094	CLINITEK		053 055	053 055		053 - 1+	106	2	105	100	
2024-454	094	CLINITEK		053 055	053 055		056 - 4+	106	1	105	0	
2024-454	094	CLINITEK		053 055	053 055		055 - 3+	106	3	105	100	
2024-454	102	ACON LAB		053 055	053 055		055 - 3+	125	17	125	100	
2024-454	102	ACON LAB		053 055	053 055		053 - 1+	125	5	125	100	
2024-454	102	ACON LAB		053 055	053 055		054 - 2+	125	103	125	100	
2024-454	131	iCHEM VELO		053 055	053 055		055 - 3+	32	5	32	100	
2024-454	131	iCHEM VELO		053 055	053 055		054 - 2+	32	27	32	100	
2024-454	138	URS-10T		053 055	053 055		055 - 3+	21	7	21	100	
2024-454	138	URS-10T		053 055	053 055		054 - 2+	21	14	21	100	
2024-454	140	MISSION A		053 055	053 055		055 - 3+	42	1	42	100	
2024-454	140	MISSION A		053 055	053 055		054 - 2+	42	37	42	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-454	140	MISSION A		053 055	053 055		053 - 1+	42	4	42	100	
2024-454	145	CLINITEK		053 055	053 055		053 - 1+	37	1	37	100	
2024-454	145	CLINITEK		053 055	053 055		054 - 2+	37	36	37	100	
2024-454	147	Mission120		053 055	053 055		054 - 2+	43	37	43	100	
2024-454	147	Mission120		053 055	053 055		053 - 1+	43	6	43	100	
2024-454	148	Mission500		053 055	053 055		055 - 3+	123	6	122	100	
2024-454	148	Mission500		053 055	053 055		053 - 1+	123	9	122	100	
2024-454	148	Mission500		053 055	053 055		054 - 2+	123	107	122	100	
2024-454	148	Mission500		053 055	053 055		052 - TRACES	123	1	122	0	
2024-454	151	Clari. Uro		053 055	053 055		055 - 3+	20	1	20	100	
2024-454	151	Clari. Uro		053 055	053 055		054 - 2+	20	19	20	100	
064 URIN-PROTEIN QUALI.												
2024-455	011	AMES NM10S		053 055	054 056		056 - 4+	40	1	40	100	
2024-455	011	AMES NM10S		053 055	054 056		055 - 3+	40	18	40	100	
2024-455	011	AMES NM10S		053 055	054 056		054 - 2+	40	19	40	100	
2024-455	011	AMES NM10S		053 055	054 056		053 - 1+	40	2	40	100	
2024-455	013	BAYER CLI		053 055	054 056		055 - 3+	23	8	23	100	
2024-455	013	BAYER CLI		053 055	054 056		054 - 2+	23	15	23	100	
2024-455	067	URISCAN		053 055	054 056		055 - 3+	55	4	55	100	
2024-455	067	URISCAN		053 055	054 056		054 - 2+	55	40	55	100	
2024-455	067	URISCAN		053 055	054 056		053 - 1+	55	11	55	100	
2024-455	072	URS-9-TECO		054 056	054 056		055 - 3+	52	26	52	100	
2024-455	072	URS-9-TECO		054 056	054 056		054 - 2+	52	26	52	100	
2024-455	080	ROCHE (CHE		053 055	054 056		054 - 2+	37	25	37	100	
2024-455	080	ROCHE (CHE		053 055	054 056		055 - 3+	37	12	37	100	
2024-455	089	AIMSTRIP		053 055	054 056		055 - 3+	145	60	145	100	
2024-455	089	AIMSTRIP		053 055	054 056		054 - 2+	145	84	145	100	
2024-455	089	AIMSTRIP		053 055	054 056		053 - 1+	145	1	145	100	
2024-455	094	CLINITEK		053 055	054 056		053 - 1+	106	1	105	100	
2024-455	094	CLINITEK		053 055	054 056		054 - 2+	106	88	105	100	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-455	094	CLINITEK		053 055	054 056		056 - 4+	106	2	105	100		
2024-455	094	CLINITEK		053 055	054 056		052 - TRACES	106	1	105	0		
2024-455	094	CLINITEK		053 055	054 056		055 - 3+	106	14	105	100		
2024-455	102	ACON LAB		053 055	054 056		055 - 3+	125	31	125	100		
2024-455	102	ACON LAB		053 055	054 056		054 - 2+	125	88	125	100		
2024-455	102	ACON LAB		053 055	054 056		053 - 1+	125	6	125	100		
2024-455	131	iCHEM VELO		054 056	054 056		054 - 2+	32	9	32	100		
2024-455	131	iCHEM VELO		054 056	054 056		056 - 4+	32	2	32	100		
2024-455	131	iCHEM VELO		054 056	054 056		055 - 3+	32	21	32	100		
2024-455	138	URS-10T		053 055	054 056		054 - 2+	21	12	21	100		
2024-455	138	URS-10T		053 055	054 056		055 - 3+	21	9	21	100		
2024-455	140	MISSION A		053 055	054 056		053 - 1+	42	2	42	100		
2024-455	140	MISSION A		053 055	054 056		055 - 3+	42	3	42	100		
2024-455	140	MISSION A		053 055	054 056		054 - 2+	42	37	42	100		
2024-455	145	CLINITEK		053 055	054 056		055 - 3+	37	17	37	100		
2024-455	145	CLINITEK		053 055	054 056		054 - 2+	37	17	37	100		
2024-455	145	CLINITEK		053 055	054 056		053 - 1+	37	1	37	100		
2024-455	145	CLINITEK		053 055	054 056		056 - 4+	37	2	37	100		
2024-455	147	Mission120		053 055	054 056		053 - 1+	43	3	43	100		
2024-455	147	Mission120		053 055	054 056		054 - 2+	43	40	43	100		
2024-455	148	Mission500		053 055	054 056		052 - TRACES	123	1	122	0		
2024-455	148	Mission500		053 055	054 056		055 - 3+	123	36	122	100		
2024-455	148	Mission500		053 055	054 056		053 - 1+	123	6	122	100		
2024-455	148	Mission500		053 055	054 056		054 - 2+	123	80	122	100		
2024-455	151	Clari. Uro		053 055	054 056		054 - 2+	20	16	20	100		
2024-455	151	Clari. Uro		053 055	054 056		055 - 3+	20	4	20	100		
066 URINAL.-UROBILINOGEN													
2024-451	011	AMES NM10S		062 064	061 063		061 - NORMAL,NEG	40	6	40	100		
2024-451	011	AMES NM10S		062 064	061 063		062 - 2	40	14	40	100		
2024-451	011	AMES NM10S		062 064	061 063		063 - 4	40	19	40	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-451	011	AMES NM10S		062 064	061 063		064 - 8	40	1	40	100	
2024-451	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	23	7	23	100	
2024-451	013	BAYER CLI		061 063	061 063		063 - 4	23	5	23	100	
2024-451	013	BAYER CLI		061 063	061 063		062 - 2	23	11	23	100	
2024-451	067	URISCAN			061 063		062 - 2	55	8	55	100	
2024-451	067	URISCAN			061 063		063 - 4	55	28	55	100	
2024-451	067	URISCAN			061 063		061 - NORMAL,NEG	55	19	55	100	
2024-451	072	URS-9-TECO		061 063	061 063		063 - 4	52	8	48	100	
2024-451	072	URS-9-TECO		061 063	061 063		062 - 2	52	30	48	100	
2024-451	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	52	10	48	100	
2024-451	072	URS-9-TECO		061 063	061 063		064 - 8	52	4	48	0	
2024-451	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	37	34	37	100	
2024-451	080	ROCHE (CHE		061 061	061 063		062 - 2	37	3	37	100	
2024-451	089	AIMSTRIP		061 061	061 063		063 - 4	146	2	145	100	
2024-451	089	AIMSTRIP		061 061	061 063		062 - 2	146	26	145	100	
2024-451	089	AIMSTRIP		061 061	061 063		061 - NORMAL,NEG	146	117	145	100	
2024-451	089	AIMSTRIP		061 061	061 063		064 - 8	146	1	145	0	
2024-451	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	106	14	106	100	
2024-451	094	CLINITEK		062 064	061 063		062 - 2	106	36	106	100	
2024-451	094	CLINITEK		062 064	061 063		063 - 4	106	56	106	100	
2024-451	102	ACON LAB		061 061	061 063		061 - NORMAL,NEG	122	100	122	100	
2024-451	102	ACON LAB		061 061	061 063		063 - 4	122	4	122	100	
2024-451	102	ACON LAB		061 061	061 063		062 - 2	122	18	122	100	
2024-451	131	iCHEM VELO		062 064	061 063		062 - 2	32	5	32	100	
2024-451	131	iCHEM VELO		062 064	061 063		063 - 4	32	27	32	100	
2024-451	138	URS-10T		061 063	061 063		061 - NORMAL,NEG	21	3	21	100	
2024-451	138	URS-10T		061 063	061 063		063 - 4	21	3	21	100	
2024-451	138	URS-10T		061 063	061 063		062 - 2	21	15	21	100	
2024-451	140	MISSION A		061 061	061 063		061 - NORMAL,NEG	42	34	42	100	
2024-451	140	MISSION A		061 061	061 063		063 - 4	42	3	42	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-451	140	MISSION A		061 061	061 063		062 - 2	42	5	42	100	
2024-451	145	CLINITEK		061 063	061 063		062 - 2	37	36	37	100	
2024-451	145	CLINITEK		061 063	061 063		061 - NORMAL,NEG	37	1	37	100	
2024-451	147	Mission120		061 061	061 063		062 - 2	43	3	43	100	
2024-451	147	Mission120		061 061	061 063		061 - NORMAL,NEG	43	40	43	100	
2024-451	148	Mission500		061 061	061 063		061 - NORMAL,NEG	123	118	123	100	
2024-451	148	Mission500		061 061	061 063		063 - 4	123	2	123	100	
2024-451	148	Mission500		061 061	061 063		062 - 2	123	3	123	100	
2024-451	151	Clari. Uro			061 063		064 - 8	20	1	19	0	
2024-451	151	Clari. Uro			061 063		061 - NORMAL,NEG	20	13	19	100	
2024-451	151	Clari. Uro			061 063		062 - 2	20	4	19	100	
2024-451	151	Clari. Uro			061 063		063 - 4	20	2	19	100	
066 URINAL.-UROBILINOGEN												
2024-452	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-452	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	23	23	23	100	
2024-452	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	55	55	55	100	
2024-452	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	52	52	52	100	
2024-452	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-452	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100	
2024-452	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2024-452	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	122	122	100	
2024-452	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	32	32	32	100	
2024-452	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	21	21	21	100	
2024-452	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2024-452	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-452	147	Mission120		061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-452	148	Mission500		061 061	061 061		062 - 2	123	1	122	0	
2024-452	148	Mission500		061 061	061 061		061 - NORMAL,NEG	123	122	122	100	
2024-452	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	20	20	20	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
066 URINAL.-UROBILINOGEN													
2024-453	011	AMES NMI0S		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-453	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	23	23	23	100		
2024-453	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	55	55	55	100		
2024-453	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	52	52	52	100		
2024-453	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		
2024-453	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100		
2024-453	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100		
2024-453	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	122	122	100		
2024-453	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	32	32	32	100		
2024-453	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	21	21	21	100		
2024-453	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	42	42	42	100		
2024-453	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		
2024-453	147	Mission120		061 061	061 061		061 - NORMAL,NEG	43	43	43	100		
2024-453	148	Mission500		061 061	061 061		061 - NORMAL,NEG	123	123	123	100		
2024-453	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	20	20	20	100		
2024-454	011	AMES NMI0S		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-454	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	23	23	23	100		
2024-454	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	55	55	55	100		
2024-454	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	52	52	52	100		
2024-454	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		
2024-454	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100		
2024-454	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100		
2024-454	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	122	122	100		
2024-454	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	32	32	32	100		
2024-454	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	21	21	21	100		
2024-454	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	42	42	42	100		
2024-454	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-454	147	Mission120		061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-454	148	Mission500		061 061	061 061		061 - NORMAL,NEG	123	123	123	100	
2024-454	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	20	20	20	100	
066 URINAL.-UROBILINOGEN												
2024-455	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-455	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	23	23	23	100	
2024-455	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	55	55	55	100	
2024-455	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	52	52	52	100	
2024-455	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-455	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100	
2024-455	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2024-455	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	122	122	100	
2024-455	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	32	32	32	100	
2024-455	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	21	21	21	100	
2024-455	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2024-455	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-455	147	Mission120		061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-455	148	Mission500		061 061	061 061		061 - NORMAL,NEG	123	123	123	100	
2024-455	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	20	20	20	100	
184 URINALYSIS LEUKOCYTE												
2024-451	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	
2024-451	013	BAYER CLI		001 001	001 001		001 - Negative	23	23	23	100	
2024-451	067	URISCAN		001 001	001 001		001 - Negative	55	55	55	100	
2024-451	072	URS-9-TECO		001 001	001 001		001 - Negative	50	49	49	100	
2024-451	072	URS-9-TECO		001 001	001 001		002 - Traces	50	1	49	0	
2024-451	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	
2024-451	089	AIMSTRIP		001 001	001 001		001 - Negative	144	144	144	100	
2024-451	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2024-451	102	ACON LAB		001 001	001 001		001 - Negative	116	116	116	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-451	131	iCHEM VELO		001 001	001 001		001 - Negative	32	32	32	100	
2024-451	138	URS-10T		001 001	001 001		001 - Negative	20	20	20	100	
2024-451	140	MISSION A		001 001	001 001		004 - Moderate	47	1	46	0	
2024-451	140	MISSION A		001 001	001 001		001 - Negative	47	46	46	100	
2024-451	145	CLINITEK		001 001	001 001		001 - Negative	36	35	35	100	
2024-451	145	CLINITEK		001 001	001 001		002 - Traces	36	1	35	0	
2024-451	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-451	148	Mission500		001 001	001 001		001 - Negative	125	125	125	100	
2024-451	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	
184 URINALYSIS LEUKOCYTE												
2024-452	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	
2024-452	013	BAYER CLI		001 001	001 001		001 - Negative	23	23	23	100	
2024-452	067	URISCAN		001 001	001 001		001 - Negative	55	55	55	100	
2024-452	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100	
2024-452	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	
2024-452	089	AIMSTRIP		001 001	001 001		001 - Negative	144	143	143	100	
2024-452	089	AIMSTRIP		001 001	001 001		005 - Large	144	1	143	0	
2024-452	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2024-452	102	ACON LAB		001 001	001 001		001 - Negative	116	116	116	100	
2024-452	131	iCHEM VELO		001 001	001 001		001 - Negative	32	32	32	100	
2024-452	138	URS-10T		001 001	001 001		001 - Negative	20	20	20	100	
2024-452	140	MISSION A		001 001	001 001		001 - Negative	47	47	47	100	
2024-452	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100	
2024-452	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-452	148	Mission500		001 001	001 001		001 - Negative	125	125	125	100	
2024-452	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	
2024-453	011	AMES NM10S		002 004	003 005		002 - Traces	40	1	40	100	
2024-453	011	AMES NM10S		002 004	003 005		004 - Moderate	40	8	40	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-453	011	AMES NM10S		002 004	003 005		003 - Small	40	31	40	100
2024-453	013	BAYER CLI		002 004	003 005		004 - Moderate	23	2	23	100
2024-453	013	BAYER CLI		002 004	003 005		003 - Small	23	21	23	100
2024-453	067	URISCAN		004 005	003 005		002 - Traces	55	1	54	0
2024-453	067	URISCAN		004 005	003 005		005 - Large	55	33	54	100
2024-453	067	URISCAN		004 005	003 005		003 - Small	55	5	54	100
2024-453	067	URISCAN		004 005	003 005		004 - Moderate	55	16	54	100
2024-453	072	URS-9-TECO		002 004	003 005		003 - Small	50	27	50	100
2024-453	072	URS-9-TECO		002 004	003 005		002 - Traces	50	1	50	100
2024-453	072	URS-9-TECO		002 004	003 005		004 - Moderate	50	22	50	100
2024-453	080	ROCHE (CHE		004 005	003 005		004 - Moderate	34	3	34	100
2024-453	080	ROCHE (CHE		004 005	003 005		005 - Large	34	31	34	100
2024-453	089	AIMSTRIP		002 004	003 005		003 - Small	144	100	144	100
2024-453	089	AIMSTRIP		002 004	003 005		002 - Traces	144	33	144	100
2024-453	089	AIMSTRIP		002 004	003 005		004 - Moderate	144	11	144	100
2024-453	094	CLINITEK		002 004	003 005		004 - Moderate	105	1	105	100
2024-453	094	CLINITEK		002 004	003 005		002 - Traces	105	2	105	100
2024-453	094	CLINITEK		002 004	003 005		003 - Small	105	102	105	100
2024-453	102	ACON LAB		002 004	003 005		001 - Negative	116	5	111	0
2024-453	102	ACON LAB		002 004	003 005		004 - Moderate	116	8	111	100
2024-453	102	ACON LAB		002 004	003 005		005 - Large	116	1	111	100
2024-453	102	ACON LAB		002 004	003 005		002 - Traces	116	34	111	100
2024-453	102	ACON LAB		002 004	003 005		003 - Small	116	68	111	100
2024-453	131	iCHEM VELO		004 005	003 005		005 - Large	32	30	32	100
2024-453	131	iCHEM VELO		004 005	003 005		004 - Moderate	32	2	32	100
2024-453	138	URS-10T		003 005	003 005		005 - Large	20	2	20	100
2024-453	138	URS-10T		003 005	003 005		003 - Small	20	8	20	100
2024-453	138	URS-10T		003 005	003 005		004 - Moderate	20	10	20	100
2024-453	140	MISSION A		002 004	003 005		004 - Moderate	47	6	47	100
2024-453	140	MISSION A		002 004	003 005		005 - Large	47	1	47	100

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-453	140	MISSION A		002 004	003 005		002 - Traces	47	17	47	100	
2024-453	140	MISSION A		002 004	003 005		003 - Small	47	23	47	100	
2024-453	145	CLINITEK		003 005	003 005		003 - Small	36	1	36	100	
2024-453	145	CLINITEK		003 005	003 005		004 - Moderate	36	35	36	100	
2024-453	147	Mission120		001 003	003 005		004 - Moderate	42	1	42	100	
2024-453	147	Mission120		001 003	003 005		001 - Negative	42	1	42	100	
2024-453	147	Mission120		001 003	003 005		002 - Traces	42	28	42	100	
2024-453	147	Mission120		001 003	003 005		003 - Small	42	12	42	100	
2024-453	148	Mission500		001 003	003 005		002 - Traces	125	74	125	100	
2024-453	148	Mission500		001 003	003 005		004 - Moderate	125	12	125	100	
2024-453	148	Mission500		001 003	003 005		001 - Negative	125	3	125	100	
2024-453	148	Mission500		001 003	003 005		003 - Small	125	36	125	100	
2024-453	151	Clari. Uro		002 004	003 005		002 - Traces	20	6	20	100	
2024-453	151	Clari. Uro		002 004	003 005		003 - Small	20	9	20	100	
2024-453	151	Clari. Uro		002 004	003 005		004 - Moderate	20	5	20	100	
184 URINALYSIS LEUKOCYTE												
2024-454	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	
2024-454	013	BAYER CLI		001 001	001 001		001 - Negative	23	23	23	100	
2024-454	067	URISCAN		001 001	001 001		001 - Negative	55	55	55	100	
2024-454	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100	
2024-454	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	33	33	100	
2024-454	080	ROCHE (CHE		001 001	001 001		005 - Large	34	1	33	0	
2024-454	089	AIMSTRIP		001 001	001 001		001 - Negative	144	143	143	100	
2024-454	089	AIMSTRIP		001 001	001 001		005 - Large	144	1	143	0	
2024-454	094	CLINITEK		001 001	001 001		001 - Negative	105	104	104	100	
2024-454	094	CLINITEK		001 001	001 001		002 - Traces	105	1	104	0	
2024-454	102	ACON LAB		001 001	001 001		002 - Traces	116	1	115	0	
2024-454	102	ACON LAB		001 001	001 001		001 - Negative	116	115	115	100	
2024-454	131	iCHEM VELO		001 001	001 001		001 - Negative	32	32	32	100	
2024-454	138	URS-10T		001 001	001 001		001 - Negative	20	20	20	100	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-454	140	MISSION A		001 001	001 001		001 - Negative	47	47	47	100	
2024-454	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100	
2024-454	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-454	148	Mission500		001 001	001 001		001 - Negative	125	125	125	100	
2024-454	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	
184 URINALYSIS LEUKOCYTE												
2024-455	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	
2024-455	013	BAYER CLI		001 001	001 001		001 - Negative	23	23	23	100	
2024-455	067	URISCAN		001 001	001 001		001 - Negative	55	55	55	100	
2024-455	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100	
2024-455	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	
2024-455	089	AIMSTRIP		001 001	001 001		001 - Negative	144	144	144	100	
2024-455	094	CLINITEK		001 001	001 001		005 - Large	105	1	104	0	
2024-455	094	CLINITEK		001 001	001 001		001 - Negative	105	104	104	100	
2024-455	102	ACON LAB		001 001	001 001		001 - Negative	116	116	116	100	
2024-455	131	iCHEM VELO		001 001	001 001		001 - Negative	32	32	32	100	
2024-455	138	URS-10T		001 001	001 001		003 - Small	20	1	19	0	
2024-455	138	URS-10T		001 001	001 001		001 - Negative	20	19	19	100	
2024-455	140	MISSION A		001 001	001 001		001 - Negative	47	47	47	100	
2024-455	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100	
2024-455	147	Mission120		001 001	001 001		001 - Negative	42	41	41	100	
2024-455	147	Mission120		001 001	001 001		002 - Traces	42	1	41	0	
2024-455	148	Mission500		001 001	001 001		001 - Negative	125	125	125	100	
2024-455	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
063 URI-PREGNANCY TEST														
2024-451	091	AIM STEP		002	002	002	002	002	-	POSITIVE	37	37	37	100
2024-451	101	HCG Alere		002	002	002	002	002	-	POSITIVE	22	22	22	100
2024-452	091	AIM STEP		001	001	001	001	001	-	NEGATIVE	37	37	37	100
2024-452	101	HCG Alere		001	001	001	001	001	-	NEGATIVE	22	22	22	100
2024-453	091	AIM STEP		001	001	001	001	001	-	NEGATIVE	37	37	37	100
2024-453	101	HCG Alere		001	001	001	001	001	-	NEGATIVE	22	22	22	100
2024-454	091	AIM STEP		001	001	001	001	001	-	NEGATIVE	37	37	37	100
2024-454	101	HCG Alere		001	001	001	001	001	-	NEGATIVE	22	22	22	100
2024-455	091	AIM STEP		002	002	002	002	002	-	POSITIVE	37	37	37	100
2024-455	101	HCG Alere		002	002	002	002	002	-	POSITIVE	22	22	22	100

## Participant Summary

MONTH 5 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2024-461					031	031	004 - HYALINE C.	915	2	911	0
2024-461					031	031	031 - FIBERS	915	911	911	100
2024-461					031	031	006 - WAXY CAST	915	2	911	0
2024-462					023	023	014 - CA. OXALAT	914	1	904	0
2024-462					023	023	018 - HIPPURIC	914	8	904	0
2024-462					023	023	023 - URIC ACID	914	904	904	100
2024-462					023	023	017 - CYSTINE C.	914	1	904	0
2024-463					042	042	007 - WHITE CELL	914	1	859	0
2024-463					042	042	042 - WBC in clu	914	859	859	100
2024-463					042	042	009 - LEUKOCYTE	914	54	859	0
2024-464					006	006	004 - HYALINE C.	914	207	696	0
2024-464					006	006	003 - GRANULAR C	914	2	696	0
2024-464					006	006	002 - FATTY CAST	914	1	696	0
2024-464					006	006	011 - SQUAMOUS E	914	1	696	0
2024-464					006	006	006 - WAXY CAST	914	696	696	100
2024-464					006	006	030 - CYLINDROID	914	2	696	0
2024-464					006	006	031 - FIBERS	914	5	696	0
2024-465					032	032	032 - MUCOUS TH.	914	912	912	100
2024-465					032	032	006 - WAXY CAST	914	1	912	0
2024-465					032	032	031 - FIBERS	914	1	912	0

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
154 FECAL OCCULT BLOOD												
2024-471	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	388	388	388	100
2024-471	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	739	738	738	100
2024-471	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	739	1	738	0
2024-472	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	388	388	388	100
2024-472	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	739	738	738	100
2024-472	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	739	1	738	0
2024-473	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	388	388	388	100
2024-473	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	739	737	737	100
2024-473	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	739	2	737	0
2024-474	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	388	387	387	100
2024-474	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	388	1	387	0
2024-474	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	739	738	738	100
2024-474	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	739	1	738	0
2024-475	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	388	388	388	100
2024-475	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	739	739	739	100

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. LABS	PART	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
068 CARCINOE. ANTIG. CEA				CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}			
2024-421	29	VITROS		12		4.408	0.138	3.13	4.000	4.800	
2024-421	38	ROCHE E		16		4.675	0.299	6.39	3.800	5.600	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-421	44	BECK.COUL.		20	5.140	0.193	3.76	4.600	5.700		
2024-421	50	ARC		10	5.470	0.456	8.34	4.100	6.800		
068	CARCINOE. ANTIG. CEA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}								
2024-422	29	VITROS		12	2.450	0.076	3.12	2.200	2.700		
2024-422	38	ROCHE E		16	2.525	0.222	8.80	1.900	3.200		
2024-422	44	BECK.COUL.		20	2.195	0.209	9.50	1.600	2.700		
2024-422	50	ARC		10	2.690	0.416	15.46	2.000	3.400		
2024-423	29	VITROS		12	14.675	0.359	2.44	13.600	15.800		
2024-423	38	ROCHE E		16	13.963	0.953	6.83	11.100	16.800		
2024-423	44	BECK.COUL.		20	16.730	0.771	4.61	14.400	19.000		
2024-423	50	ARC		10	17.030	1.360	7.99	12.900	21.100		
2024-424	29	VITROS		12	0.400	0.041	10.21	0.300	0.500		
2024-424	38	ROCHE E		16	0.713	0.111	15.59	0.500	0.900		
2024-424	44	BECK.COUL.		20	0.510	0.044	8.55	0.400	0.600		
2024-424	50	ARC		10	1.080	0.513	47.54	0.800	1.400		
2024-425	29	VITROS		12	29.917	0.615	2.06	28.100	31.800		
2024-425	38	ROCHE E		16	26.813	1.949	7.27	21.000	32.700		
2024-425	44	BECK.COUL.		20	33.670	1.804	5.36	28.300	39.100		
2024-425	50	ARC		10	33.110	2.069	6.25	26.900	39.300		
069	PROS. SPEC-ANTIG-PSA										
2024-421	29	VITROS		48	2.489	0.131	5.26	2.100	2.900		
2024-421	36	TOSOH AIA		10	3.310	0.301	9.11	2.500	4.100		
2024-421	38	ROCHE E		49	4.679	0.312	6.66	3.700	5.600		
2024-421	44	BECK.COUL.		51	4.702	0.377	8.02	3.600	5.800		
2024-421	50	ARC		22	3.891	0.373	9.58	2.900	4.900		
2024-421	57	S. EXL 200		65	4.534	0.309	6.82	3.600	5.500		
2024-421	58	ATELLICA		12	4.142	0.198	4.77	3.500	4.700		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}				
2024-422	29	VITROS		48	0.100	0.000	0.00	0.100	0.100	
2024-422	36	TOSOH AIA		10	0.070	0.046	65.47	0.100	0.100	
2024-422	38	ROCHE E		49	0.008	0.028	331.66	0.000	0.000	
2024-422	44	BECK.COUL.		51	0.000	0.000	0.00	0.000	0.000	
2024-422	50	ARC		22	0.000	0.000	0.00	0.000	0.000	
2024-422	57	S. EXL 200		65	0.077	0.042	54.77	0.100	0.100	
2024-422	58	ATELLICA		12	0.017	0.037	223.61	0.000	0.000	
2024-423	29	VITROS		48	7.667	0.347	4.52	6.600	8.700	
2024-423	36	TOSOH AIA		10	10.730	0.836	7.79	8.200	13.200	
2024-423	38	ROCHE E		49	15.488	0.995	6.42	12.500	18.500	
2024-423	44	BECK.COUL.		51	15.566	0.980	6.30	12.600	18.500	
2024-423	50	ARC		22	13.314	1.011	7.59	10.300	16.300	
2024-423	57	S. EXL 200		65	15.489	0.924	5.97	12.700	18.300	
2024-423	58	ATELLICA		12	13.900	0.763	5.49	11.600	16.200	
2024-424	29	VITROS		48	0.100	0.000	0.00	0.100	0.100	
2024-424	36	TOSOH AIA		10	0.070	0.046	65.47	0.100	0.100	
2024-424	36	TOSOH AIA		10	0.000	1.000	0.00	0.000	0.000	
2024-424	38	ROCHE E		49	0.052	0.050	95.92	0.000	0.100	
2024-424	44	BECK.COUL.		51	0.100	0.000	0.00	0.100	0.100	
2024-424	44	BECK.COUL.		51	0.000	1.000	0.00	0.000	0.000	
2024-424	50	ARC		22	0.000	0.000	0.00	0.000	0.000	
2024-424	57	S. EXL 200		65	0.078	0.041	52.39	0.100	0.100	
2024-424	57	S. EXL 200		65	0.000	1.000	0.00	0.000	0.000	
2024-424	58	ATELLICA		12	0.075	0.043	57.74	0.100	0.100	
2024-424	58	ATELLICA		12	0.000	1.000	0.00	0.000	0.000	
2024-425	29	VITROS		48	14.643	0.623	4.25	12.800	16.500	

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-425	36	TOSOH AIA		10	20.200	2.615	12.94	15.200	25.300
2024-425	38	ROCHE E		49	29.392	2.029	6.90	23.300	35.500
2024-425	44	BECK.COUL.		51	29.766	1.734	5.82	24.600	35.000
2024-425	50	ARC		22	25.918	2.059	7.94	19.700	32.100
2024-425	57	S. EXL 200		65	29.667	1.752	5.91	24.400	34.900
2024-425	58	ATELLICA		12	26.108	1.184	4.54	22.600	29.700
071 VITAMIN B 12		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2024-421	29	VITROS		29	347.034	13.952	4.02	305.000	389.000
2024-421	38	ROCHE E		34	359.735	54.049	15.02	270.000	450.000
2024-421	44	BECK.COUL.		30	266.167	21.438	8.05	202.000	330.000
2024-421	50	ARC		21	367.286	32.229	8.77	275.000	459.000
2024-421	57	S. EXL 200		21	374.571	34.141	9.11	281.000	468.000
2024-422	29	VITROS		29	0.000	0.000	0.00	0.000	0.000
2024-422	38	ROCHE E		34	899.118	83.261	9.26	674.000	1124.000
2024-422	44	BECK.COUL.		30	558.690	80.130	14.34	419.000	698.000
2024-422	50	ARC		21	842.333	87.657	10.41	632.000	1053.000
2024-422	57	S. EXL 200		21	730.143	55.820	7.65	563.000	898.000
2024-423	29	VITROS		29	724.069	47.869	6.61	580.000	868.000
2024-423	38	ROCHE E		34	727.394	46.554	6.40	588.000	867.000
2024-423	44	BECK.COUL.		30	519.600	33.219	6.39	420.000	619.000
2024-423	50	ARC		21	680.300	49.240	7.24	533.000	828.000
2024-423	57	S. EXL 200		21	670.333	44.691	6.67	536.000	804.000
2024-424	29	VITROS		29	240.714	9.180	3.81	213.000	268.000
2024-424	38	ROCHE E		34	226.029	48.450	21.44	170.000	283.000
2024-424	44	BECK.COUL.		30	173.300	12.160	7.02	137.000	210.000
2024-424	50	ARC		21	254.857	20.945	8.22	192.000	318.000
2024-424	57	S. EXL 200		21	257.952	28.070	10.88	193.000	322.000

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
071 VITAMIN B 12		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}							
2024-425	29 VITROS			29	873.724	41.094	4.70	750.000	997.000	
2024-425	38 ROCHE E			34	1215.353	88.572	7.29	950.000	1481.000	
2024-425	44 BECK.COUL.			30	832.533	56.469	6.78	663.000	1002.000	
2024-425	50 ARC			21	1131.095	66.464	5.88	932.000	1330.000	
2024-425	57 S. EXL 200			21	1097.619	57.146	5.21	926.000	1269.000	

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
146 GLYCOHEMOGLOBIN										
2024-431	12 COBAS/INT.			26	5.808	0.175	3.02	5.300	6.300	
2024-431	14 IMMUNOTUR.			16	6.031	0.165	2.73	5.500	6.500	
2024-431	22 VITROS			55	5.729	0.093	1.62	5.500	6.000	
2024-431	31 IMMUNOTURB			42	5.837	0.149	2.56	5.400	6.300	
2024-431	40 SIEMENS DI			84	5.895	0.131	2.22	5.500	6.300	
2024-431	46 ARCHITECT			19	6.160	0.185	3.01	5.600	6.700	
2024-431	46 ARCHITECT			19	5.478	0.147	2.69	5.000	5.900	
2024-431	48 ATELLICA			12	5.525	0.101	1.83	5.200	5.800	
2024-432	12 COBAS/INT.			26	8.332	0.149	1.79	7.900	8.800	
2024-432	14 IMMUNOTUR.			16	8.494	0.383	4.51	7.300	9.600	
2024-432	22 VITROS			55	8.055	0.150	1.86	7.600	8.500	
2024-432	31 IMMUNOTURB			42	8.352	0.232	2.78	7.700	9.000	
2024-432	40 SIEMENS DI			84	8.192	0.177	2.17	7.700	8.700	
2024-432	46 ARCHITECT			19	7.728	0.124	1.60	7.400	8.100	
2024-432	46 ARCHITECT			19	8.720	0.194	2.22	8.100	9.300	
2024-432	48 ATELLICA			12	7.850	0.104	1.33	7.500	8.200	



**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
146	GLYCOHEMOGLOBIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}			
2024-433	12	COBAS/INT.		26	5.220	0.155	2.97	4.800	5.700
2024-433	14	IMMUNOTUR.		16	5.294	0.175	3.30	4.800	5.800
2024-433	22	VITROS		55	4.951	0.085	1.72	4.700	5.200
2024-433	31	IMMUNOTURB		42	5.012	0.213	4.25	4.400	5.700
2024-433	40	SIEMENS DI		84	5.181	0.128	2.46	4.800	5.600
2024-433	46	ARCHITECT		19	5.440	0.265	4.88	4.600	6.200
2024-433	46	ARCHITECT		19	4.806	0.154	3.21	4.300	5.300
2024-433	48	ATELLICA		12	4.817	0.099	2.05	4.500	5.100
2024-434	12	COBAS/INT.		26	8.324	0.166	1.99	7.800	8.800
2024-434	14	IMMUNOTUR.		16	8.394	0.439	5.24	7.100	9.700
2024-434	22	VITROS		55	8.047	0.161	1.99	7.600	8.500
2024-434	31	IMMUNOTURB		42	8.360	0.212	2.53	7.700	9.000
2024-434	40	SIEMENS DI		84	8.200	0.158	1.92	7.700	8.700
2024-434	46	ARCHITECT		19	7.717	0.121	1.57	7.400	8.100
2024-434	46	ARCHITECT		19	8.640	0.224	2.60	8.000	9.300
2024-434	48	ATELLICA		12	7.825	0.109	1.39	7.500	8.200
2024-435	12	COBAS/INT.		26	5.154	0.242	4.70	4.400	5.900
2024-435	14	IMMUNOTUR.		16	5.260	0.120	2.28	4.900	5.600
2024-435	22	VITROS		55	4.951	0.089	1.80	4.700	5.200
2024-435	31	IMMUNOTURB		42	5.038	0.191	3.80	4.500	5.600
2024-435	40	SIEMENS DI		84	5.199	0.133	2.56	4.800	5.600
2024-435	46	ARCHITECT		19	5.440	0.150	2.75	5.000	5.900
2024-435	46	ARCHITECT		19	4.800	0.156	3.26	4.300	5.300
2024-435	48	ATELLICA		12	4.833	0.094	1.95	4.600	5.100

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D	
--------------------	--	-----------------------	--	-------------------	--

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	20 %							
2024-281	3	VITROS		49	53.224	5.640	10.60	43.000	64.000		
2024-281	5	ROCHE E		34	16.412	2.591	15.79	13.000	20.000		
2024-281	5	ROCHE E		34	45.000	4.000	8.89	36.000	54.000		
2024-281	9	BECK.COUL.		47	36.622	2.719	7.42	29.000	44.000		
2024-281	9	BECK.COUL.		47	45.000	1.000	2.22	36.000	54.000		
2024-281	11	ARC		18	25.353	1.998	7.88	20.000	30.000		
2024-281	25	S. DIME		34	26.273	2.206	8.40	21.000	32.000		
2024-281	27	APELLICA		10	55.000	3.493	6.35	44.000	66.000		
2024-281	27	APELLICA		10	45.000	4.000	8.89	36.000	54.000		
2024-282	3	VITROS		49	19.125	3.413	17.85	15.000	23.000		
2024-282	5	ROCHE E		34	6.000	0.000	0.00	5.000	7.000		
2024-282	5	ROCHE E		34	21.000	1.000	4.76	17.000	25.000		
2024-282	9	BECK.COUL.		47	17.000	1.000	5.88	14.000	21.000		
2024-282	9	BECK.COUL.		47	13.681	2.105	15.38	11.000	16.000		
2024-282	11	ARC		18	8.706	0.570	6.55	7.000	10.000		
2024-282	25	S. DIME		34	10.676	1.567	14.67	9.000	13.000		
2024-282	27	APELLICA		10	14.800	1.778	12.01	12.000	18.000		
2024-282	27	APELLICA		10	17.000	1.000	5.88	14.000	21.000		
2024-283	3	VITROS		49	118.837	6.018	5.06	95.000	143.000		
2024-283	5	ROCHE E		34	78.727	5.796	7.36	63.000	94.000		
2024-283	5	ROCHE E		34	105.000	10.000	9.52	84.000	125.000		
2024-283	9	BECK.COUL.		47	86.426	5.874	6.80	69.000	104.000		
2024-283	9	BECK.COUL.		47	105.000	1.000	0.95	84.000	125.000		
2024-283	11	ARC		18	74.353	3.955	5.32	59.000	89.000		
2024-283	25	S. DIME		34	69.529	3.913	5.63	56.000	83.000		
2024-283	27	APELLICA		10	105.000	10.000	9.52	84.000	125.000		
2024-283	27	APELLICA		10	128.200	4.833	3.77	103.000	154.000		

**Participant Summary**

**MONTH 5 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	20 %						
2024-284	3	VITROS		49	81.809	5.233	6.40	65.000	98.000	
2024-284	5	ROCHE E		34	36.088	3.745	10.38	29.000	43.000	
2024-284	5	ROCHE E		34	72.000	5.000	6.94	57.000	86.000	
2024-284	9	BECK.COUL.		47	72.000	1.000	1.39	57.000	86.000	
2024-284	9	BECK.COUL.		47	57.596	3.841	6.67	46.000	69.000	
2024-284	11	ARC		18	41.647	2.056	4.94	33.000	50.000	
2024-284	25	S. DIME		34	42.636	2.544	5.97	34.000	51.000	
2024-284	27	APELLICA		10	85.900	3.300	3.84	69.000	103.000	
2024-284	27	APELLICA		10	72.000	5.000	6.94	57.000	86.000	
2024-285	3	VITROS		49	104.521	7.211	6.90	84.000	125.000	
2024-285	5	ROCHE E		34	56.182	4.951	8.81	45.000	67.000	
2024-285	5	ROCHE E		34	89.000	5.000	5.62	71.000	107.000	
2024-285	9	BECK.COUL.		47	72.851	5.263	7.22	58.000	87.000	
2024-285	9	BECK.COUL.		47	89.000	1.000	1.12	71.000	107.000	
2024-285	11	ARC		18	58.059	2.412	4.16	46.000	70.000	
2024-285	25	S. DIME		34	57.294	3.769	6.58	46.000	69.000	
2024-285	27	APELLICA		10	89.000	5.000	5.62	71.000	107.000	
2024-285	27	APELLICA		10	109.800	4.771	4.34	88.000	132.000	